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Abstract
Health economic evaluations, developed for the purposes of informing technology adoption
decisions in publicly-funded health care systems, should strive to make use of all relevant
evidence. Any failure to meet this objective will result in a partial representation of the
evidence base and, consequently, there is a potential risk of obtaining misleading results.
Unfortunately, a lack of comparability amongst the alternative measures of health-related
quality of life (HRQoL) complicates the synthesis of this type of evidence. One solution
to this problem is to specify a reference case measurement to promote comparability,
although this may provide an incomplete representation of HRQoL effects or, in some
cases, no evidence at all.
The application of mapping functions – statistical algorithms that link HRQoL measures –
might provide a means to incorporate a broader range of heterogeneous outcome measures
for evidence synthesis. One method in particular, known as the common factor model
(CFM), has been proposed in this regard due to its coherent mapping properties. Research
involving the CFM has been conceptual to date and only a handful of case studies have
ever been conducted. However, this method can be formulated as a structural equation
model (SEM), an approach that has benefited from extensive application in other areas
of research.
The primary aim of this thesis is to investigate the plausibility of SEM methods serving
as a generalised framework for the handling of HRQoL evidence. SEM methods are tested
across scenarios involving aggregate data, individual patient data and a combination of
both; in each case, a comprehensive synthesis of heterogeneous HRQoL outcomes using
the SEM approach is compared against a restrictive synthesis involving a reference case
measurement. In addition, the implications of these alternative approaches are explored
from a decision-making viewpoint.
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Chapter 1
Introduction
This thesis looks at some of the methodological issues encountered in the analysis of
health-related quality of life (HRQoL) data for the purposes of health economic evaluation
(HEE). In recent years, this has become an important area of research for two reasons:
first, because policy-makers around the world are increasingly looking at HEE as a tool
to inform the reimbursement decisions in health care (Drummond, 2013a,b); and second,
because researchers and policy-makers alike have recognised the importance of valuing
changes in HRQoL when conducting these evaluations.
The purpose of this chapter is to provide some necessary context relating to the topics
covered in this thesis. A description of HEE is provided along with an outline of its role
in health policy. An outline of the methods used for measuring and valuing HRQoL as a
part of the evaluation process is then provided. This is followed by a description of the
role that modelling techniques play in the consolidation of evidence for HEE. The final
section of the chapter provides an overview of the content of each of the chapters covered
in the thesis.
1.1 Health Economic Evaluation
Health policy-makers around the world are faced with the fundamental economic problem
- how to allocate finite resources when there are (potentially) infinite, competing demands
for those resources. Health economic research strives to address this problem by producing
evidence which can be used to guide the efficient and equitable allocation of healthcare
resources. HEE is a branch of health economics that examines the costs and benefits
of alternative healthcare interventions (e.g. services, drugs, devices) in order to inform
decisions about the reimbursement of those services.
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Economic evaluation is an umbrella term covering a range of methodologies, the alternative
forms of which differ chiefly in two regards: firstly, the way in which the benefits from
health care services are measured and valued; and second, the assumptions made with
regards to the changes in welfare occurring as a result of a policy change. Outside the
field of health care, cost-benefit analysis (CBA) has been the most prominent method of
economic evaluation, with notable applications having been conducted in the evaluation
of public investments in infrastructure and transportation (Fuguitt and Wilcox, 1999).
This branch of evaluation involves placing a monetary value upon the costs and benefits
attributed to the alternative courses of action available. Sometimes, these values can be
determined using data from real world markets, however, such values will not always be
available. In these cases, analysts typically go about deriving non-market values by other
means, principally using stated preference or revealed preference techniques.
Thus far, application of the CBA approach for the evaluation of health care services has
been rare in practice. A body of methodological research exists in this area, particularly
willingness to pay studies (Baker et al., 2014), although there have been reservations
expressed regarding the appropriateness of measuring the benefits attributable to health
care services in monetary terms. The willingness to pay approach has attracted criticism
over concerns that individuals’ responses are influenced by their ability to pay which could
skew valuations disproportionally in favour of health care services that improve the health
of wealthier respondents. Above all, this type of approach is unlikely to serve a publicly-
funded health care system seeking to deliver health care services for all, irrespective of
ability to pay (e.g. the National Health Service in the United Kingdom).
Another approach, more commonly used, is broadly referred to as cost-effectiveness anal-
ysis (CEA). Historically, the application of CEA has, for the most part, focused upon the
identification of health care services expected to deliver maximum health improvements
for a given budget (Dolan and Tsuchiya, 2006). Note that the exact measurement of
health has yet to be specified; in practice, there are a number of ways in which one might
go about quantifying the health effects of a given intervention including patient survival,
clinical endpoints or through patients’ responses to self-assessed questionnaires.
A critical aspect of the CEA methodology is the selection of an outcome measure capable
of capturing all of the aspects of health considered to be relevant to the decision problem.
In publicly-funded health care systems, reimbursement decisions need to be made across a
broad spectrum of disease areas and consequently the outcome measure selected should be
sufficiently broad to account for the health domains encompassed across this spectrum. To
meet this requirement, the health economics research community developed the quality-
13
adjusted life year (QALY), a measure of health that combines survival and HRQoL into
one numeraire. QALYs are estimated by adjusting the length of time alive by valuations
of HRQoL typically ranging between 0 and 1, where 1 reflects perfect health and 0 reflects
death (the methods for valuing HRQoL are discussed in the next section). For example,
four years spent in a health state with an associated HRQoL value of 0.5 would be equiv-
alent to two QALYs. The generic nature of the QALY enables policy-makers to compare
the estimated health effects stemming from policy decisions across-the-board of disease
areas.
The investigations carried out in this thesis are focused exclusively upon the application
of economic evaluation where the benefits of health care are captured by the QALY. This
approach is consistent with the methods employed in practice. Economic evaluation with
the QALY has been adopted as a key tool in health technology assessment (HTA), a
multi-disciplinary process aiming to inform best practice and, in some cases, reimburse-
ment decisions in health care. Following the establishment of the Pharmaceutical Benefits
Advisory Committee (PBAC) in Australia over 20 years ago, many countries have set
up HTA agencies applying the QALY-based approach to economic evaluation to inform
health policy decisions.
The generic nature of the QALY facilitates informed decision-making in the reimbursement
of services across the entire spectrum of health care. However, HEE involving QALYs
require decision rules in order to determine whether or not services are considered to be
welfare improving. For instance, the simple rule of dominance states that any policy that
generates more health benefits and lower costs than the alternative options dominates
those options and represents an improvement in welfare. In reality, many decisions need
to be made in relation to the adoption of expensive new technologies that result in more
QALYs as well as increased costs relative to standard practice. With this in mind, the
optimal bundle of services could theoretically be determined by ranking all of the services
according to their incremental cost-per-QALY and then select those that make the best
use of the budget available.1 Given that this is not a feasible task in practice, many
decision makers have adopted an alternative solution which involves setting a (arbitrary)
cost per QALY threshold below which new technologies could be considered to be cost-
effective (for examples see Cleemput et al. (2008)). This threshold should represent the
cost-per-QALY of the marginal technology currently being reimbursed, thus representing
the opportunity cost in any decision involving the reimbursement of a new technology.
1That is, maximizing population net (of costs) health benefits (as measured by QALYs), given existing
constraints
14
Identification of the true threshold is a challenging task and work in this area has only
recently been undertaken (Claxton et al., 2013).
Despite having a central role in HEE, it is important to recognise that there are on-going
methodological issues that have yet to be resolved regarding the use of the QALY, as
well as normative issues to consider that are often overlooked. In particular, the often-
quoted mantra ‘a QALY is a QALY is a QALY’ – used in reference to the assumption
that all health gains captured by the QALY should be valued equally – has been subject
to considerable scrutiny (Dolan et al., 2005; Rawlins and Culyer, 2004). Amongst other
things, debates have revolved around claims that the QALY is ageist (Harris, 2005; Paulden
et al., 2010) and questioned whether society might value health improvements differently
depending upon severity of illness (Shah, 2009) and remaining life expectancy (Shah et al.,
2014). Whilst work in this area is still ongoing, these questions fall outside the scope of
this thesis.
Moving forward, it is important to recognize the normative underpinnings associated with
the cost-per-QALY approach to evaluation and to understand where these fit in relation
to the foundations of welfare theory in economics. The conventional approach to welfare
economics, often referred to as the welfarist approach, assumes that social welfare is op-
timised according to policies that maximize the sum of individual utilities, where utility
represents an individual’s preferences for different states of the world (Brouwer et al., 2008;
Hurley, 2014). The term extra-welfarism is used to describe any approach that deviates
from the assumptions of the welfarist approach (Brouwer et al., 2008; Hurley, 2014). As we
shall see in the next section, CEA with QALYs might be seen as being an extra-welfarist
approach owing to the fact that the preferences beyond those of the individual are seen as
being important when valuing health. Although these concepts might be beyond the scope
of this thesis, a pragmatic perspective is assumed to be the most appropriate standpoint
for the purposes of decision-making in health policy: that the assumptions required for
the welfarist approach to be valid are unnecessarily restrictive for this to be a requirement
(i.e. that the extra-welfarist approach is acceptable).
1.2 The Measurement and Valuation of HRQoL
Having established the rationale for using QALYs to capture health benefits when evaluat-
ing health care interventions, this section considers some of the competing approaches for
the measurement and valuation of HRQoL. The development of techniques for the valua-
tion of HRQoL has been one of the critical areas of research in health economic evaluation.
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In particular, efforts have focused upon techniques that enable the quantification of peo-
ples’ preferences for specific health states. Valuation exercises that have predominated
– the Standard Gamble (SG) and Time Trade-Off (TTO) – obtain values by exploring
the willingness of respondents to accept increases in the risk of death or decreases in life
expectancy (Gafni, 1994; Gudex et al., 1994). The origins of these valuation exercises can
be traced back to attempts to derive health-related utility scores with methods similar to
those in the expected utility theory framework. It is for this reason that many people still
refer to SG and TTO values as being utilities despite both measures having been shown to
produced biased estimates that violate expected utility theory (Bleichrodt, 2002). How-
ever, the question over whether or not HRQoL values should constitute utilities in the true
sense is not a priority for research in this thesis. Instead, a pragmatic stance is assumed,
one that sees SG and TTO values as being acceptable for the purposes of the application
at hand.
Another source of debate in the methodological literature has been the question of whose
values should be used. Arguments in favour of the use of patient values typically point
to the fact that patients have first-hand experience of the condition and so have the best
understanding of the impacts upon HRQoL (Menzel, 2014). An opposing view to this is
that, for a government-provided health care system, values from the general population
should be used on the basis that provision of health care should reflect the preferences
of the tax-payer (Gold and Siegel, 1996). What makes this debate more complicated is
the fact that the general population tends to value the HRQoL of a given health state
lower than patients experiencing that health state (Menzel, 2014). This phenomenon is
sometimes attributed to the idea that patients adapt to their condition over time and,
accordingly, don’t see the negative aspects.
The debate over whose values should be used in economic evaluation has largely been put
to one side since the development and adoption of preference-based measures (PBMs) of
HRQoL. This might be partly due to the fact that these measures involve both patients
and the general population in the valuation exercise. There are two components to these
methods, the first being a multilevel descriptive system designed to cover the core dimen-
sions of health and the second being a pre-specified set of values associated with each
of the states in the descriptive system. The value set is usually derived from a random
sample of the general population using valuation techniques such as the standard gamble,
time trade off or visual analogue scale (Brazier et al., 2002; Dolan, 1997; Feeny et al.,
2002).
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PBMs are widely used thanks to their relative ease of use, the relatively low burden for re-
spondents and their claimed generic properties (Brazier, 2007). The collection of HRQoL
values using PBMs is straightforward because it simply involves asking patients to rate
their own health using the descriptive system and then assigning the pre-specified value set.
Despite the advantages of these instruments, research has shown that there are important
differences in the values derived using the different instruments available (Conner-Spady
and Suarez-Almazor, 2003). The lack of comparability amongst the instruments available
has led some policy-makers to recommend that all studies should use the same generic
measure - a reference case measurement - in order to promote comparability across stud-
ies (NICE, 2013). However, the downside to this approach is that it may result in an
incomplete representation of HRQoL effects or, in some cases, no evidence at all. This
thesis will focus attention upon the notion of setting a reference case instrument and the
challenges that the challenges this poses around the use of available evidence.
1.3 Decision Analytic Modelling
As previously mentioned, CEA is used to inform reimbursement decisions in health care.
Informing such a decision requires appropriate consideration of all relevant treatment
options, inclusion of all relevant evidence and an appropriate time horizon (Drummond,
2005). It is unlikely that one source of evidence, such as a clinical trial, will provide all of
the evidence necessary to derive a relevant estimate of cost-effectiveness (Sculpher et al.,
2006). Instead, Sculpher and colleagues recommended an evidence synthesis and decision
modelling approach to CEA for decision-making (Sculpher et al., 2006). The decision
modelling approach provides a framework to incorporate evidence form a range of sources
in order to address a specific policy decision. More specifically, decision models estimate
outputs, in the form of expected costs and QALYs for different treatment strategies, using
model inputs that relate to patient survival, treatment effects, HRQoL, resource use and
costs. These models are typically structured to reflect some underlying biological or clinical
process that characterises patients’ movements between defined health states using clinical
evidence (Briggs et al., 2006).
In principle, all of the parameter types employed in decision analytic models for CEA
should make comprehensive use of relevant evidence (Sculpher et al., 2006). Any failure
to meet this objective will result in a partial representation of the evidence base bringing
with it the potential risk of obtaining misleading results. One of the main challenges for
researchers undertaking this task is the matter of how to utilize the available evidence
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when there are multiple studies addressing the same research question. A large body of
methodological research can be found concerning the synthesis of clinical evidence from
published studies using statistical methods, a practice broadly known as meta-analysis
(Sutton et al., 2012). Meta-analysis can be defined as a statistical analysis that combines
or integrates the results from several independent studies (Egger and Smith, 1997). One
of the main reasons for implementing this type of procedure is the possibility of attaining
increased statistical power for the estimation of parameters (Higgins et al., 2009). This
thesis will explore how these methods can be used to incorporate HRQoL evidence within
the decision modelling framework.
1.4 Economic Evaluation in Policy
Health technology assessment (HTA) is a multi-disciplinary process that involves the eval-
uation of evidence of health care services in order to inform the reimbursement of those
services (Hutton et al., 2006). Economic evaluation has come to play an important role
in HTA, along with evidence on clinical effects and safety. The routine application of
economic evaluation in some countries has led to the production of guidance outlining
recommendations for best practice in the methods employed (CADTH, 2006; NICE, 2013;
PBAC, 2008). This followed advice from Gold and colleagues proposing the implemen-
tation of a methodological reference case to ensure consistency and comparability across
cost-effectiveness studies (Weinstein et al., 1996). Many agencies have specified a prefer-
ence for the submission of economic evidence with QALYs, although there is variation in
the degree to which this is a requirement. One agency – the National Institute for Health
Care Excellence (NICE) in England and Wales – has gone as far as recommending a refer-
ence case measure for the valuation of HRQoL, the EQ-5D, due to the inconsistences that
can arise between the different measurement options (NICE, 2013).
1.5 Thesis Overview
The broad aims of this thesis are to explore the methodological issues in the analysis of
HRQoL for cost-effectiveness analysis. More specifically, this thesis is concerned with sta-
tistical methods for incorporating HRQoL evidence within the decision modelling frame-
work. The objectives of this thesis can be set out into four research questions:
• Research question 1: Evaluate the current state of practice with respect to the sta-
tistical methods used to analyse HRQoL data in health economic modelling (chapter
2).
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• Research question 2: Evaluate the methods and guidance currently available, offer
further guidance where possible and identify areas where future research would be
worthwhile (chapters 3 and 4).
• Research question 3: Undertake a series of empirical case studies to test the method-
ological issues identified in research question 2 (chapters 5 – 7).
• Research question 4: What recommendations can be made on the basis of the find-
ings in this thesis? (chapter 8).
In Chapter 2, a review of submissions to NICE is carried out to characterise the statistical
methods used to incorporate HRQoL evidence in HEEs. The findings show that statistical
methods are used on an irregular basis and, as a result, there are fundamental inconsis-
tencies with respect to the use of HRQoL evidence. Chapter 3 reviews the methodological
literature and policy guidance relating to the methods for synthesising HRQoL evidence.
The review finds the policy guidance in this area to be vague and the statistical methods
available to be inadequate for researchers seeking to make comprehensive use of HRQoL
evidence. One of the key challenges in this regard is the issue of between-instrument het-
erogeneity. A recent study has suggested that this problem may be circumvented through
the use of mapping techniques. Chapter 4 reviews some of the statistical issues associated
with the development of mapping algorithms. A handful of studies are found to show that
structural equation modelling (SEM) techniques exhibit a great deal of promise when it
comes to the synthesis of HRQoL evidence involving heterogeneous outcome measures. In
light of these findings, investigations throughout the remainder of the thesis focus upon
the application of these methods.
Chapters 5 to 7 present a series of case studies applying SEM methods across the range
of plausible scenarios that researchers might expect to encounter in practice :
• Chapter 5 looks at the synthesis of multiple sources of evidence in the aggregate for-
mat;
• Chapter 6 looks at the synthesis of multiple sources of patient-level evidence;
• Chapter 7 looks at synthesising a combination of aggregate and patient-level studies
Chapter 8 provides a discussion that relates the findings of the thesis to the original aims
and objectives. Furthermore, the work covered in the thesis is considered in relation to
the broader implications for cost-effectiveness research in practice for policy-makers.
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Chapter 2
Taxonomy and Review of Current
Practice
The previous chapter argued that HRQoL evidence, along with other parameters used in
CEA, should be identified and synthesised from all available studies in order to avoid the
bias in the selection of evidence and to ensure that uncertainty surrounding the HRQoL
parameter estimates is fully characterised (Sutton et al., 2000). Yet this would rarely
appear to be the case in practice when compared to the synthesis of clinical evidence
(Cooper et al., 2005). The objective of this chapter is to review the current state of practice
with respect to the use of HRQoL data in health economic modeling and consider this in
relation to the evidence space that a researcher might plausibly encounter (Saramago
et al., 2012). A review of NICE technology appraisals is carried out in order to explore the
methodological landscape in this area. Existing research has found considerable variety
in the methods used to select and incorporate evidence into cost-effectiveness models for
NICE appraisals (Tosh et al., 2011). This chapter looks more closely at how the format
and diversity of the available HRQoL evidence influences the statistical methods employed
to derive model inputs. The methods are categorised using an existing taxonomy outlining
the possible scenarios faced by the analyst when dealing with available evidence (Saramago
et al., 2012). The original study focused mainly upon available techniques for the statistical
synthesis of clinical evidence given that the majority of the methodological developments
have taken place in this area. The review in this chapter looks at two of the key issues
from the study by Saramago and colleagues – the format of the evidence and the number
of data sources – with the objective to explore how the choice of methods for analysing
and synthesising the available HRQoL evidence depend upon these issues. An additional
data feature considered in this chapter is the instrument(s) used to measure HRQoL and
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how that might affect the choice of analytical method.
2.1 Methods
This chapter looks to characterize the methodological landscape with regards to the tech-
niques for analysing and synthesising HRQoL evidence for the purposes of health economic
evaluation. This section provides a description of the following: the process of selecting
NICE technology appraisals for review; the taxonomy employed to categorise methodolog-
ical approaches for the analysis of HRQoL data; and the process of identifying, selecting
and critically appraising information from the NICE technology appraisals.
Selection of NICE Technology Appraisals
The decision to look specifically at evidence submitted to NICE was predicated by two
key factors. Firstly, the methodological issues under investigation are only relevant insofar
as they have important implications for health policy decision-making. Given that NICE
submissions are used to inform real-world policy decisions, these were considered on the
grounds that they would provide an understanding of current practice in this context.
The second reason for looking at submissions to NICE was more practical; whilst there
might be other organisations with a similar remit to NICE, none are as transparent or
comprehensive in the reporting of evidence used to inform decisions. Despite focusing
upon NICE in this review, it is important to note that the thesis is not solely concerned
with NICE but rather deals with issues that are relevant to any organization interested in
the evaluation of technology adoption decisions using QALYs.
The sample of NICE technology appraisals selected for review in this chapter includes all
Single Technology Appraisals (STA) with recommendations issued in 2012. STAs consider
technology adoption decisions for a single health technology, typically a branded pharma-
ceutical scheduled for release, and differ from Multiple Technology Appraisals (MTA) that
evaluates technology adoption decisions for multiple competing health technologies devel-
oped for the treatment of patients in the same clinical indication. The STA process was
established in 2006 and involves the submission of an evidence dossier, including a health
economic evaluation, by the manufacturer of the technology. This differs from the MTA
process where there are multiple submissions from each of the relevant manufacturers as
well as the submission of a health economic evaluation from an Evidence Review Group
(ERG). The decision to focus solely upon STAs was pragmatic and taken in light of the
differences that exist in the public availability of reports (www.nice.org.uk) for the two
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processes, specifically: (i) the reporting of manufacturers’ submissions in the MTA pro-
cess is extremely limited and (ii) the format selected for the reporting of AGs’ submissions
differed from that in manufacturers’ submissions in the STA process.
Taxonomy
Given that this task is largely a qualitative exercise, a taxonomy has been employed in
order to categorise the methods used to analyse and synthesise HRQoL data, as well
as identifying areas requiring further research. The taxonomy has been adapted from
an existing study that categorised methods according to the possible scenarios that an
analyst might encounter when seeking to populate a cost-effectiveness model (Saramago
et al., 2012). The original study put forth three factors for consideration when choosing a
method for estimating model parameters describing clinical effects.
The first factor to consider is the number of sources of evidence available. Often, the
analyst might encounter a scenario where there are multiple studies available addressing
the same research question. Where this is the case, Saramago and colleagues emphasized
the importance of combining all relevant evidence in order to avoid a biased selection of
evidence (also known as evidence synthesis). Meta-analytic techniques are typically used
to pool data from multiple (reasonably homogeneous) studies and obtain more precise
treatment effects, which is particularly important when these effects are small (Egger and
Smith, 1997). Meta-analytic techniques have proved to be extremely popular with regards
to the synthesis of clinical evidence for health economic evaluation (Cooper et al., 2005).
A second factor considered as being an important determinant of the statistical methods
employed to analyse evidence for the purposes of HEE and included in Saramago and col-
leagues’ taxonomy is the format of the available evidence. The evidence may be available
either 1) in aggregate form only (also known as summary data), 2) at the individual-patient
level only, or 3) in a combination of aggregate- and individual-level data. Whichever sce-
nario applies, the researcher will typically require a mean estimate of the parameter(s)
of interest in order to calculate expected cost-effectiveness, and an associated measure
of uncertainty with a view to understanding the uncertainty associated with the decision
at hand (Briggs et al., 2006). Individual patient data (IPD) holds a number of advan-
tages over aggregate data (AD). With AD, the validity of the results is constrained by
the statistical methods undertaken in the original study; in contrast, access to IPD al-
lows researchers to use a wider range of methods for the analysis and synthesis of the
data. Furthermore, there may be the option to explore statistical heterogeneity in the
cost-effectiveness results using IPD by controlling for variables describing patient char-
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acteristics. This capability means that cost-effectiveness research with IPD can result in
more appropriate decision-making when compared to research with AD, particularly when
there are substantial differences in the estimated cost-effectiveness for a given intervention
across different patient subgroups.
The third and final factor in the taxonomy developed by Saramago and colleagues relates
to the number of parameters scheduled for estimation (single or multiple). This feature
bears particular relevance to the application of MCMC methods, conducted to explore
the uncertainty surrounding the cost-effectiveness results. Where possible, researchers
should seek to account for correlation between the various model input parameters when
conducting this type of exercise (Ades and Sutton, 2006); otherwise, they risk simulating
implausible combinations of input parameters that lead to a misrepresentation of the
uncertainty surrounding the cost-effectiveness results and decision problem.
For the purposes of this chapter, it was felt that the contribution by Saramago and col-
leagues lacked a crucial focal point in the process of utilizing HRQoL evidence for cost-
effectiveness analysis; namely, the type of instrument or process for deriving preference-
based HRQoL scores. In the interest of promoting the comparability of evidence across
technology appraisals, NICE has specified a preference for the valuation of HRQoL us-
ing the EQ-5D measurement in cost-effectiveness submissions (NICE, 2008, 2013). The
taxonomy has been extended to investigate whether statistical methods are being used to
promote consistency in the use of HRQoL evidence. Table 2.1 shows the modified tax-
onomy for the purposes of the review in this chapter. Note that it no longer accounts
for the number of parameters to be estimated; whilst this is still a relevant factor with
regards to the analysis of HRQoL data for cost-effectiveness analysis, it has been excluded
to prioritize the key factors without overcomplicating the taxonomy.
Data Extraction
The following documents outlining cost-effectiveness studies submitted to NICE were
downloaded from its website (www.nice.org.uk) for review:
• Manufacturer’s Submission This provides detailed information about the cost-effectiveness
model submitted by the sponsor to NICE as part of the STA process.
• Full Guidance This document outlines the whole appraisal process including the evi-
dence submitted, assessment of this evidence by the nominated ERG and the reim-
bursement decision taken by the NICE appraisal committee.
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Table 2.1: Modified Taxonomy
Single Source Multiple Sources
EQ-5D Alternative Homogeneous Heterogeneous
Outcomes Outcomes
Aggregate A1 B1 C1 D1
Data
Individual A2 B2 C2 D2
Patient Data
Combination - - C3 D3
• ERG Report This provides an overview of the ERG’s assessment of the evidence sub-
mitted to NICE and includes any additional analyses or modifications requested by
the group.
Data was extracted to classify the evidence used to derive model inputs according to
the gallery of scenarios in table 2.1. Information about the statistical methods employed
within each of those scenarios was also extracted. The review was primarily concerned
with the data and methods at the parameter level in line with the taxonomy although a
series of items were extracted at the model level, particularly with regards to the avail-
ability of patient-level data for each appraisal and the consistency of HRQoL evidence in
a given model. Table 2.2 outlines the items to be identified and extracted chiefly from the
Manufacturer’s Submission documents although the other two documents were checked to
see if there were any subsequent modifications in the analytical techniques employed. The
process of identifying information for extraction was relatively straightforward due to the
consistent and well-defined formatting in the NICE documentation.
2.2 Results
Sample Description
A total of 19 NICE STAs are reviewed in this chapter, the details of which are provided
in table 2.3. All of the cost-effectiveness analyses identified in the review were model-
based rather than trial-based, reflecting NICE methods guidance (NICE, 2013). One
appraisal surveyed two models corresponding to different indications (TA252). The models
differed in terms of the HRQoL evidence used so each was considered separately. The
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Table 2.2: Information Extracted
Model-level findings: issues concerned with format
- Evidence available: was there HRQoL data collected in a clinical trial?
- Evidence employed: was IPD used when available? If not, justification?
- Evidence employed: was the same source of evidence used to populate all of the
parameters in the model?
Model-level findings: HRQoL instruments
- Evidence available: where IPD was available, which instrument was collected?
- Evidence employed: where IPD was used, what was the HRQoL instrument?
- Evidence employed: was there consistency in the valuation methods for a given
model?
Parameter-level findings: issues concerned with format
- Evidence employed: how many sources of evidence were used to derive the param-
eters?
- Evidence employed: what was the format of the available evidence?
- Evidence employed: provide a description of the methods employed to analyse the
available evidence and derive parameter estimates.
- Evidence available: where available evidence wasn’t used, was a justification pro-
vided?
Parameter-level findings: HRQoL instruments
- Evidence employed: which instruments were used to measure and value HRQoL?
generalizability of the sample seems to be reasonable given that it covers a range of disease
areas, with cancer treatments being the most prevalent.
Model-Level Results
Table 2.4 shows a number of statistics related to the availability and use of HRQoL evidence
at the model-level. Almost all of the appraisals acknowledged the availability of HRQoL
data in the clinical trial associated with the treatments under investigation; however, only
around sixty percent of those submissions with such data utilised it to derive HRQoL model
input parameters. Where HRQoL data from clinical trials was disregarded, the following
justifications were provided: the data was not collected using the reference case instrument,
the EQ-5D (TA250), or similarly that the data collected did not include a preference-based
measurement (TA269); there were insufficient numbers of patients experiencing the defined
health states set out in the cost-effectiveness model (TA248); there was a low proportion
of patients completing the questionnaire (TA269); EQ-5D available but only available in
patients representing a subset of health states encountered in the cost-effectiveness model
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Table 2.3: List of STAs in the review
STA Disease Area
244 Respiratory
245 Cardiovascular
248 Endocrine, nutritional and metabolic
249 Cardiovascular
250 Cancer
252 Digestive system/Infectious diseases
253 Digestive system/Infectious diseases
254 Central nervous system
255 Cancer/Urogenital
256 Cardiovascular
258 Cancer/Respiratory
259 Cancer/Urogenital
260 Central nervous system
261 Cardiovascular
263 Cancer
266 Digestive system/Respiratory
267 Cardiovascular
268 Cancer
269 Cancer
(TA254). Two additional studies did not provide any justification, although in both cases
it would appear that the data was disregarded on the grounds that the HRQoL outcomes
were non-preference-based (TA258, TA261). Interestingly, even when trial evidence was
used, it was rarely suitable for estimating all of the HRQoL input parameters in a given
model; only two submissions relied entirely upon trial data for the estimation of the HRQoL
parameters (TA260, TA267). One notable issue was the inability of clinical trials to capture
the HRQoL effects of acute health events represented in the cost-effectiveness model, e.g.
stroke or myocardial infarction (TA244, TA249, TA266). Clinical trials developed to
capture data at defined time points may struggle to capture the HRQoL impact of acute
health events if the effects have elapsed between fixed follow-up visits (Bansback et al.,
2008).
Parameter-Level Results
Table 2.5 shows the use of HRQoL evidence in the sample categorised according to the
taxonomy. In the majority of cases, individual parameters (e.g. HRQoL values for a given
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Table 2.4: Results at the model level
Evidence available Frequency
Was there HRQoL data collected in a clinical
trial?
16/19 (84%)
Where IPD was available, which instrument was
collected?
- EQ-5D 8/16 (50%)
- Alternative PBM 1/16 (6%)
- Disease-specific patient-reported outcome 7/16 (44%)
Evidence employed
Was IPD used when available? 10/16 (63%)
Where IPD was used, which instrument was
used?
- EQ-5D 6/10 (60%)
- Alternative PBM 1/10 (10%)
- Disease-specific patient-reported outcome 3/10 (30%)
Was the same source of evidence used to popu-
late all of the parameters in the model?
4/19 (21%)
Was there homogeneity in the valuation methods
for a given model?
- Yes 7/19 (37%)
- No 10/19 (53%)
- Unclear 2/19 (11%)
health state in the model) were informed by a single source of evidence and heavily reliant
upon aggregate data from existing studies. Table 2.6 provides a more detailed breakdown
of the evidence according to the method of valuation. Despite NICE having specified a
preference for EQ-5D data, a large proportion of parameters employed alternative outcome
measures.
2.3 Taxonomy
This section outlines the analytical methods employed for the derivation of HRQoL inputs
across the range of scenarios set out the taxonomy in Table 2.1.
Scenarios A1 and B1
This section includes those scenarios where only one relevant source of aggregate data
has been identified for the purposes of informing a model input parameter. The review
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found, perhaps unsurprisingly, that there were no analytical methods employed in such
scenarios for the derivation of model estimates. Typically, mean estimates of HRQoL
associated with health states in the model (along with evidence to account for uncertainty
surrounding these values) were selected from an existing study, usually in the published
literature, and used directly in the cost-effectiveness model. For example, one model in
the review (TA249), evaluating treatments for the prevention of stroke and systemic atrial
fibrillation, used HRQoL estimates for three health states (mild, moderate and major
post-stroke health states) that were directly extracted from one study. Ideally, estimates
selected for use in the cost-effectiveness model should be based upon mean values in line
with a rationale set out in the cost literature which says that summary statistics other
than the arithmetic mean are inappropriate for health policy decisions because they don’t
take all of the observations in the sample into account (Thompson and Barber, 2000).
Moreover, the population average impact of a strategy is required for policy decisions,
which can only be obtained by multiplying the mean treatment effect by the number of
individuals that need treatment (Briggs and Gray, 1999).
Table 2.6: Parameter-level results
Instrument
EQ-5D (reference case) 84/193 (44%)
EQ-5D (Non-UK value set) 1/193 (<1%)
EQ-5D (mapping) 17/193 (9%)
Alternative Generic PBM 5/193 (3%)
Disease specific PBM 1/193 (<1%)
Valuation exercise (TTO, SG, VAS)
- General public valuing vignettes
(UK population)
19/193 (10%)
- General public valuing vignettes
(non-UK population)
5/193 (3%)
- Patient values 16/193 (8%)
- Health professional values 2/193 (1%)
- Lack of information 12/193 (6%)
Combination
- Homogeneous (EQ-5D) 15/193 (8%)
- Homogeneous (Other) 3/193 (2%)
- Heterogeneous 7/193 (4%)
- Unclear 2/193 (1%)
Not explicitly stated 4/193 (2%)
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Scenarios A2 and B2
Evidence available at the IPD level might come from a randomised controlled trial (RCT),
observational study or clinical registries. These data may have either been collected at a
single point in time (cross-sectional data) or across multiple time points for each individual
(repeated measures data). In total, there were sixteen cases in the review, relating to four
separate cost-effectiveness models that could be categorised as being either in scenario A2
or B2 (TA249, TA255, TA266, TA267).
The simplest approach in these scenarios involved the calculation of mean preference-based
HRQoL scores in a patient population or in patients groups relevant to the model input of
interest. One model (TA266), evaluating treatments for cystic fibrosis, used patient-level
HRQoL data from a clinical trial to populate model input parameters. First, baseline
HRQoL in the model was estimated on the basis of the mean score at baseline in the trial.
In addition, the data was used to provide estimates of change in HRQoL at week 14 relative
to baseline for each of the treatments under consideration. Mean estimates of change in
HRQoL were calculated for those patients who experienced an improvement in respiratory
symptoms as well as for those patients who did not experience an improvement.
There was one example identified in the review where regression methods were applied
to IPD to estimate multiple HRQoL input parameters (TA267). The cost-effectiveness
model, evaluating treatments for chronic heart failure, had a Markov cohort structure
with two health states (alive and dead) and captured HRQoL using a measure of disease
severity (the New York Heart Association classification or NYHA). All of the HRQoL
evidence used in the model came from one study, a subset of a clinical trial. In the study,
where patients were treated with either of the therapies under evaluation in the model,
EQ-5D data was collected at repeated time points.
Model inputs were derived from this dataset by analysing the impact of NYHA upon
EQ-5D using a mixed regression model specifically designed to handle multilevel data.
The analysis also accounted for the effect of patients’ baseline characteristics, the rate of
hospitalisation and the impact of the treatment group. The methodology employed for the
derivation of model inputs in this particular model was notable because it accounted for the
impact of treatment upon HRQoL over and above that explained by the model structure.
Typically, HRQoL inputs are associated with health states or events and assume that
these estimates are independent of the treatment that patients are receiving. The methods
employed in NICE appraisal 267 show that, with suitable evidence, this assumption can be
tested. Furthermore, regression methods might be considered for the analysis of HRQoL
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data at the IPD level for a number of other reasons. As previously mentioned, one of
the benefits of having access to IPD is the potential to explore heterogeneity in cost-
effectiveness estimates across patient subgroups. Whilst there were no such examples
in the review, others can be found in the published literature (Henriksson et al., 2008).
Alternatively, one might use regression methods to analyse HRQoL data in order to identify
and control for confounding factors that mask the true estimates of interest.
Scenarios C1 - C3 and D1 - D3
The review identified three types of methods involving the use of multiple sources of evi-
dence for the estimation of HRQoL parameters. Despite the extensive use of meta-analytic
methods for the synthesis of clinical evidence (Cooper et al., 2005), only two models in the
review were found to employ similar methods for the synthesis of HRQoL evidence (TA244,
TA255). Four of these cases pertained to a model evaluating treatments for metastatic
hormone-refractory prostate cancer (TA255) that accounted for the impact of several ad-
verse events upon HRQoL, including pulmonary embolism, febrile neutropenia, fatigue
and nausea. A literature search identified two studies with HRQoL estimates associated
with the impact of pulmonary embolism and two separate studies both providing HRQoL
estimates associated with the impact of febrile neutropenia, fatigue and nausea. For three
of the health states (febrile neutropenia, fatigue and nausea), the decision to synthesise
evidence from multiple studies looks justifiable on the grounds that the valuation methods
were homogeneous. Unfortunately, it was not possible to ascertain the homogeneity of the
evidence for the pulmonary embolism health state due to a lack of reporting.
Provided that patient-level datasets are sufficiently homogeneous, they can be pooled using
evidence synthesis methods for the derivation of HRQoL model inputs (either scenario C2
or D2). As with a single source of IPD, pooled IPD requires some form of analysis to
derive model inputs with the same analytical techniques being applicable. There were
two cases in the review where model inputs were derived using patient-level datasets that
pooled multiple sources of data, although unfortunately the analytical methods used for
the derivation of the model inputs were not specified (TA244).
There were a number of cases where a single source of evidence was employed when in fact
multiple sources were available with no obvious grounds for the restricted approach. One
noteworthy example of this can be found in TA254, an appraisal evaluating treatments
for multiple sclerosis. In here, EQ-5D data was collected in the clinical trial but this was
discarded from the model in the original submission on the grounds that the study popula-
tion only captured a subset of the health states set out in the model; instead, evidence was
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derived from a published study. However, experts reviewing the cost-effectiveness model
on behalf of NICE (the ERG) felt that the original submission had excluded potentially
relevant evidence, including the trial data, and so conducted an additional analysis that
involved taking the average of estimates from the trial data combined with those derived
from the published study. There were further examples in the review where analysts ap-
peared to have access to multiple sources of evidence but only opted to select a single source
with no discernable justification for doing so (TA244, TA245, TA249, TA256, TA263). In
many cases, alternative sources of evidence were utilized in sensitivity analyses.
Another method involving the use of multiple sources of evidence for the estimation of
HRQoL parameters is the adjustment of HRQoL values (twenty-three cases in total).
Given that HRQoL evidence is rarely collected specifically for the purposes of informing
a cost-effectiveness model, analysts often rely upon evidence collected in patients whose
characteristics do not exactly match those set out in the model. In such circumstances,
analysts might consider combining multiple HRQoL scores to adjust for factors such as
comorbidities or age (Ara and Wailoo, 2011). In most cases of adjustment, the evidence
being combined appeared to be homogeneous in terms of the valuation methods employed.
However, there were five cases of adjustment involving heterogeneous HRQoL values, all
in TA 256, two of which combined EQ-5D and standard gamble valuation and three that
combined EQ-5D valuations derived using different value sets.
There were nine cases in the review which employed adjustment techniques to account for
comorbidities, five of which applied a multiplicative approach, two that applied an additive
approach, whilst the remaining cases were unclear. For example, there was one case in
the review where literature searching was unable to identify HRQoL values for patients
in a post myocardial infarction (MI) health state with atrial fibrillation (AF). However,
there was one estimate for post-MI patients without AF (data in AD format) and another
for patients with AF without an MI (data also in AD format). An adjusted value was
then estimated by multiplying these two values together, also known as the multiplicative
approach. In contrast, the additive approach involves applying the estimated decrement in
HRQoL associated with one of the comorbidities to the absolute HRQoL value associated
with the other health state. Unfortunately, the choice of approach was not justified by
the authors. There were a further twelve cases of adjustment to account for the direct
effect of different treatments (all in TA252). In each case, the baseline value in the cost-
effectiveness model was adjusted (using the additive approach) according to the treatment
received. In addition, there were two cases of adjustment for age but unfortunately the
methods weren’t clearly specified (TA268).
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A third methodology observed in the review that involved the combination of evidence
from multiple sources was the use of mapping techniques for the indirect estimation of
model input parameters. Mapping, also known as cross-walking, refers to the prediction
of HRQoL values from an alternative outcome measure (Longworth and Rowen, 2011).
Relevant PBM values are not always available for the derivation of model inputs, especially
where a reference case measurement has been nominated, as is the case with NICE. In
this type of situation, analysts may turn to using evidence measured with an alternative
outcome measure in combination with a mapping algorithm, derived using an external
dataset, that links the reference case measure (as the dependent variable) to the outcome
measure available (the explanatory variable(s)). This algorithm might have either been
derived by the analyst using patient-level data or have come from an existing study in the
aggregate data format.
In total, there were seventeen model parameters spanning three separate models derived
via mapping techniques in the review. Owing to the fact that there is more than one
outcome measure involved when mapping, all of these cases have been categorised in
scenarios D1-D3. In two of the models, the input parameters were derived by applying
mapping algorithms to disease-specific patient-reported outcomes collected in clinical trials
(TA259 and TA260). In each case, the algorithms were predicted from IPD using ordinary
least squares (OLS) estimation techniques. The third model utilized a disease-specific
patient-reported outcome measure from a clinical trial (IPD) but the mapping process
was slightly different (TA268). Instead, a set of values (AD) associated with the disease-
specific measure was identified in the published literature (Rowen et al., 2011). This last
case does not constitute mapping in the traditional sense but rather the use of disease-
specific preference weights.
2.4 Discussion
The review in this chapter set out to identify the statistical methods employed to derive
HRQoL parameters for cost-effectiveness models and explore the factors influencing the
approach employed. The review identified four separate applications involving the use
of statistical methods to analyse HRQoL evidence for the purposes of cost-effectiveness
analysis. The first application concerns the methods employed when the analyst has IPD,
specifically in scenarios A2 or B2 of the taxonomy. Unfortunately, the methods employed
to derive model parameters in these scenarios were rarely set out explicitly, although
there was one notable exception, the NICE appraisal TA267. Despite the majority of
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appraisals having accessible trial data with HRQoL outcome measures, IPD played a
limited role in the population of the associated parameters in the cost-effectiveness model.
Two issues related to the collection of HRQoL data in clinical trials underpin this finding.
Firstly, just under half of the trials with HRQoL evidence collected measures without
associated preference weights, necessary for the estimation of HRQoL values. Whilst
some of the submissions overcame this problem by employing mapping procedures, for
others this provided sufficient grounds for discarding the evidence. Another observed
flaw with trial data contributing to this low usage was the inability of trials to capture
HRQoL effects – those typically associated with defined health states and events – captured
within the cost-effectiveness models. More generally, this points to a broader problem
regarding the collection of HRQoL data for cost-effectiveness models; such data is typically
collected as a secondary outcome measure, along the lines of clinical outcome measures,
with the intention to estimate the effects of the treatments under evaluation. These
findings would suggest that more consideration should be paid to the HRQoL requirements
of cost-effectiveness models in practice.
Another application requiring statistical methods to derive HRQoL parameters for cost-
effectiveness analysis is the use of pooling or meta-analytic techniques to combine HRQoL
evidence from multiple sources. As previously mentioned, these methods enjoy widespread
usage for the synthesis of clinical evidence (Cooper et al., 2005). Only a handful of cases
were identified in this review and those conducted synthesised evidence either by pooling or
calculating the mean. The lack of more formal synthesis techniques applied in this context
could be interpreted in two ways. Firstly, this could be viewed as being a consequence
of a limited evidence base; that is, meta-analytic techniques are rarely ever necessary
because analysts typically only have access to a single source of HRQoL evidence, at best.
However, there were many cases in the review where multiple sources of evidence were
available and synthesis techniques were not considered. This points to a second possible
explanation – a lack of recognition that HRQoL evidence, as with all other parameters,
should be identified and selected in a comprehensive manner to avoid bias. This second
point would also indicate a lack of exemplars and guidance with regards to the synthesis
of HRQoL evidence.
The third and fourth applications requiring statistical methods to derive HRQoL param-
eters – mapping and adjustment techniques – are similar in that they both seek to derive
inputs where there is no evidence of direct relevance to the cost-effectiveness model. The
relevance of the evidence depends upon a number of factors including: (a) the instrument
used to value HRQoL, especially where a reference case measurement has been specified;
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(b) whose values were used (patients, general population, other) and whether they re-
flect the jurisdiction in question (e.g. country-specific values); (c) the degree to which
the patient population (or health state description) in the study corresponds to that in
the model. Whilst analysts might not have access to HRQoL evidence fulfilling all of the
desired criteria, statistical methods may be employed to derive indirect estimates using
evidence satisfying at least some of the criteria.
One approach involved the adjustment of HRQoL values from studies where the patient
characteristics did not correspond to those set out in the model, particularly with regards
to factors such as age and comorbidities. The findings of the review would suggest that
there is no consistency with regards to the application of adjustment techniques. Where
adjustment techniques were used there were no justifications provided for the specific
approach selected (either additive or multiplicative). More generally, these techniques did
not appear to be employed routinely throughout the appraisals in the review. Many of
the models reviewed accounted for the effects of changes in health status by applying a
‘disutility’ – that is, a decrement in HRQoL – to the baseline HRQoL value. Despite
this, only there were only a handful of cases recognizing that found to have explicitly
acknowledged this issue.
Another approach involving the indirect estimation of model inputs is the combination
of evidence from multiple sources using of mapping techniques. As with the utilization
of adjustment techniques, there did not appear to be consistency regarding the usage of
mapping techniques. Of the seven appraisals that reported having access to a disease-
specific measure of HRQoL in the IPD format, only three made use of this evidence using
mapping techniques. For the remaining appraisals, this evidence was typically discarded
despite the fact that there appeared to be relevant mapping algorithms available in two of
these cases.1 However, neither of the two appraisals in question utilized values derived by
the reference case measurement, the EQ-5D. Whilst NICE has stated that mapped EQ-
5D values are regarded as being “second-best” when compared to EQ-5D scores derived
directly, it is unclear whether they are also inferior to values obtained via other means.
1TA250 reported having access to data for the EORTC-QLQ C30 and two studies were found containing
relevant mapping algorithms (Crott and Briggs, 2010; McKenzie and Van Der Pol, 2009). TA 269 reported
having access to data for the FACT-M and one study was found containing a relevant mapping algorithm
(Askew et al., 2011).
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Limitations
Whilst the sample selected for review in this chapter would appear to be generalizable in
the sense that it covers a range of disease areas, it is not without limitations. Firstly, the
review only considers cost-effectiveness evidence developed by pharmaceutical manufac-
turers seeking a positive adoption decision from NICE with regards the health technology
under review. It may be the case that manufacturers have a propensity to use different
methods from those that might be used by an independent assessment group; in particu-
lar, one could argue that manufacturers may have an incentive not to be comprehensive
in the selection of evidence. Whilst the review might only provide a partial viewpoint of
methodological practice in terms of the groups developing cost-effectiveness models, this
is not to say that it is unusable. In fact, the main finding of this chapter – the inconsistent
application of statistical methods – transcends the issue of which group was responsible for
submissions in the review and points to a broader issue regarding a lack of methodological
guidance.
Another issue concerning the generalizability of the findings in this chapter is the exclusive
focus upon NICE and cost-effectiveness evidence in the UK setting. As such, these results
are not necessarily indicative of practice globally. Nevertheless, NICE appraisals were
viewed as representing the best resource for the purposes of the review given the compre-
hensiveness in the reporting of the methods. Even so, the reporting of the evidence review
process was limited and this meant that it was difficult to ascertain whether all relevant
evidence was put into practice.
Finally, one might question whether the scope of the review is limited given that it deals ex-
clusively with model-based cost-effectiveness studies and there may be plausible scenarios
involving trial-based cost-effectiveness studies. The fact that all of the cost-effectiveness
submissions in the review employed a model-based approach is unsurprising given that
this method is considered to be the best method for adequate representation of costs and
outcomes of interest to policy makers.
Priorities for Future Research
The review of NICE technology appraisals outlined in this chapter has highlighted a num-
ber of fundamental inconsistencies regarding the application of statistical methods for the
analysis of HRQoL evidence. Synthesis, mapping and adjustment techniques were em-
ployed on an ad hoc basis and this raises concerns over the degree of comparability across
cost-effectiveness studies. Although HRQoL evidence should be identified and synthesised
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comprehensively to avoid biased selection of evidence, as well as adequately characteriz-
ing the associated uncertainty, the results in this chapter would suggest that this is not
the case in practice. Regardless of whether there are AD or IPD, from a single study or
multiple ones, researchers will often have to deal with a HRQoL evidence base that is het-
erogeneous in terms of the patient-reported outcomes available. As such, the development
of methods for the comprehensive utilization of HRQoL evidence, particularly in the face
of heterogeneous outcome measures, should be a priority for future research. The next
chapter looks at the existing methodological literature in this area to explore the statistical
techniques available for the synthesis of HRQoL evidence. A second issue established in
the review is the problem of data collection. One of the key factors complicating the use
of HRQoL data is the fact that evidence is rarely collected specifically for the purposes of
populating a cost-effectiveness model, i.e. so that one could estimate the HRQoL effects
associated with defined health states and events. Although further work is required in
relation to this issue, it will not be a research priority in this thesis.
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Chapter 3
Review of the Methodological
Literature
3.1 Introduction
The previous chapter identified a number of inconsistencies in the use of statistical methods
to derive HRQoL parameters for CEA. One trend of particular concern was the utilization
of a single source of evidence in scenarios where multiple sources were in fact available,
with no obvious grounds for the restricted approach. This approach implies a partial repre-
sentation of the evidence base and increases the risk of obtaining misleading results. This
chapter aims to evaluate the methods and guidance relating to the synthesis of HRQoL
evidence in HEE, to offer guidance where possible and identify areas where future research
would be worthwhile. A citation-search strategy is employed in order to identify any rel-
evant studies in this area. In addition, documents containing methodological guidance
issued on behalf of bodies employing health economic evaluation are also selected.
3.2 Literature Review: Methods
Following recommendations from Hinde and Spackman, a citation searching approach
was considered to be most appropriate approach for identifying relevant literature given
the discursive nature of the review (Hinde and Spackman, 2015). This recommendation
was based upon an illustrative methodological review showing that a citation-searching
approach, specifically bidirectional citation searching to completion (BCSC), was able to
identify a larger number of relevant studies that the standard Boolean logical approach,
based upon a keyword search.
38
For the purposes of this review, the BCSC approach was employed, starting with four
studies as the initial pearls (Ara and Wailoo, 2011; Papaioannou et al., 2011; Peasgood
and Brazier, 2015; Saramago et al., 2012). These studies were selected based on prior
knowledge of their relevance to the review. The next step involved appraising the studies
referenced by the initial pearls, as well as the studies found to cite the initial pearls, and
selecting those studies identified as being relevant to the review. This process was repeated
until no additional studies were identified.
Additional search techniques were required in order to capture relevant information in the
grey literature (i.e. information outside of academic publishing), specifically any method-
ological guidance issued by policy-making bodies utilising economic evidence to inform
health technology adoption recommendations. The documents were identified from an ex-
isting review conducted on behalf of the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) (Eldessouki and Dix Smith, 2012). This was considered to
be a credible source given the important role that ISPOR has played globally in advancing
the science and practice of CEA in health policy over the past twenty years.
3.3 Literature Review: Results
In total, the review found nineteen potentially relevant studies, in addition to the four
references used as the initial pearls. These studies can be divided into two categories:
(i) applied meta-analytic studies involving the synthesis of HRQoL evidence, and (ii)
methodological studies providing discussion without any empirical evidence. The grey
literature review identified thirty-eight methodological guidance documents.
3.3.1 Applied Studies
A total of seventeen applied meta-analytic studies were identified as being potentially
relevant. One study was excluded on the grounds that it only provided a protocol outlining
plans for a systematic review and meta-analysis of HRQoL values associated with diabetic
retinopathy health states (Sampson et al., 2015). Another study was excluded given that
it did not pertain to the synthesis of preference-based HRQoL values (Kinney et al., 1996).
It would appear that all of the remaining studies synthesised aggregate data only (i.e. no
IPD), given that they referred to the identification and selection of evidence from the
published literature. Only two out of the fifteen remaining studies examined the direct
effects of health care interventions upon HRQoL (Cheng and Niparko, 1999; Wyld et al.,
2012). The remainder of the studies instead focused upon the estimation of HRQoL
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values associated with defined health states or events; for example, Lung and colleagues
combined evidence using a meta-regression approach to explore the impact of diabetes
and its related complications upon HRQoL values (Lung et al., 2011). The fact that
the majority of studies deal with defined health states and events (rather than treatment
effects) is unsurprising given that most cost-effectiveness studies are model-based and
estimate QALYs via surrogate health outcomes (see Chapter 2).
A descriptive outline of each of the applied studies is provided in table A.1 (see Appendix
A). One of the most notable observations in this review is the issue of how to handle
heterogeneity when dealing with different outcome measures. A selection of studies might
be considered to be homogeneous if they are all capturing a common parameter estimate.
However, this assumption relies upon the studies being identical in terms of the factors that
may influence the dependent variable, including the patient populations involved and the
exposures or interventions under investigation. In practice, some degree of heterogeneity
is inevitable and, provided that the studies are assumed to be sufficiently similar for meta-
analysis to be considered viable, two methods have been proposed to deal with this: (i)
the inclusion of study-level covariates, also known as meta-regression, and (ii) embracing
a random effects modeling approach (Higgins et al., 2009).
Meta-regressions seek to explain heterogeneity in parameter estimates obtained through
the synthesis of evidence from multiple studies in relation to one or more characteristics
of the studies involved (Thompson and Higgins, 2002). This approach featured in the
majority of applied studies identified in the review as a means to explore variations in
HRQoL values according to disease stage or health state. Covariates were also included
to control for imbalances in study-level characteristics such as age and gender. A large
proportion of studies also included dummy-variable covariates in an effort to overcome
the lack of comparability existing between alternative instruments for valuing HRQoL
(Conner-Spady and Suarez-Almazor, 2003). Two studies took a different approach and
selected a reference case measurement, the EQ-5D, and exclusively synthesised evidence
pertaining to this measure (Doth et al., 2010; Peasgood et al., 2009). Although this method
might alleviate concerns about a lack of comparability between instruments, restricting
searches to a reference case measure may provide an incomplete representation of HRQoL
effects or, in some cases, no evidence at all. Two further studies opted to undertake
separate analyses for different outcome measures (Liem et al., 2008; Mohiuddin and Payne,
2014).
The random-effects approach to evidence synthesis is often utilized as a means of control-
ling for unobservable heterogeneity between studies (Higgins et al., 2009). In a Bayesian
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context, the concept of exchangeability is often used to consider the a priori judgments
regarding the similarity of evidence (Lunn et al., 2012). A large proportion of applied
studies identified in the review were found to employ random-effects models to synthesise
HRQoL evidence. Another trend with important methodological implications is the fact
that many of the applied meta-analytic studies used values obtained from the same study.
The standard approach to meta-analysis, which assumes that all data points are indepen-
dent of one another, is inappropriate when observations are in fact correlated; specifically,
this can lead to biased estimation of the standard errors associated with the parameter
estimates. As such, it would seem incorrect to assume independence between values when
some have been obtained from the same study and so different assumptions are necessary.
A number of studies employed a clustering approach that treats the data clusters (i.e.
values from the same study) as being independent of one another (Djalalov et al., 2014;
Peasgood et al., 2010; Wyld et al., 2012). Other studies chose to employ hierarchical
modelling techniques (McLernon et al., 2008; Sturza, 2010; Tengs and Lin, 2002, 2003).
This method is considered to be more flexible than the clustering method given that it
allows for some exchangeability between the clusters (Baio, 2012).
3.3.2 Methodological Studies
The BCSC search strategy identified two methodological studies (Ara and Wailoo, 2012;
Papaioannou et al., 2013), although both of these were adapted versions of references
used as the initial pearls (Ara and Wailoo, 2011; Papaioannou et al., 2011). There were
two additional methodological studies also used as initial pearls (Peasgood and Brazier,
2015; Saramago et al., 2012). A report commissioned by NICE recognised that whilst
NICE does not require a formal quantitative synthesis of HRQoL evidence, there may
be situations where the use of such methods is warranted (Ara and Wailoo, 2012). The
same report recommended that where HRQoL values are sufficiently homogeneous then
pooling should be considered as a way to improve the precision of the estimates of the
mean utility values and their variances. Although the report does not provide an explicit
clarification regarding the necessary degree of homogeneity, it does suggest that this could
refer to those scenarios where values have been “collected in the same patient population
using the same instrument and using the same UK value (set)”, which may only apply in
a selected number of scenarios. Another report issued by the DSU identified the challenge
of synthesizing HRQoL evidence in practice given the heterogeneity that is often observed
between studies (Papaioannou et al., 2011). The authors noted that the methods for
undertaking this type of synthesis are unclear and that further research is necessary.
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Much of the methodological discourse regarding the synthesis of HRQoL evidence focuses
upon the issue of between-study heterogeneity. Saramago and colleagues identified three
challenges in this regard: (i) variation in the instrument used to derive HRQoL values;
(ii) variation in the population whose values are used; (iii) inadequacy of the available
statistical methods in the handling of these issues (Saramago et al., 2012). The authors
recommended the prioritisation of future research efforts concentrated on the development
of methods for synthesising heterogeneous PRO measures. This call is echoed by a recent
study by Peasgood and Brazier (2015); they argue that the inclusion of covariates to
account for differences in valuation methods (in a meta-regression) is unlikely to pick up the
relative weights attributed to the different domains. The differences between alternative
preference-based measures of HRQoL can be attributed to a number of factors – differences
in their descriptive systems, as well as the techniques used to obtain the associated value
sets – and it is unlikely that a dummy variable will be able to characterise these differences.
Peasgood and Brazier (2015) point to the use of mapping techniques as a potential means
of resolving the differences between values from heterogeneous outcome measures (Peas-
good and Brazier, 2015). As previously mentioned, mapping involves the prediction of
HRQoL values for a reference case instrument using scores or responses to some other
outcome measure in combination with a mapping algorithm linking the two outcome mea-
sures. Another appealing prospect associated with the use of mapping techniques would
be the ability to draw upon non-preference-based measures of HRQoL, which could un-
cover a much greater evidence base for researchers to draw upon. Despite the potential
of the mapping approach, Peasgood and Brazier (2015) are careful to acknowledge that
these techniques have a number of limitations, especially the prediction errors that oc-
cur as a result of their usage. There is already a significant body of literature devoted to
methodological issues associated with the development of mapping algorithms (Longworth
and Rowen, 2011). The next section outlines some of these issues and considers them in
relation to a methodology for evidence synthesis.
3.3.3 Grey Literature
There was only one document found in the grey literature that made a reference to the
synthesis of HRQoL evidence, issued on behalf of the Health Intervention and Technology
Assessment Program in Thailand (Sakthong, 2008). However, the reference was limited to
a single remark recognising the need for “a systemic approach including meta-analysis. . . to
combine utilities taken from different studies”. Whilst NICE makes no reference to the
synthesis of HRQoL evidence in its ‘Guide to the methods of technology appraisal’ (NICE,
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2013), further guidance developed by the Decision Support Unit (DSU) – a body commis-
sioned by NICE to provide research and educational activities – makes recommendations
with regards to this matter. One of the reports written by the DSU recognised that whilst
NICE does not require a formal quantitative synthesis of HRQoL evidence, there may be
situations where the use of such methods is warranted (Ara and Wailoo, 2011). The same
report recommended that where HRQoL values are sufficiently homogeneous then pooling
should be considered as a way to improve the precision of the estimates of the mean utility
values and their variances. Although the report does not provide an explicit clarification
regarding the necessary degree of homogeneity, it does suggest that this could refer to
those scenarios where values have been “collected in the same patient population using the
same instrument and using the same UK value (set)”, which may only apply in a selected
number of scenarios. Another report issued by the DSU identified the challenge of synthe-
sising HRQoL evidence in practice given the heterogeneity that is often observed between
studies (Papaioannou et al., 2011). The authors noted that the methods for undertaking
this type of synthesis are unclear and that further research is necessary.
3.4 Discussion
Researchers undertaking economic evaluations may find that they have more than one
relevant source of HRQoL evidence for the estimation of QALYs. Ideally, HRQoL evidence
should be identified and synthesised from all available studies in order to avoid bias in
the selection of evidence and to ensure that uncertainty surrounding the estimates is fully
characterised (Sculpher et al., 2006). However, chapter 2 found that there are fundamental
inconsistencies regarding the use of statistical methods for the purposes of achieving this
objective. Guidance on this matter – typically issued on behalf of the policy-making
bodies that use economic evaluation to inform health technology adoption decisions – was
found to be severely lacking. In the case of NICE guidance, synthesis of HRQoL evidence
from multiple sources is recommended but only where studies are sufficiently homogeneous
(Ara and Wailoo, 2011). Observing this recommendation in the strictest sense would imply
synthesis should only be considered in HRQoL values captured using the same instrument
given the lack of comparability in values derived via different instruments (Conner-Spady
and Suarez-Almazor, 2003).
A review of the methodological literature found that researchers looking to synthesise
HRQoL evidence have struggled contend with two competing objectives. A review of the
methodological literature found that researchers looking to synthesise HRQoL evidence
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have struggled to strike a balance between achieving both completeness – that is, making
use of all available HRQoL evidence, irrespective of the outcome measure – and compara-
bility – where HRQoL effects can be compared on a common scale. This situation is far
from ideal as it brings a potential risk of obtaining misleading results as a consequence
of the partial representation of the evidence base. A recent study has suggested that this
problem might be circumvented through the use of mapping techniques (Peasgood and
Brazier, 2015). There is already a significant body of literature devoted to methodological
issues associated with the development of mapping algorithms (Longworth and Rowen,
2011). The next chapter outlines some of these issues and considers them in relation to a
methodology for evidence synthesis.
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Chapter 4
Methods for Synthesising
Heterogeneous HRQoL Evidence
4.1 Introduction
Traditionally, mapping has been seen as a second-best option for the estimation of preference-
based HRQoL values, when compared to the collection of values first-hand (NICE, 2008).
As such, the application of mapping techniques has only been advocated in those scenarios
where direct evidence is unavailable and, even with these restrictions, concerns exist about
the validity of mapped estimates of HRQoL (Longworth and Rowen, 2011). However, a
recent study has proposed their usage more broadly as a means of making comprehensive
use of available evidence whilst also capturing HRQoL effects on a comparable scale (Peas-
good and Brazier, 2015). This chapter considers the potential role of mapping techniques
in combination with evidence synthesis techniques. It starts by reviewing some of the
statistical issues associated with the development of mapping algorithms. It then consid-
ers the bias introduced when mapping algorithms do not account for measurement error
across all outcome measures and how this can be avoided by employed structural equation
modeling techniques. Finally, the structural equation modeling framework is described in
relation to the challenges involved in the analysis of preference-based measures of HRQoL
4.2 Statistical Methods for Mapping
Much of the methodological debate in this area has revolved around the development of
statistical methods capable of overcoming the shortcomings of standard regression meth-
ods for the analysis of preference-based measures of HRQoL. Despite the popularity and
simplicity of the ordinary least squares (OLS) approach to regression analysis, the main
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drawback of this method is that it does not guarantee that predictions will lie within a
plausible range – OLS can lead to the prediction of values greater than 1, the highest value
achievable (Chuang and Kind, 2009).
The methodological literature aimed at overcoming this problem can be broadly cate-
gorised into two groups. The first of these groups has focused upon the development of
methods better suited to characterising the distribution of HRQoL index values. Regres-
sion models based upon the beta distribution have been put forward to account for the
bounded nature of health index values (Basu and Manca, 2012; Hunger et al., 2011). The
rationale for the beta regression is that the dependent variable is assumed to be restricted
between 0 and 1. A simulation exercise showed these methods to be more robust for the
estimation of covariate effects compared to OLS (Basu and Manca, 2012). However, em-
pirical studies have shown this approach to be comparable to OLS in terms of predictive
performance (Basu and Manca, 2012; Hunger et al., 2011).
Hernandez Alava and colleagues developed a model to capture some specific distributional
features of the EQ-5D (with a UK value set) (Alava et al., 2012, 2014). This model
incorporated an adjusted limited dependent variable model to deal with the gap in EQ-5D
values between 0.883 and 1, as well as restricting values above 1. For the remainder of the
distribution, a mixture model was employed to account for the multimodality observed
in the EQ-5D values, in part explained by the weightings assigned to the N3 term in
the UK value set. This model was defined as the adjusted limited dependent variable
mixture model (ALDVMM) and the initial studies indicate that it performs well in terms
of predictive performance (Alava et al., 2012, 2014). Whilst other methods have been
employed to analyse HRQoL index values, on-going research in this area has indicated
that the Beta and ALDVMM approaches hold the most potential.1.
An alternative strand of mapping research, known as response mapping, analyses responses
to the health state descriptions of preference-based measures as opposed to the health index
values predicted using such responses. Response mapping has an intuitive appeal because
it deals directly with subjects’ responses and therefore ensures the prediction of feasible
health index values. Another advantage is that the predicted response values can be used
in different countries with country-specific valuations (Rivero-Arias et al., 2010).
The modelling approach required for response mapping is fundamentally different from the
previous techniques dealing with index values given that it involves analysing categorical
outcomes. In many of the existing response mapping studies, a separate analysis was
1See research grant http://gtr.rcuk.ac.uk/project/5A46044C-DC5B-4A0D-B21E-863FCFF87114
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conducted for each of the different dimensions of the health state descriptive system with
modelling techniques including multinomial logit (Gray et al., 2006), ordered logistic (van
Hout et al., 2012) and ordered probit (Alava et al., 2014). There have been concerns
raised over whether or not response mapping should account for correlations between
dimensions (Alava et al., 2014). A recent study by Coniglian and colleagues (2015) has
demonstrated that dependences between dimensions can be modelled using a multivariate
approach (Conigliani et al., 2015).
The outputs of these models are not especially intuitive given that the outcomes have to
be transformed to facilitate their analysis. In the case of the logistic models, parameter
estimates show the impact of predictors upon the log-odds of a given response level whilst
the ordered probit captures effects in terms of the standard normal distribution. However,
these outputs can be converted into probabilities such that there is a probability associated
with each of the potential responses within a given dimension according to a given set of
predictors. With these probabilities, one can predict HRQoL values by combining them
with the associated value sets either using an expected utility approach, using the response
with the highest probability or using Monte Carlo procedure (Gray et al., 2006).
The evidence pertaining to the predictive performance of response mapping techniques is
mixed but overall comparable performance to OLS (Chuang and Kind, 2009; Gray et al.,
2006; McKenzie and Van Der Pol, 2009; van Hout et al., 2012). Hernandez-Alava and
colleagues found that predictive performance of the generalized ordered probit model was
worse than the ALDVMM (Alava et al., 2014). Despite this, one advantage of the response
mapping approach over the ALDVMM is that, unlike the ALDVMM, it does not apply to
a single instrument and value set. Furthermore, response mapping ensures the prediction
of feasible health index values whilst also providing a more detailed understanding of the
relationships between different outcome measures (Dakin et al., 2013).
4.2.1 Measurement Error and Mapping
Although conventional wisdom holds that mapped estimates of HRQoL are second-best
to observed estimates for use in cost-effectiveness studies, recent studies have proposed a
rationale for the use of mapped estimates of HRQoL in cost-effectiveness analysis (Lu et al.,
2013). This concept relies upon an alternative mapping approach, known as the common
factor model (CFM), which characterises the relationship between outcome measures in
terms of a shared, latent factor. Not only does this approach potentially pave the way
towards the synthesis of heterogeneous HRQoL outcome measures (Lu et al., 2014), it
is also claimed to potentially deliver more efficient HRQoL estimates than those derived
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directly (Ades et al., 2013).
Lu et al. (2013) were the first to put forward the CFM for the purposes of mapping in
CEA. Their study developed a mapping algorithm to predict generic HRQoL scores from
disease-specific measures (DSM) based upon the assumptions (a) that both measures share
some underlying construct, known as the common factor model, and (b) that the DSM
is a pure measure of the variability of interest with the exception of measurement error.
These assumptions were set out in formulaic terms by splitting the measures into separate
components, as represented by the equation below:
DSMi = α1 + β1CFi + ε1i (4.1)
Geni = α2 + β2CFi + β3Otheri + ε2i (4.2)
Based upon the equations above, the authors postulated that a coherent mapping between
the two measures should be realized in terms of the common factor, specifically the ratio
of the coefficients upon this factor, β1/β2. The authors demonstrated that this term
can be derived by re-parameterizing the common factor model in terms of reliability and
responsiveness. In practice, estimation of this term requires external information about
the reliability of the DSM as well as the covariance structure associated with the DSM
and generic measure (or patient-level data from which this can be estimated).2
The authors proposed three key properties for a mapping system to be considered coherent:
invertability, transitivity and scale invariance. A case study was conducted using trial data
with three outcome measures – EQ-5D, SF-12 and the Beck Depression Inventory – that
demonstrated the adherence of the CFM to each of these properties. A range of other
regression techniques were conducted, including OLS, but none were shown to consistently
possess all of these properties. The geometric mean regression was the only method, other
than the CFM, shown to be capable of possessing all three properties, although only in
specific circumstances.
Lu and colleagues have recently claimed that the CFM framework would be well placed
to synthesise evidence from multiple heterogeneous HRQoL outcome measures (Lu et al.,
2014). The CFM approach assumes that these different measures capture alternative real-
isations of the same underlying construct(s). In doing so, this method avoids disregarding
2Note that the authors show another method that does not require external information about reliability
but instead uses information for two generic measures and one DSM. However, the methods associated
with this approach are not considered in this chapter.
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potentially relevant evidence, simply because it has not been produced using the bench-
mark PRO instrument chosen by the decision maker (e.g. in the case of NICE, the EQ-5D)
or a commonly reported outcome in the disease area.
The CFM developed by Lu and colleagues (2013), whilst promising, is not without limita-
tions; thus far, research has been conceptual and only a handful of case studies have been
conducted (Lu et al., 2013). First, the CFM applications to date have been concerned
with the synthesis of HRQoL evidence relating to treatment effects. In practice, most
cost-effectiveness models require HRQoL parameters associated with defined health states
and events, rather than just treatment effects and, as a consequence, require baseline
HRQoL values associated with not experiencing the event or health condition (Ara and
Wailoo, 2012). Given that the CFM in its current form is only capable of synthesising
evidence capturing relative effects, further research is required to determine if and how
one could go about synthesising evidence associated with absolute values.
Another limitation of the methods currently available is that they assume that the common
factor representing treatment effects can be captured by a unitary construct. Lu et al.
(2013) noted that certain disease areas might not be characterised by a single construct.
The paper does not suggest how one might go about extending the CFM to deal with
multiple health domains. This would seem particularly important given that many DSMs
are composed of several subscales capturing different dimensions of health.
Finally, the CFM developed by Lu and colleagues (2013) employed a simple linear esti-
mation procedure that does not take into account some of the unique features of HRQoL
data. This approach does not guarantee that predictions will lie within a feasible range,
nor does it adequately account for the unique distribution of health index values. As such,
the CFM would benefit from further research to generate methods better suited to the
handling of these features.
The next section considers many of the issues raised in the context of the structural equa-
tion model framework given that the CFM developed by Lu and colleagues (2013) can
be formulated as a structural equation model (SEM). SEMs have enjoyed extensive ap-
plication in other areas of research, particularly psychometrics research, which has seen
significant methodological advances to contend with the complex relationships often hy-
pothesized in terms of latent variables. The descriptive systems of preference-based mea-
sures of health share a likeness with the outcome measures used in psychometrics in that
they are both attempting to measure human perceptions of subjective concepts. As such,
the capability of SEMs opens up a range of opportunities for effectively contending with
49
the challenges of analysing preference-based measures to derive HSVs for the estimation
of QALYs.
4.3 Structural Equation Models
The term structural equation model refers to a broad family of related statistical models
rather than a single specific technique (Kline, 2006). In fact, many well-known statistical
techniques, such as variance and regression analysis, can be undertaken within the SEM
framework. One of the distinguishing features of SEM’s is that they allow an explicit
representation of observable and latent variables. These relationships are commonly ex-
pressed in algebraic form or in a graphical format (Moon-Ho et al., 2012). An abstract
example is provided in Figure 3.1 to explain some of the concepts further.
SEM diagrams typically employ circles to represent latent variables and rectangles to
represent observed variables (Moon-Ho et al., 2012). In Figure 4.1, there is one variable
representing a hypothetical construct of interest, labelled “CF” representing a “common
factor”, and a further four latent variables representing error terms. The relationships
between variables are represented using arrows, with each starting at the independent
variable and ending at the dependent variable.
The model in Figure 4.1 assumes that the observed variables, indicators 1 to 4, are related
due to the action of the unobserved construct, CF. Any observed correlations between the
indicators are assumed to occur as a result of this construct. The relationship between the
construct, CF, and the indicators is represented by the coefficients on each of the arrows
(λ1,λ2,λ3 and λ4), known as factor loadings. It is also assumed that the observed variables
are partly determined by other factors and this is captured in the model with the error
terms (ε1,ε2,ε3 and ε4). As such, the model has decomposed the variance of each of the
observed variables into two parts: a shared part (CF) and a unique part (εi).
Figure 4.1: Graphical Example of a Structural Equation Model
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The model in Figure 4.1 can be tested provided that there is data available containing
each of the variables of interest, specifically a variance-covariance matrix. The analysis
undertaken, known as a confirmatory factor analysis (CFA), aims to identify a set of
parameters, or more specifically the factor loadings, that minimize the difference between
the observed and estimated data (Lei and Wu, 2012). This method for deriving parameter
estimates is very similar to that with an OLS regression analysis.
An important assumption made in SEMs, such as the one in Figure 4.1, is that of model
identification. There are two key conditions that must be satisfied for a model to be
identified. First, the amount of unknown information in the model should be less than or
equal to the amount of observed information available. The term unknown information
relates to the number of free parameters in the model, which may include factor loadings,
factor variances and error terms3. The amount of observed information refers to the
number of elements in the variance-covariance matrix. For example, the model in Figure
4.1 has ten pieces of information – four observed variables with four variances and six
covariances4.
The second condition for model identification is that every factor must have a scale.
Latent variables are not directly measured and require a scale so that their variances are
interpretable. This can be achieved in two ways. The first involves fixing the variance of
a factor to equal a constant (e.g. equal to 1). Alternatively, one might fix a factor loading
for one of the indicators to equal 1, effectively scaling the variance of the latent variable
to equal that of the indicator variable.
The two aforementioned conditions represent the minimum theoretical requirements for a
model to be correctly identified5. Where these conditions are not met, the model is said
to be under-identified and the analyst should consider an alternative specification. The
first condition implies that a standard CFA requires at least three factors in order to be
correctly identified. Interestingly, the CFM developed by Lu and colleagues (2013) would
have been under-identified were it not for the addition of external information relating
to the reliability of the DSM. This model, represented in equations (1) and (2), is set
out graphically in Figure 4.2. Note that the latent factor, Otheri, has been incorporated
within the error term, εi. The following sections will consider the extension of this model
3It is worth noting that not all model parameters will necessarily be free; sometimes parameters are
constrained to a specific value, also known as fixed parameters.
4In general, for k observed variables, there are k(k + 1)/2 pieces of information (Kenny and Milan,
2011).
5Note: models that are theoretically identified are still prone to empirical under-indentification due to
data related problems (Kline, 2006).
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to handle DSMs with multiple constructs and dealing with item-level responses rather
than the index values from generic instruments.
Figure 4.2: Graphical Representation of the Common Factor Model
4.3.1 Dealing with Multi-Construct Outcome Measures
The model set out in Figure 4.2 assumes that the observed DSM is represented by a single
score. In practice, DSMs are often composed of many multi-choice questions, known as
items, and these items may be organised into groups that measure separate constructs.
For example the cancer-specific questionnaire, the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C-30),
has 30 items that cover several health domains including five functioning scales, a global
QoL scale and nine symptom scales (Fayers et al., 1999). As such, analysts may wish to
characterise DSMs within SEMs at the item-level or sub-score level and, in some cases,
this might be necessary where there is no overall summary score.
First, let us consider the scenario of a DSM with several sub-scores, each measured on
a continuous scale, and the summary scores for a generic measure, also measured on
a continuous scale. In practice, the sub-scores of DSMs are often designed to capture
different aspects of the condition of interest. For example, the EORTC QLQ-C30 covers
five functioning scales, including physical, role, social, emotional and cognitive functioning.
For this reason, it will often be more appropriate to assume that the separate sub-scores
are explained by different factors. Figure 4.3 illustrates a model with separate factors
corresponding with the different sub-scores.
This model assumes that the sub-scores, DSM1 and DSM2, are explained by separate
underlying constructs. As with the CFM set out in Figure 4.2, the sub-scores here can
be assumed to be “pure” measures of these constructs with the inclusion of external
information about the reliability of the sub-scores. However, the model in Figure 4.3 relies
upon a strong assumption that the error terms (ε1,ε2,ε3) are uncorrelated. In practice,
this might be too strong an assumption given that there may be remaining shared variance
between the sub-scores of the DSM, beyond that explained by the model. Where there
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Figure 4.3: Graphical Example of a Structural Equation Model with a Multi-Construct
Disease-Specific Measurement
are concerns that this might be the case, one solution would be to introduce an additional
factor into the model that accounts for the shared variance between the sub-scores of the
DSM.
4.3.2 Dealing with Item-Level Responses
SEMs are capable of analysing item-level responses to both generic measures and DSMs
thanks to methodological advances in the way that categorical data is handled (Edwards
et al., 2012). However, this raises a number of challenges in relation to the application
of the CFM, all of which relate to the question of how many latent factors should be
specified. First, suppose that we have item-level responses for the DSM and index values
for the generic measure; should we specify a different latent factor for each of the items, in
a similar fashion to the model in Figure 4.3? It will often be the case that different items
on the same measure will be specified to capture different aspects of the same construct.
As such, one would expect to specify a model such as the one in Figure 4.4.
Figure 4.4: Graphical Example of a Structural Equation Model with Multiple Categorical
Items Loading on the Same Factor
This model represents an important departure from the original CFM because it no longer
assumes that we have one pure measure of the construct of interest. Instead, it assumes
that there are several items that capture slightly different aspects of the construct and
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that we are interested in the variability that is shared between these items6. This raises
the question of whether we really need external information about the reliability of the
items. Unlike the models in Figures 4.2 and 4.3, this model is correctly identified thanks
to the additional items on the latent factor.
The benefits of having access to IPD for the purposes of synthesising HRQoL data with
structural equation modeling techniques – in particular, the ability to exploit item-level
information – have yet to demonstrated in the context of HEE. Only one study has been
found to employ an SEM-type approach, specifically a multidimensional item response
theory (IRT) method, to analyse preference-based measures of HRQoL at the item level
(Gibbons et al., 2014). This study showed that the multidimensional IRT model performed
well in terms of its ability to predict EQ-5D scores compared to traditional regression
methods. Despite showing early promise, the predictive performance of this approach
has yet to be externally validated. These issues are explored further in the case study
presented in chapter 6.
4.4 Priorities for Future Research
Although promising, early research involving SEM techniques for the synthesis of HRQoL
evidence has been conceptual and lacking in generalisability. Critically, most of these
studies do not even involve preference-based measures of HRQoL. Further research ex-
ploring the application of SEM methods in a greater range of scenarios is required to
inform policy makers and the research community alike about the likely implications of
adopting such methods. The primary objective for the remainder of the thesis is to in-
vestigate the plausibility of the SEM framework serving as a generalised framework for
the handling of HRQoL evidence. SEM methods are tested across each of the scenarios
illustrated in the taxonomy in Chapter 2; in each case, a comprehensive synthesis of het-
erogeneous HRQoL outcomes using the SEM approach is compared against a restrictive
synthesis involving a reference case measurement. Whilst the methods for identifying and
selecting HRQoL evidence for CEA are not the primary concern of this thesis, it is impor-
tant to distinguish between the alternative inclusion criteria for study selection that may
be specified. For convenience, the term “reference case” approach is used to refer to a
systematic review of HRQoL evidence with the inclusion criteria restricted to select only
those studies that collecting the reference case measurement (e.g. the EQ-5D for NICE).
6This model is said to be uni-dimensional because it assumes that there is a single factor loading on all
of the item responses.
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The term “all-inclusive” approach is used to refer to a systematic review that incorporates
a range of outcomes beyond the reference case measurement. The additional measures
could potentially include any of the following: alternative generic preference-based mea-
sures, condition-specific preference-based measures, generic PROs (non-preference-based)
or disease-specific PROs (non-preference-based). Assuming that the “reference case” and
“all-inclusive” approaches are identical in all other aspects of the inclusion criteria (i.e. the
population characteristics of interest), the studies selected in the former approach should
always either be the same as or a subset of those studies selected in the latter approach.
In addition, the implications of these alternative approaches will be explored in the con-
text of a cost-effectiveness model. The thesis also looks to investigate the advantage for
researchers having access to patient-level data, rather than aggregate data.
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Chapter 5
Case Study I: Synthesis of
Aggregate Data
5.1 Introduction
Chapter 3 identified the SEM framework as a potential avenue for the synthesis of het-
erogeneous HRQoL in CEA. It was decided that further empirical research was required
in order to evaluate the feasibility of this methodology in practice. This chapter focuses
upon scenario D1 from the taxonomy in Table 2.1 where researchers, seeking to estimate
HRQoL parameters for CEA, are faced with an evidence base involving multiple sources
of evidence in the AD format. One study has been identified to date as having used SEM
techniques in this context although it did not involve preference-based HRQoL values
(Lu et al., 2014). Furthermore, this study did not consider the implications of using the
SEM approach for CEA in comparison to current methods. As such, this chapter seeks
to (a) identify the methodological challenges unique to scenario D1, and (b) to compare
HRQoL parameter estimates, derived using an “all-inclusive” approach to evidence syn-
thesis with SEM methods, against those obtained using a “reference case” approach to
evidence synthesis with standard meta-analytic methods.
5.2 Background
This section provides context in relation to the application of SEM techniques using evi-
dence in the AD format.
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5.2.1 Evidence Synthesis via Standard Meta-Analytic Methods
In this chapter, the meta-analytic approach used to synthesise the “reference case” evi-
dence includes both covariates, for explained heterogeneity, and random effects, for resid-
ual heterogeneity. This method is implemented using a Bayesian approach and the model
specification is illustrated in Equations 5.1 – 5.5. The Bayesian approach to evidence
synthesis assumed that model parameters are random quantities and a likelihood function
is defined to reflect the plausibility of the data given the model parameter values (Sutton
and Abrams, 2001).
Equations 5.1 – 5.2 represent the likelihood function. The term HRQoLi represents the
observed mean HRQoL value in study i with the associated standard error represented
by the term SEi. A covariate, Eventi, has been included in order to explore differences
between patients’ reported HRQoL values depending upon whether or not they have ex-
perienced a health event. In addition, study specific random effects have been included in
order to capture unexplained heterogeneity between values coming from different studies.
These random effects are captured by the term θz and are assumed to be samples from a
normal distribution with mean µ and and variance τ2z
HRQoLi ∼ Normal(θ[studyi] + β · Eventi, SEi) (5.1)
θz ∼ Normal(µ, τ2z ) (5.2)
A defining feature of the Bayesian approach to evidence synthesis is the specification of
prior distributions for the unknown model parameters. Prior distributions can be based
upon external evidence (so-called “informed” priors) or subjective a priori beliefs (Lung
et al., 2011). Equations 5.3 – 5.5 illustrate the prior distributions for all of the unknown
parameters in this model.
µ ∼ Uniform(0, 1) (5.3)
β ∼ Normal(0, 0.1) (5.4)
τ2z ∼ Uniform(0.001, 0.2) (5.5)
In this chapter, it is assumed that there is no external evidence available to inform the prior
distributions. Instead, “reference” priors have been specified which are assumed to fulfill
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some basic desirable properties associated with the parameters under evaluation (Lunn
et al., 2012). The constant term has been assigned a uniform distribution, ranging between
0 and 1, based on the fact that this typically reflects the plausible range of HRQoL values.1
The coefficient β has been assigned a normal distribution with a mean at zero to reflect
the fact that the impact of the health event is unknown. Finally, the variance component
τ2z requires a prior distribution that guarantees non-negative values and a decision was
made to use the uniform distribution.
5.2.2 Evidence Synthesis via SEM Methods
The linear structural equation modeling approach, also known as the LISREL method,
readily lends itself to the analysis of data in the AD format. This is because the parameter
estimation procedure typically involves minimizing some form of discrepancy between a
sample variance-covariance matrix and a model-implied covariance matrix (Lei and Wu,
2012). In addition to the sample variance-covariance matrix, researchers might consider
the inclusion of sample means for all of the outcome measures involved as intercepts in
the model. If this doesn’t happen, as was the case in the study by Lu and colleagues (Lu
et al., 2014), then there are no intercepts and the means scores for each of the outcomes are
assumed to equal zero. This approach was reasonable in the study by Lu and colleagues
given that the main objective was to synthesise evidence relating to treatment effects
for six measures of HRQoL. However, supposing that one wants to synthesise evidence
pertaining to baseline or absolute HRQoL values, then inclusion of the sample means is
necessary.
Aside from the work by Lu and colleagues (Lu et al., 2014), the intuition behind the
intersection of SEM and meta-analysis has only come about very recently and the early
work in this area has put forward two distinctive applications: (i) the implementation
of standard multivariate meta-analyses (MVMA) in a SEM framework (Cheung, 2013,
2014b); (ii) a meta-analytic SEM approach that involves pooling correlation (or covariance)
matrices (Cheung, 2014a). The former deals only with the structural part of the SEM
framework, rather than the measurement part. The motivation behind this approach is the
promise of ‘borrowing of strength’ across mean outcomes and the potential for subsequent
reductions in uncertainty surrounding parameter estimates. MVMA has been put forward
as a means of incorporating evidence from several correlated outcome measures for the
1Note that this range will vary depending upon the instrument under evaluation. For example, a range
between -0.594 and 1 would be appropriate for the EQ-5D with population weights from the study by
Dolan (1997).
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purposes of populating input parameters in cost-effectiveness models (Bujkiewicz et al.,
2013). Although very similar to the model by Lu and colleagues in terms of the evidence
requirements, the MVMA approach does not produce coherent mappings between the
various outcomes under evaluation.
The meta-analytic SEM approach involves two steps: first, a synthesis of multiple correla-
tion or covariance matrices is performed and then an SEM is fitted to the output (Cheung,
2014a). This approach is potentially useful for researchers interested in the synthesis of
multiple sample covariance matrices involving HRQoL outcome measures. However, ap-
plications involving the meta-analytic SEM method are not investigated in this chapter
for two reasons. First, the likelihood of researchers managing to obtain a single sample
covariance matrix, let alone multiple matrices, from the published literature is contested in
this chapter. Second, the meta-analytic SEM method is currently unable to accommodate
the synthesis of mean scores in addition to covariance matrices.
The chapter considers two separate approaches involving SEM techniques for the synthesis
of heterogeneous HRQoL evidence: (i) a two-step method with mapping undertaken sepa-
rately from evidence synthesis, and (ii) an integrated approach that undertakes these steps
simultaneously. These methods are implemented in conjunction with the “all-inclusive”
approach to evidence identification and selection, i.e. there will be HRQoL values from
multiple instruments. A prerequisite for the implementation of either method is the avail-
ability of covariance matrix data, capturing all of the relevant outcome measures. For the
purposes of this case study, we will consider a scenario where researchers obtain a sample
covariance matrix for one of the studies identified in the review.2
Equations 5.6 – 5.16 illustrate the first step of the two-step method for evidence synthesis
involving SEM techniques. A confirmatory factor analysis (CFA) modeling approach is
shown in equations 5.6 – 5.9; this model specifies the relationships between observed values
for different HRQoL instruments according to an underlying latent factor, LF. The CFA
falls within the broad family of SEM methods and estimation of this model provides the
parameter estimates (λ2 and λ3) necessary for mapping between the different instruments.
Equations 5.10 – 5.12 show the model-implied covariance matrices, which are a product
of the factor loadings and factor variance score (Brown and Moore, 2012). The parameter
estimation procedure typically involves minimizing some form of discrepancy between the
sample covariance matrix and the model-implied covariance matrix.
2That is, one study provides mean HRQoL values associated with one of the defined health states for
all of the relevant instruments, as well as providing a sample covariance matrix.
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EQ5Di = µEQ5D + LFi (5.6)
SF6Di = µSF6D + λ2 · LFi (5.7)
HUI3i = µHUI3 + λ3 · LFi (5.8)
LFi ∼ Normal(0, 1) (5.9)
Cov(EQ5D,SF6D) = 1 · λ2 · 1 (5.10)
Cov(EQ5D,HUI3) = 1 · λ3 · 1 (5.11)
Cov(SF6D,HUI3) = λ2 · λ3 · 1 (5.12)
Once the factor loadings (λ2 and λ3) have been obtained, HRQoL values can be predicted
on the scale of the reference case instrument (in this case, the EQ-5D) for all of the studies
available. Equations 5.13 – 5.16 show how mean SF-6D and HUI-3 values, along with the
associated standard errors, can be mapped onto the EQ-5D scale. Once all of the evidence
has been mapped onto the EQ5D scale (if it wasn’t already), the evidence synthesis step
can be undertaken using the methods from equation 5.1 – 5.5.
Mapped EQ5Di = µEQ5D +
SF6Di − µSF6D
λ2
(5.13)
Mapped EQ5Di = µEQ5D +
HUI3i − µHUI3
λ3
(5.14)
SE(Mapped EQ5Di) =
SE(SF6Di)
λ2
(5.15)
SE(Mapped EQ5Di) =
SE(HUI3i)
λ3
(5.16)
The so-called integrated method aims to use a single model to explain all aspects of the
available data. The motivation behind this method is that it should, theoretically, provide
a more logical approach to evidence synthesis compared to the two-step method given that
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all of the observed evidence is interpreted in a consistent manner. However, the process
of developing a more logical approach to evidence synthesis brings greater complexity in
terms of the model specification required to implement this technique.
Equations 5.17 - 5.40 illustrate the mathematical notation for the integrated method. This
approach relies heavily upon an assumption of fixed factor loadings across studies given
that there is only a single study containing the sample covariance information (Equations
5.17 and 5.18). The factor loadings (λ2, λ3) are estimated using the steps outlined in
Equations 5.6 – 5.12, along with the associated standard errors (SE(λ2), SE(λ3)). Estima-
tion of the standard errors is an important step as it allows the uncertainty surrounding
the factor loadings to be captured.
λ2t ∼ Normal(λ2, SE(λ2)) (5.17)
λ3t ∼ Normal(λ3, SE(λ3)) (5.18)
Although most of the studies are missing information for some of the outcome measures,
this problem is circumvented by the fact that all of the outcomes are related to each other
via the latent factor. As such, if a study is missing sample statistics for one outcome (e.g.
EQ-5D) then information can be borrowed from another measure (e.g. SF-6D) through
the relationships set out in Equations 5.25 – 5.30. Note that this borrowing of information
applies to standard errors (5.28 – 5.30), in addition to mean values (5.25 – 5.27).
EQ5Di ∼ Normal(θ1i, SE(EQ5Di)) (5.19)
SF6Di ∼ Normal(θ2i, SE(SF6Di)) (5.20)
HUI3i ∼ Normal(θ3i, SE(HUI3i)) (5.21)
SE(EQ5Di) ∼ Normal(φ1i, ψ1) (5.22)
SE(SF6Di) ∼ Normal(φ2i, ψ2) (5.23)
SE(HUI3i) ∼ Normal(φ3i, ψ3) (5.24)
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The scale of latent factor is fixed to that of the EQ-5D, which is illustrated by the fact that
there is no factor loading in Equation 5.25 (i.e. the factor loading is equal to one). Random
effects are included to capture any unexplained heterogeneity between latent factor scores
coming from different studies (Equation 5.31). The term υ captures the mean population
HRQoL for patients with no previous experience of an MI. This parameter is scaled in
a way such that deviations from zero on the latent factor scale reflect deviations from
µEQ5D on the EQ-5D scale. As such, we should add µEQ5D to our estimate of υ in order
to interpret it on the EQ-5D scale.
θ1i = µEQ5D + LFi (5.25)
θ2i = µSF6D + λ2t · LFi (5.26)
θ3i = µHUI3 + λ3t · LFi (5.27)
φ1i = SE(LFi) (5.28)
φ2i = λ2t · SE(LFi) (5.29)
φ3i = λ3t · SE(LFi) (5.30)
LFi ∼ Normal(δ[studyi] + β · Eventi, ε) (5.31)
δz ∼ Normal(υ, τ2z ) (5.32)
υ ∼ Normal(0, 0.1) (5.33)
β ∼ Normal(0, 0.1) (5.34)
ε ∼ Uniform(0.001, 0.2) (5.35)
SE(LFi) ∼ Uniform(0.001, 0.2) (5.36)
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ψ1 ∼ Uniform(0.001, 0.2) (5.37)
ψ2 ∼ Uniform(0.001, 0.2) (5.38)
ψ3 ∼ Uniform(0.001, 0.2) (5.39)
τ2z ∼ Uniform(0.001, 0.2) (5.40)
5.3 Methods
An empirical case study was conducted in order to compare HRQoL parameter estimates
obtained using standard meta-analytic methods against those obtained using each of the
proposed SEM methods. The standard meta-analytic approach draws solely upon HRQoL
evidence for a reference case measurement, the EQ-5D. In contract, the SEM methods
exploit HRQoL evidence from a broader range of measurements. The case study also
explores the implications of using the different methods in terms of the impact upon
cost-effectiveness results. The case study selected investigates the cost-effectiveness of an
early surgical intervention compared to medical management for the treatment of acute
coronary syndrome in a patient subgroup with diabetes.
5.3.1 HRQoL Evidence
Health state valuations were extracted from an existing meta-analytic study exploring the
effects of diabetes and related complications upon HRQoL. Lung and colleagues performed
a search and review of published databases to identify studies containing relevant values,
the details of which can be found in the original study (Lung et al., 2011). The criteria
for study selection was not confined to any one HRQoL instrument and no efforts were
made to adjust values from alternative instruments onto the same scale. The studies were
grouped according to the type of complications experienced by patients that included
the following: no complications, stroke, myocardial infarction, end-stage renal disease,
blindness, amputation and ulcers. In total, Lung and colleagues identified forty-six health
state values, along with associated standard errors. Not all of these values were used for
the purposes of this chapter given that they varied not only in terms of the instruments
used but also the population index values for a given instrument. It is well established
that different population index values for a given same instrument can result in different
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valuations and, hence, undermine the comparability (Kharroubi et al., 2010, 2014). For
this reason, specific preference weights were defined for each instrument and health state
values were extracted if they were met any of the following criteria:
• EQ-5D values derived using population weights from the study by Dolan (1997).
• SF-6D values derived using population weights from the study by Brazier et al. (2002).
• HUI-3 values derived using population weights from the study by Feeny et al. (2002).
For those values meeting the inclusion criteria, the following information is extracted:
mean value; standard error; publication author; publication year; preference-based instru-
ment; information regarding any diabetes-related complications; the number of patients
in the sample.
A variance-covariance matrix relating to the three instruments was obtained from the
National Health Measurement Survey (NHMS). The NHMS was conducted in the United
States and collected a variety of measures of HRQoL, including the EQ-5D, HUI-3 and
the SF-36, in a sample of the general population. Further details about this dataset can
be found elsewhere (Fryback et al., 2007). The variance-covariance matrix was derived in
a subset of patients recorded as having diabetes. In addition, the mean values for each
of the measures are extracted so that they can be included in the synthesis. Whilst the
individual-patient data might have been available to estimate this matrix, we assume that
the statistics have been identified in the aggregate format.
5.3.2 Health Economic Model
The health economic model has been derived from an existing study, the details of which
can be found elsewhere (Henriksson et al., 2008). The expected costs and QALYs for
competing interventions are estimated indirectly as follows: (i) modeling the impact of
treatments upon the probability of a given patient either experiencing a myocardial in-
farction or dying; (ii) linking these intermediate endpoints to the ‘final’ endpoints, namely
length of life, HRQoL and costs. This chapter is solely concerned with the estimation of
HRQoL inputs for this model, referred to as the RITA-3 model, so the remaining param-
eters have been left unchanged from those in the original study.
The HRQoL input parameters employed in this case study have been simplified from the
original study. Specifically, the model not longer accounts for the impact of a myocardial
infarction in the last twelve months. Instead, the model in this study only contains three
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health states that differentiate between HRQoL – one for patients with diabetes who have
yet to experience a myocardial infarction; another for patients with diabetes who have
experienced a myocardial infarction; and finally, death (assumed to equal zero).
5.3.3 Estimation of Parameter Inputs
The following statistical procedures for evidence synthesis will be compared:
• Hierarchical Meta-Regression (Model 5.1): health state values derived using the EQ-5D
are analysed using the model set out in Equations 5.1 – 5.5. Note that the Equation
5.3 is modified to account for the range of EQ-5D values as follows:
µ ∼ Uniform(−0.594, 1) (5.41)
• CFA-Approach to Evidence Synthesis (Model 5.2): the confirmatory factor analysis, set
out in Equations 5.6 – 5.12, is fitted using the sample statistics from the NHMS. The
parameter estimates from this model (λ2 and λ3) and the mean values (µEQ5D, µSF6D
and µHUI3) are then used to map health values for the HUI-3 and SF-6D onto the EQ-
5D scale. Health state values derived using the EQ-5D, including those that have been
mapped onto the EQ-5D scale, are then combined using the hierarchical meta-regression
method.
• SEM-Approach to Evidence Synthesis (Model 5.3): the confirmatory factor analysis set
out in Equations 5.6 – 5.12 is fitted using the sample statistics from the NHMS. Using
the parameter estimates for the factor loadings, the health state values derived using
the EQ-5D, SF-6D and HUI-3 are synthesised using the model set out in Equations 5.17
– 5.40.
For any statistical analysis, it is important to assess how well the estimated model fits the
observed data. As such, the posterior mean of the residual deviance has been estimated,
given that this method is recommended for the assessment of model fit in evidence synthesis
applications involving Bayesian methods (Sutton et al., 2012). In addition, cross-validation
of the results has been undertaken in order to assess the degree to which the data from
different evidence sources are consistent. If there are prominent differences between the
results from different studies, then this may reduce confidence in the conclusions draw
from a synthesis of these results. Cross-validation involves omitting an individual study
from the analysis and then comparing the findings from the omitted study against the
predictive distribution from the analysis (Sutton et al., 2012). If the omitted data point
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is shown to lie within the random effects distribution obtained from the analysis, then it
is reasonable to assume that it is consistent with the remaining data.
5.3.4 Statistical Software
The meta-analytic models are estimated using the JAGS software, which is run through
the R program using the R2jags package (Su and Yajima, 2012). Each model is run with
three Markov chains over total of 10,000 iterations, the first 1,000 of which are discarded
as the burn-in period. For each method, the posterior distribution is fed directly into the
health economic model for the probabilistic sensitivity analysis. The factor loadings are
estimated using the Lavaan package in R (Rosseel, 2012). The relevant code for each of
the different methods can be found in Appendix B.
5.4 Results
Of the original forty-six values with health state description in the original study by Lung
and colleagues, five values were identified as meeting the inclusion criteria for the “reference
case” approach. An additional four values were identified as meeting the inclusion criteria
for the “all-inclusive” approach. These values are shown in Table 5.1. Note that additional
values were extracted from the NHMS study.
5.4.1 Evidence Synthesis
Three alternative methods for synthesising evidence were implemented to estimate HRQoL
parameter inputs. Model 5.1 combined evidence from six separate studies, all of which
collected EQ-5D values (the “reference case” approach). Models 5.2 and 5.3 used evidence
from an additional four studies that collected alternative PBMs (the “all inclusive” ap-
proach). The forest plot in Figure 5.1 provides a graphical representation of the summary
statistics from all of the studies selected for synthesis, as well as summary measures for
each of the synthesis methods evaluated. All of the estimates are on the EQ-5D scale,
including those from Glasziou et al. (2007), Maddigan et al. (2005) and Wee et al. (2005).
The parameter estimates obtained using the “all-inclusive” evidence (Models 5.2 and 5.3)
are consistently higher than those obtained using the “reference case” evidence (Model
5.1). In addition, the estimated impact of a MI upon HRQoL is reduced when the “all-
inclusive” evidence is used instead of the “reference case” evidence. This is likely to be
explained by the additional evidence from the study by Maddigan et al. (2005). The
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Table 5.1: HRQoL Values extracted from the study by Lung and colleagues (2011)
Study Sample Patient Instrument Mean Standard
Size Subgroup Estimate Error
UKPDS62 2,636 Diabetes, no EQ-5D 0.785 0.005
(2002) complications
Morgan et al. 360 Diabetes, no EQ-5D 0.735 0.015
(2006) complications
Redekop et 1,136 Diabetes, no EQ-5D 0.810 0.007
al. (2002) complications
Glasziou et 210 Diabetes, no SF-6D 0.780 0.009
al. (2007) complications
UKPDS62 200 Diabetes, EQ-5D 0.719 0.020
(2002) Post-MI
Morgan et al. 172 Diabetes, EQ-5D 0.676 0.042
(2006) Post-MI
Glasziou et 183 Diabetes, SF-6D 0.764 0.010
al. (2007) Post-MI
Wee et al. 46 Diabetes, SF-6D 0.770 0.019
(2005) Post-MI
Maddigan et 172 Diabetes, HUI-3 0.770 0.015
al. (2005) Post-MI
NHMS 479 Diabetes, no EQ-5D 0.712 0.014
complications SF-6D 0.755 0.007
HUI-3 0.675 0.015
parameter estimates obtained using the “all-inclusive” evidence also exhibit reduced un-
certainty when compared to those obtained using the “reference case” evidence. This
finding is particularly encouraging given that one of the main reasons for synthesising
evidence is the possibility of attaining increased statistical power for the estimation of
parameters (Higgins et al., 2009). Models 5.2 and 5.3 produce similar results with one
exception being the uncertainty surrounding the parameter representing the health state
’No Previous MI’. One possible explanation for this finding could be the fact that Model
5.3 has a larger number of unknown parameters.
The residual deviance for Model 5.1 has a posterior mean equal to 5.09 which is close
to the number unconstrained data points (N =5) used in the estimation of Model 5.1.
Similarly, the posterior mean of the residual deviance for Model 5.2 (D¯RES=9.12) is close
to the number unconstrained data points (N =10) used in the estimation of Model 5.2.
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These results do not indicate a lack of fit for Models 5.1 and 5.2. Residual deviance was
not estimated for Model 5.3 given that there are three dependent variables with lots of
missing data. For all three models, cross-validation of the results found the data from
different evidence sources to be consistent.
Figure 5.1: Forest Plot
5.4.2 Cost-Effectiveness Results
Tables 5.2 – 5.4 show the implications of using the different methods in terms of the
impact upon the expected cost-effectiveness results. Ideally, HEE for decision-making
purposes should investigate (a) whether a health intervention is expected to be cost-
effective based on existing evidence, and (b) whether or not additional evidence is required
to support its use (Griffin et al., 2011). In order to inform the first objective, researchers
can present probabilistic results from their cost-effectiveness model in a cost-effectiveness
acceptability curve (CEAC) (Briggs et al., 2006). The CEAC shows the probability of
an intervention being cost-effective for a given threshold value when compared to other
strategies. Figure 5.2 shows a series of CEACs associated with the various parameter
estimation methods assessed in this chapter. Comparison of the curves shows that the
choice of methodology has a negligible impact upon decision uncertainty for this particular
case study. This information is also presented in terms of error probabilities in Table 5.5,
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assuming threshold values of £20,000 per QALY and £30,000 per QALY respectively.
These results present the probability of making an incorrect decision, for a given patient,
on the basis of the expected cost-effectiveness results.
Table 5.2: Cost-Effectiveness Results Using Model 5.1 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £36,940 £32,188 £4,752
QALYs (discounted) 12.83 12.70 0.12
Cost-per-QALY - - £38,306
Table 5.3: Cost-Effectiveness Results Using Model 5.2 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £36,940 £32,188 £4,752
QALYs (discounted) 13.07 12.95 0.12
Cost-per-QALY - - £38,179
Table 5.4: Cost-Effectiveness Results Using Model 5.3 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £36,940 £32,188 £4,752
QALYs (discounted) 13.03 12.91 0.12
Cost-per-QALY - - £38,444
In order to inform the second objective, researchers can use their probabilistic results
to estimate the expected value of perfect information (EVPI). The EVPI puts an upper
bound estimate on the value of resolving the decision uncertainty. Figure 5.3 shows that
the choice of methodology also has little impact upon the EVPI. However, the additional
evidence exploited with the “all-inclusive” approach appears to have slightly reduced the
cost of the decision uncertainty over the threshold range associated with NICE decisions
(i.e. 20, 000−30,000 per QALY (NICE, 2013)). Despite the lack of variability in the
cost-effectiveness results, it is important to remember that these findings are case study
dependent. Additional analyses in Appendix C show that the impact of HRQoL is rela-
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tively modest in the RITA-3 model.
Table 5.5: Error Probabilities
Threshold = £20K Threshold = £30K
Model 5.1 0.070 0.262
Model 5.2 0.057 0.265
M0del 5.3 0.051 0.276
Figure 5.2: Cost-Effectiveness Acceptability Curves
5.5 Discussion
The aims of this chapter were to (a) identify the methodological challenges unique to
scenario D1, and (b) to compare HRQoL parameter estimates, derived using an “all-
inclusive” approach to evidence synthesis with SEM methods, against those obtained using
a “reference case” approach to evidence synthesis with standard meta-analytic methods.
Two separate approaches involving SEM techniques for the synthesis of heterogeneous
HRQoL evidence were proposed, both of which rely upon the assumption of fixed factor
loadings across studies. The two methods differed in terms of the point at which these
factor loadings were applied to map between outcomes. A two-step method separated
the mapping and evidence synthesis procedures, while an integrated approach conducted
these tasks simultaneously. Of the two methods proposed, the integrated method would
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Figure 5.3: Expected Value of Perfect Information
appear to be the logically correct approach insofaras it employs a single model to explain
all aspects of the available data. The implementation of this method was made possible,
in large part, thanks to the flexibility allowed by the Bayesian framework. However, the
integrated approach has a greater number of unknown parameters and so is more likely to
be affected by the choice of priors. Moreover, the additional complexity with the integrated
method may create problems when it comes to the interpretation of results.
The additional evidence incorporated with the “all-inclusive” approach in this study did
not have a substantial impact upon the parameter estimates compared to the “reference
case” approach. However, it is important to acknowledge that these findings are case study
dependent and, thus, should not be used to make conclusions about the benefits of the
SEM evidence synthesis methods in general. These methods are likely to be particularly
important where generic instruments, such as the EQ-5D, are subject to measurement error
in the estimation of population parameters. For instance, HRQoL parameter estimates
may be susceptible to noise occurring as a result of unrelated comorbidities. In scenarios
such as these, parameter estimates derived solely using evidence pertaining to the reference
case measure may exhibit a high degree of imprecision depending upon the combined
sample size of patients. Increasing the sample size, through the inclusion of evidence
relating to alternative HRQoL measures, provides greater statistical power to detect the
true population values. Consequently, any improvements in the precision with which these
parameters are estimated could potentially result in reduced decision uncertainty.
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A key priority for future research will be to undertake simulation exercises to fully under-
stand the mechanisms at work. The benefit of simulation exercises is that the researcher
has full control over all of the underlying parameters feeding into the model. However, even
if the “all-inclusive” approach had shown a more substantial impact upon the parameter
estimates compared to the “reference case” approach, this would not have necessarily had
an impact upon the cost-effectiveness results. The EVPPI results presented in Appendix
C show that the impact of HRQoL is modest in the RITA-3 model. This means that the
choice of method for the estimation of HRQoL parameters is unlikely to have a substantial
impact upon the decision uncertainty for this study and, thus, would be unlikely to have
any implications for policy decision-making. It is important to note that the influence of
HRQoL parameters within a given decision model is a function of the model structure,
as well as the other model parameters, and is therefore also case study dependent. In
practice, researchers are unlikely to know the extent to which HRQoL parameters will
influence cost-effectiveness prior to construction of a model. As such, this issue would
not constitute grounds for assessing whether or not to pursue implementation of these
methods.
Thus far, the discussion around uncertainty has focused upon the implications for pa-
rameter estimation of conducting evidence synthesis with SEM methods. The adoption
of these methods also has important implications for structural uncertainty and method-
ological uncertainty in decision modeling for health economic evaluation. Methodological
uncertainty occurs when there is disagreement over the most appropriate methodological
approach (Briggs and Gray, 1998). One issue contributing to methodological uncertainty
regarding the use of the SEM approach to evidence synthesis is the lack of consensus
regarding the indirect estimation of HRQoL effects (i.e. mapping). As previously men-
tioned, mapping has traditionally been seen as a second-best option for the estimation
of preference-based HQRoL values, when compared to the collection of values first hand
(NICE, 2008). Taking this stance would imply that non-reference case HRQoL evidence
should only be considered where directly relevant reference case evidence is not available.
Of course, there are counterarguments that could be made against this position, not least
the potential benefits of estimating parameters with greater precision. Moreover, one
could point to the fact that there are other parameter estimation techniques employed in
health economic evaluation that rely upon indirect evidence, i.e. treatment comparisons
(Sutton et al., 2012).
Structural uncertainty refers to forms of uncertainty characterised in other ways from those
already mentioned (i.e. not parameter or methodological uncertainty), including the sta-
72
tistical methods selected to estimate model parameters (Bojke et al., 2009). The LISREL
approach, employed in Models 5.2 and 5.3, assumes that outcome measures are linearly
related to one another and that the outcomes are normally distributed. It is important
to recognise that the validity of these structural assumptions has been questioned in the
context of HRQoL research (Alava et al., 2012; Basu and Manca, 2012). However, there
is currently a lack of clarity as to the methods that should be used to evaluate structural
uncertainties (Bojke et al., 2009). Future research should investigate the plausibility of
alternative model specifications that are better suited to the handling of HRQoL outcome
measures.
It is important to consider that the evidence selected for synthesis in this chapter was ob-
tained from an existing review. This limited the case study to a synthesis exercise involving
three preference-based measures of HRQoL. In theory, the SEM methods for evidence syn-
thesis would allow researchers to draw upon the wealth of non-preference-based HRQoL
measures available. As well as synthesising a broader range of outcome measures, the SEM
methodology is capable of estimating parameters with greater precision by incorporating
disease-specific outcome measures. A recent study by Ades and colleagues illustrated how
this might be achieved using SEM-type mapping techniques (Ades et al., 2013). Of course,
the inclusion of disease-specific measures would have important implications for the identi-
fication of HRQoL evidence given that the range of outcomes would vary according to the
patient population of interest. Further empirical research is needed to demonstrate this
potential and also establish how these considerations would be integrated within a search
strategy. For instance, this could encompass a scoping process prior to the commencement
of the literature search to identify all relevant outcome measures. For certain conditions,
research may have even been conducted already to determine which patient-reported out-
comes are appropriate for the measurement of HRQoL (Gibbons et al., 2014; Hadi et al.,
2010; Mackintosh et al., 2009).
The empirical work outlined in this chapter is not without limitations. The case study in
this chapter assumes a scenario where researchers can obtain a sample covariance matrix
from an existing study. The plausibility of such information being readily accessible in the
published literature has been debated elsewhere (Riley et al., 2014; Wei and Higgins, 2013).
In practice, implementation of the SEM meta-analytic techniques is likely to rely upon the
availability of IPD containing all of the relevant outcomes of interest. The availability of
evidence in IPD format affords researchers analytical opportunities beyond the LISREL
method. These opportunities are considered further in chapters 5 and 6.
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Chapter 6
Case Study II: Synthesis of
Individual Patient Data
6.1 Introduction
The previous chapter demonstrated how to use structural equation modeling techniques
for the synthesis of heterogeneous HRQoL evidence from the published literature. An em-
pirical case study showed that the SEM approach was able to exploit additional evidence
compared to the ‘reference case’ approach, and, consequently, reduce the uncertainty sur-
rounding the HRQoL parameter estimates. This finding was encouraging given that one
of the main reasons for synthesising evidence is the possibility of attaining increased sta-
tistical power for the estimation of parameters (Higgins et al., 2009). This work raises
important questions regarding the appropriate range of outcome measures to consider
when searching for HRQoL evidence. Given that Chapter 5 only considered scenarios
involving aggregate data, the analytical techniques were limited to the use of summary
scores or index values.
The benefits of having access to individual-patient data for the purposes of synthesising
HRQoL data with SEM techniques – in particular, the ability to exploit item-level informa-
tion – have yet to be demonstrated in the context of health economic evaluation. Only one
study has been found to employ an SEM-type approach, specifically a multidimensional
item response theory (IRT) method, to analyse preference-based measures of HRQoL at
the item level (Gibbons et al., 2014). This study showed that the multidimensional IRT
model performed well in terms of its ability to predict EQ-5D scores compared to tradi-
tional regression methods. Despite showing early promise, the predictive performance of
this approach has yet to be externally validated.
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This chapter presents an empirical case study involving the estimation of HRQoL input
parameters for a decision model derived through the analysis of heterogeneous PROs at
the item-level data using SEM techniques. The aims of the chapter are threefold: first, to
provide an outline of the factors that require consideration when utilizing these techniques
specifically for the purposes of CEA. The second aim is to demonstrate how parameter
estimates derived using heterogeneous outcome measures differ from those solely relying
upon the reference case. And finally, this chapter looks to explore how parameter estimates
derived via item-level analyses compare to those from analyses involving index scores at
the aggregate level.
6.2 Background
There are several factors motivating the decision to focus on the development of meth-
ods that make use of item-level responses to PROs rather than index or summary scores.
First, it has been suggested that item-level analyses are superior on the grounds of their
interpretability; in contrast, analyses involving index values have been criticized because
they conflate information about patient responses with the preference weightings (Parkin
et al., 2010). Second, and related to the previous point, is the fact that item-level analyses
exploit the detail of the available data. In particular, it would seem preferable to acknowl-
edge impacts occurring at the item level that could be easily overlooked when dealing with
index or summary scores. Finally, item-level analyses would be preferable for the purposes
of this chapter in the interests of developing a generalizable framework. Although a range
of sophisticated analytical approaches have been developed for the analysis of index values,
these may need to be tailored to handle the specific characteristics of the instrument and
value set under evaluation (Alava et al., 2012).
The primary interest of this chapter lies in the development of methods capable of han-
dling ‘Likert-type’ responses to descriptive questionnaires that ask individuals to select
one category form several options available (e.g. strongly disagree, agree, neither agree
nor disagree, disagree, strongly disagree). With this in mind, it would seem logical to
investigate methods for analysing ordinal variables given that these responses exhibit a
natural ordering. The assumption of linear dependence between observed variables and
a latent factor, made in the previous chapter, is no longer appropriate in this context
since it does not account for the discrete nature of the data. This problem can be circum-
vented, however, by looking at the item responses in terms of the probability or odds of a
particular response being selected.
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When thinking about the development of structural equation models for the investigation
of ordinal, categorical variables, a useful starting point is to consider the latent factor.
Despite the observed variables being categorical, it is often more convenient to treat the
latent factor as being a continuous variable and to assume a non-linear relationship with
the observed variables. This relationship is built upon an assumption that each of the
observed categorical variables, known as indicators, has a separate underlying continuous
scale (referred to here as the latent response scale). For a given indicator, each individual
is assumed to lie somewhere on the latent response scale and it is the location on this
scale that determines the observed category selected. Each of the latent response scales
are assumed to have an associated distribution and the aim of the model is to investigate
the extent to which a hypothesized latent factor accounts for correlations between these
distributions.
Correlations between ordinal variables, such as those involving Likert-type responses to
questionnaires, can be estimated using polychoric methods (Edwards et al., 2012). The
latent response scales are assumed to follow a normal distribution, where the area under the
curve represents the proportion of patients realizing a given response level. Distributions
are constructed for each of these scales by assigning threshold values defining the point
at which people change their selected response category. These values typically represent
points on the standard normal distribution and can be used to approximate the proportion
of patients in each category using the cumulative distribution function.
6.2.1 Model Specification
In the previous chapter, the process of model specification was simple to the extent that
it only entailed a single latent factor. With the additional item-level information that is
gained from having access to patient-level data, there is potential for greater complexity
when specifying the underlying constructs. In order to consider the issue of latent factor
specification, let us consider an illustrative example. Supposing that we are interested in
developing an SEM to capture the shared variance between two outcome measures, the
EQ-5D and a hypothetical disease-specific measure with five indicators, each with three
category responses. To start with, consider the assumptions implied by a model with
containing a single latent factor defined by all of the indicators across the two instruments,
shown in Figure 6.1. The variability of each indicator is separated into two components:
1) the variability due to the latent factor and 2) unexplained error variance (represented
by the ε terms).
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Figure 6.1: Graphical Representation of a Unidimensional Model
For estimation involving a probit link, the model can be represented using the following
formula from Bovaird and Koziol (2012):
Pr(yij = 1) = Φ(−τ1,j + λj · fi) (6.1)
Pr(yij = 2) = Φ(−τ2,j + λj · fi)− Φ(−τ1,j + λj · fi) (6.2)
Pr(yij = 3) = 1− Φ(−τ2,j + λj · fi) (6.3)
Where yij represents individual i’s response to item j, fi is individual i’s latent factor
score and λj is the factor loading for item j. The τk,j terms are thresholds indicating the
point on the latent factor response scale where individuals switch their item response. Φ
is the standard cumulative distribution function. These formulae show the probability of
an individual selecting each of the possible item responses.
Crucially, this model in Figure 6.1 assumes that the error terms are independent of one
another. One might question this assumption if there are concerns about multidimen-
sionality especially in the presence of well-defined clusters of items. An alternative model
specification that researchers might consider for scenarios involving multidimensionality in
addition to a common trait is the bi-factor model (Reise, 2012). An example is provided
in Figure 6.2 that assumes clustering is present at the instrument level. Conceptually,
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Figure 6.2: Graphical Representation of a Bifactor Model
this model posits that one general variable explains common variance in all of the items
but beyond that there is some instrument-specific variability left over. The variability
of each indicator is now separated into three components: 1) the variability due to the
general factor, 2) the variability due to the measure-specific factor (EQ5D or DSM), and
3) unexplained error variance.
In the study by Gibbons and colleagues, a bi-factor IRT model was specified containing one
primary dimension, loading on all of the items, and two scale-specific dimensions, loading
on EQ-5D and SF-12 items respectively. The same study also conducted a separate analysis
using a unidimensional model (i.e. without the scale-specific latent factors) and compared
the fit of the two models using a likelihood ratio Chi-squared statistic. This test found an
improvement in fit with the bi-factor model compared to the unidimensional model.
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6.2.2 Estimation of Parameter Inputs
As with the previous chapter, there are two plausible approaches for the estimation of
CEA inputs, a CFA method and a SEM method. Once again, the former is essentially a
mapping procedure that aims to predict the reference case outcome measure in datasets
where this measure has not been collected. However, the task of deriving predictions with
a CFA mapping algorithm is far more complex when dealing with item-level responses,
compared to index/summary scores. This is because the availability of multiple observed
items, representing a given construct of interest, introduces a dimensionality problem.
Latent variable scoring methods are required in order to reduce the dimensionality and
obtain a unique factor score for each individual. Using the parameter estimates from the
CFA model, one can predict the position of a patient on the latent factor scale even if there
is only a subset of the items in the original model. Subsequently, one can then use the
factor score estimate in combination with the parameter estimates for the missing items
to predict responses for those items.
While there are a range of alternative methods for assigning values to latent variables, the
most popular is the Empirical Bayes (EB) method (see for instance, Skrondal and Rabe-
Hesketh (2004)), also known as the ‘expected a posteriori’ (EAP) predicator. This method
can be implemented in the Mplus software package (Muthe´n and Muthe´n, 2010), using the
GSEM package for Stata (StataCorp, 2013) and using the Lavaan package for R (Rosseel,
2012). The EB method derives a posterior mean prediction of the latent variable (fˆi) for
each individual in the sample using their observed responses to each of the indicators (yij)
in combination with parameter estimates from the CFA (λj ,τk,j) as follows:
fˆi = E(fi|yij ;λj ; τk,j) (6.4)
Whilst this method is actually a Frequentist technique, its name refers to the fact that it
utilizes Bayesian principles when interpreting the latent variable in terms of a posterior
distribution. A fully Bayesian approach differs from the EB method given that it would
interpret both the latent variable and the parameter estimates in terms of a posterior
distribution.
Another challenge associated with the CFA prediction method is the fact that most soft-
ware packages are set up to obtain factor scores in the same sample used to fit the original
model. Although this makes the task of obtaining predictions for individuals missing the
reference case items more complicated, there are two ways in which this problem can be
circumvented. The first, implemented by Gibbons and colleagues, involves combining all
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of the datasets of interest before fitting the CFA under the assumption of missing data
for those individuals for whom the reference case items have not been collected. The full
information maximum likelihood (FIML) estimation method ensures an efficient and un-
biased utilization of all of the available information when fitting the CFA (Graham and
Coffman, 2012).1 By fitting the model with data that includes observations missing the
reference case items, it is possible to estimate factor scores for these cases.
Although the FIML-estimation method provides an elegant and efficient solution for the
utilization of observations with missing data, the software options currently available do
not enable an adequate characterization of parameter uncertainty. Cost-effectiveness mod-
els are typically expected to use probabilistic sensitivity analysis (PSA) to capture the
impact of parameter uncertainty upon the cost-effectiveness results (Briggs et al., 2006).
HRQoL parameter estimates derived using the techniques considered in this chapter are
subject to two sources of uncertainty: the unexplained heterogeneity surrounding the un-
derlying latent factor, and the uncertainty surrounding the factor loadings. In principle,
both forms of uncertainty could be captured within a PSA but, unfortunately, none of the
software options available are capable of incorporating the latter.
Given the current software available, a second-best approach for obtaining factor scores
is required to capture all of the possible sources of parameter uncertainty. An alternative
method would be to fit the CFA using only the complete case observations and then,
with the incomplete data, fit subsequent models with parameter estimates fixed to those
from the first analysis. Crucially, the subsequent models need to have free parameters
associated with the latent variable (mean and variance) in order to permit the estimation
of factor scores. Once factor scores have been obtained for those observations missing the
reference case items, they can be used to predict the expected responses to these items
using the relevant factor loadings and threshold values from the complete case analysis.
The previously mentioned issues in dealing with categorical data mean that item-level
responses are predicted in terms of the probability of a particular response being selected.
These probabilities can then be used, in combination with the index weightings of the
associated instrument, to estimate the expected HRQoL index scores for each patient (Le
and Doctor, 2011). In order to capture uncertainty surrounding the factor loadings and
threshold values, the process of obtaining factor scores and then using these scores to
predict the expected HRQoL index values must be incorporated within the probabilistic
sensitivity analysis. A stochastic process is employed using the standard errors associated
with the CFA parameter estimates.
1Assuming that data are missing completely at random
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The SEM approach to parameter estimation differs from the CFA approach in that it is
not concerned with the prediction of factor scores at the observation level. It employs
almost exactly the same model specification as the CFA approach but with the addition
of a structural component capturing the impact of covariates upon the latent variable (also
known as a path analysis). As such, the SEM approach to HRQoL parameter estimation is
possible via prediction of the expected latent factor distribution conditional upon patient
characteristics. Given that the SEM approach is not concerned with the prediction of
scores at the observation level, the model can be fit to a combined dataset that includes
incomplete cases using the FIML estimation procedure. This approach allows the predic-
tion of a latent factor distribution for a given patient profile, as specified by the covariates
in the SEM.
Using the latent factor distribution, item-level responses can be predicted for a given
patient profile. In this chapter, a Monte Carlo simulation procedure will be employed in
order to predict item-responses using the parameter estimates obtained from the SEM. As
with the CFA approach, it is important to ensure that the uncertainty surrounding the
parameter estimates in the statistical model has been acknowledged. A stochastic process
is implemented involving all of the parameters involved in the SEM. The simulation sample
should be sufficiently large to ensure that the latent factor distribution is adequately
represented. Once the simulation sample has been predicted the valuation weights can
be assigned in order to derive HRQoL index values, after which one can calculate the
associate mean and standard deviation.
6.3 Methods
The case study in this chapter is composed of two stages. In the first stage, HRQoL param-
eter inputs are derived using one of the alternative estimation techniques. In the second
stage, the parameter estimates are fed into the model and cost-effectiveness estimates are
obtained for each of the alternative methods. The case study selected investigates the
cost-effectiveness of an early surgical intervention compared to medical management for
the treatment of acute coronary syndrome in a patient subgroup with diabetes.
6.3.1 HRQoL Evidence
As with the previous chapter, this case study aims to estimate HRQoL values associated
with two defined health states: one for patients with diabetes who have yet to experience
a myocardial infarction and another for patients with diabetes who have experienced a
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myocardial infarction. Data from four studies that collected PROs for the measurement
of HRQoL in relevant patient subgroups were obtained.
The National Health Measurement Survey (NHMS) was conducted in the United States
and collected a variety of measures of HRQoL, including the EQ-5D, HUI-3 and the SF-
36, in a sample representative of the general population (Fryback et al., 2007). The
Medical Expenditure Panel Survey (MEPS) data collected the EQ-5D and the SF-12 in
a nationally representative sample of the United States in 2003 (Sullivan et al., 2011).
The Welsh Health Survey (WHS) collected the SF-36 in a representative sample of people
living in private households in Wales in 2013 (NatCen Social Research, 2013). Finally,
the Randomized Intervention Trial of unstable Angina (RITA-3) collected the EQ-5D in
a sample of patients diagnosed with acute coronary syndrome (Kim et al., 2005).
Whilst the EQ-5D may have been collected in the MEPS dataset, we will be assuming that
it is not available for illustrative purposes. Instead, EQ-5D responses will be predicted
using the available SF-12 data via the SEM approach. The reasoning behind this approach
is that it allows us to test the external validity of the SEM predictions (i.e. compare the
predicted EQ-5D scores against the actual scores).
6.3.2 Health Economic Model
The health economic model employed is the same as that used in Chapter 4, where further
details describing this model can be found.
6.3.3 Estimation of Parameter Inputs: CFA Approach
The CFA approach is implemented by first fitting a bi-factor model to the NHMS data.
This dataset is selected on the grounds that it is the only one containing all of the PRO
items of interest. The bi-factor model contains three latent variables: a common factor
explaining all of the items for the EQ-5D and the SF-12; an EQ-5D-specific factor explain-
ing the EQ-5D items; and a SF-12-specific factor explaining the SF-12 items. Once this
model has been fitted, the resulting parameter estimates are used in subsequent analyses
to obtain latent factor scores in the datasets without the EQ-5D as follows:
• In order to estimate factor scores for patients in the MEPS dataset a single factor model
explaining all of the SF-12 items is specified. Estimated factor loadings that explain SF-
12 item responses in terms of the common factor are taken from the NHMS analysis and
used as fixed parameters in this model, which is then fitted to the MEPS dataset. Once
this model has been fitted, latent factor scores can be predicted using the Empirical
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Bayes (EB) method. These factor scores, in combination with the parameter estimates
from the NHMS analysis, can be used to predict the expected EQ-5D responses and
index values.
• In order to estimate factor scores for patients in the WHS dataset a single factor model
explaining all of the SF-12 items is specified. Although SF-36 responses were collected
in this dataset, there were concerns that differences in the items responses between the
NHMS and WHS datasets would lead to invalid predictions. There were substantial
differences between the NHMS and WHS datasets in terms of subjects’ responses to
questions 33 through to 36 on the SF-36. In the NHMS data, fewer than 2% of subjects
were found to select a “Don’t know” response in these questions; in contrast, between
15 – 35% of subjects selected this response in the WHS data. For this reason, it was
felt that it would be more appropriate to select the items corresponding to the SF-12
instrument and employ the same method as that with the MEPS data.
The predicted EQ-5D values can be used to derive inputs for the cost-effectiveness model.
These are the sample moments (mean and standard deviation) associated with the two
health states captured in the cost-effectiveness model: one for patients with diabetes who
have yet to experience a myocardial infarction and another for patients with diabetes
who have experienced a myocardial infarction. Note that the aforementioned methods
only provide parameter estimates for a deterministic cost-effectiveness analysis. For the
purposes of a probabilistic analysis, the steps undertaken to estimate latent factor scores
and, subsequently, predict EQ-5D responses need to be implemented via a stochastic
process.
6.3.4 Estimation of Parameter Inputs: SEM Approach
The model specification of the SEM approach is essentially the same as that in the CFA
approach with the addition of a structural component capturing the impact of patients
having experienced a MI. In contrast to the CFA approach, this model is fit to a sample
combining the all of the datasets. In order to make use of observations that have missing
data, a FIML estimation procedure is employed. The estimated model captures a latent
factor distribution associated with each of the health states of interest, which can be
subsequently used to predict item-level responses using Monte Carlo simulation methods.
As with the CFA approach, a stochastic process is necessary in order to capture the
uncertainty surrounding the factor loadings and threshold values. Moreover, to ensure
that the predicted item responses reflect the latent factor distribution, a large number of
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simulations are run (100,000 for each health state). Model inputs can then be obtained
by calculating the means and standard deviations for each of the simulated samples.
6.3.5 Estimation of Parameter Inputs: Reference Case Approach
An additional analysis was undertaken to estimate HRQoL parameter inputs solely using
EQ-5D. Estimation of the HRQoL input parameters simply involved calculating the means
and standard deviations for the two groups of patients in a sample comprised of data from
the RITA-3 and NHMS studies.
6.3.6 Statistical Software
The CFA approach to parameter estimation was implemented in the R software program
using the Lavaan package. For the SEM approach, the initial model was fitted using
Mplus software package and implemented using the FIML procedure for handling missing
data. The cost-effectiveness model inputs were subsequently obtained by simulating the
expected responses to the EQ-5D based upon the initial model using the Simsem package in
R (Pornprasertmanit et al., 2013). For each of the different methods, a stochastic process
was implemented to capture the uncertainty surrounding these estimates. The subsequent
parameter estimates are then fed into the RITA-3 health economic model, also built in
R. A total of 3,000 simulations are run in the probabilistic sensitivity analysis to derive
the probability of the intervention being cost-effective for a given threshold. Measures for
comparison of model fit, such as the Akaike information criterion, are unsuitable in this
case study given that these methods are used to compare model fit for a given dataset.
Even though the alternative SEM approaches are applied to the same data, information
criteria comparisons would not be of any use given that one approach uses a single model
to simultaneously map and synthesise evidence whilst the other does this in two separate
stages.
6.4 Results
6.4.1 Descriptive Statistics
Table 6.1 provides descriptive statistics for each of the datasets used in this empirical
exercise. There are noticeable discrepancies between the samples grouped according to
health state description (i.e. whether or not patients have experienced a previous MI),
both in terms of the age and gender composition. If there is reason to believe that such
imbalances may bias the parameter estimates, it is important that statistical techniques are
84
employed to control for them. Previous research has shown that HRQoL varies according
to both age and gender (Ara and Brazier, 2010; Kind et al., 1999).
Table 6.1: Descriptive Statistics
NHMS MEPS WHS RITA-3
No MI No MI Post MI No MI Post MI No MI Post MI
Total
Sample
552 1,335 189 875 150 156 88
Analysis
Sample
520 1,228 175 729 105 156 88
Age 63.6 58.9 67.9 61.8 68.6 64.2 63.9
% Male 0.41 0.40 0.58 0.56 0.64 0.57 0.66
6.4.2 Model Results: The CFA Approach
The factor loadings for the bi-factor CFA model, fitted to the NHMS data, are presented in
Table 6.2. These values show the extent to which each of the items are correlated with the
associated latent factor; a higher factor loading estimate corresponds to a higher degree of
correlation with the factor loading. For the purposes of HRQoL parameter estimation, the
loadings on the CF latent variable are of primary interest. Increases on the latent factor
scale reflect decreases in HRQoL. As such, items with responses ordered in a way to reflect
diminishing health – e.g. the items of the EQ-5D having the best health states coded as
1 and the worst as 3 – are shown to have positive factor loadings. Conversely, those items
with responses ordered to reflect improved health have negative factor loadings.
The item threshold values for the bi-factor CFA model can be found in Appendix E. These
estimates can be interpreted as reflecting the item difficulty; how far away from the mean
on the latent factor scale, at zero, does an observation need to be to give rise to a change
in the item response. Whilst interpreting these estimates might be challenging, especially
given that they reflect values on the standard normal distribution, they can be converted
into probabilities using the cumulative normal distribution function.
A chi-squared test of model fit was employed to explore whether or not the multi-dimensional
assumption seems reasonable. The result (p=0) suggests that it would be reasonable to
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assume that the bi-factor model fits the data better than a uni-dimensional approach.2 To
ensure comparability of the modelling techniques explored in this chapter, the bi-factor
CFA model was run in Mplus, as well as R, and the results were shown to be equivalent.
Table 6.2: CFA Approach - Factor Loadings
Indicator Latent Factor 1 Latent Factor 2 Latent Factor 3
(CF) (SF-12) (EQ-5D)
SF36 Q1 0.55 0.14 0.00
SF36 Q2 -0.84 -0.24 0.00
SF36 Q3 -0.77 -0.19 0.00
SF36 Q4 -0.72 -0.34 0.00
SF36 Q5 -0.82 -0.37 0.00
SF36 Q6 -0.81 0.30 0.00
SF36 Q7 -0.76 0.29 0.00
SF36 Q8 0.83 0.06 0.00
SF36 Q9 0.58 -0.35 0.00
SF36 Q10 0.69 -0.05 0.00
SF36 Q11 -0.76 0.40 0.00
SF36 Q12 -0.77 0.80 0.00
EQ5D Q1 0.75 0.00 0.41
EQ5D Q2 0.77 0.00 0.25
EQ5D Q3 0.87 0.00 0.38
EQ5D Q4 0.74 0.00 0.37
EQ5D Q5 0.81 0.00 -0.25
6.4.3 Model Results: The SEM Approach
The model specification for SEM approach is essentially the same as that for the CFA
approach except for the addition of a structural component included to capture the im-
pact of a myocardial infarction upon the common factor CF. Following initial concerns
that imbalances in patient characteristics might bias the estimated impact of a MI, three
additional control variables were included in the structural component: one for gender
and two dummy variables for age categories (one for subjects between 50 and 80 years old
and another for those patients over 80 years old).
Table 6.3 shows the factor loadings and regression coefficients capturing the impact of
the aforementioned covariates upon the latent factor CF. Increases on the scale of the
2We can reject a null hypothesis that inclusion of instrument-specific factors does not significantly
improve model fit.
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latent variable CF reflect improvements in HRQoL. The factor loadings have remained
remarkably similar to those obtained with the CFA approach. The latent factor CF is
estimated to be over half a standard deviation lower in those subjects who have previously
had an MI compared to those subjects who have never experienced an MI. Moreover, factor
scores are estimated to be higher in men and lower with increasing age. An additional
model was fitted that did not control for age and gender to compare the coefficients for
the MI variable.
Table 6.3: SEM Approach - Factor Loadings
Indicator Latent Factor 1 Latent Factor 2 Latent Factor 3
(CF) (SF-12) (EQ-5D)
SF36 Q1 -0.70 0.07 0.00
SF36 Q2 0.86 -0.23 0.00
SF36 Q3 0.83 -0.26 0.00
SF36 Q4 0.89 -0.19 0.00
SF36 Q5 0.93 -0.20 0.00
SF36 Q6 0.80 0.48 0.00
SF36 Q7 0.78 0.39 0.00
SF36 Q8 -0.81 0.11 0.00
SF36 Q9 -0.59 -0.30 0.00
SF36 Q10 -0.71 -0.04 0.00
SF36 Q11 0.66 0.39 0.00
SF36 Q12 0.82 0.11 0.00
EQ5D Q1 -0.72 0.00 -0.52
EQ5D Q2 -0.71 0.00 -0.31
EQ5D Q3 -0.80 0.00 -0.40
EQ5D Q4 -0.61 0.00 -0.08
EQ5D Q5 -0.68 0.00 0.24
MI -0.67 0.00 0.00
Age (50 - 80) -0.16 0.00 0.00
Age (80+) -0.41 0.00 0.00
Gender (Male) 0.36 0.00 0.00
As with the CFA approach, a chi-squared test of model fit was employed to explore whether
or not the multi-dimensional assumption seems reasonable. Once again, the result (p=0)
suggests that it would be reasonable to assume that the bi-factor model fits the data better
than a uni-dimensional approach.
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6.4.4 Parameter Estimates
Table 6.4 shows the estimated HRQoL parameter inputs for the cost-effectiveness model
derived. There are clear differences between the estimates derived using heterogeneous
outcome measures (Models 6.2 and 6.3) compared to those that solely relied upon the
reference case measurement (Model 6.1). The parameter inputs derived for Model 6.1 show
that increases in age are associated with improvements in HRQoL. This counterintuitive
finding is likely to be caused by the unusual associations between age and HRQoL in the
RITA-3 data (Mahon, 2014). In addition, this finding may go some way in explaining why
these estimates are so much higher than those for Models 6.2 and 6.3.
Although similar, the discrepancies between estimates from Models 6.2 and 6.3 are likely
to be driven by the different methods used to account for covariates. In Model 6.2, EQ-
5D predictions were obtained for the MEPS and WHS datasets before the impact of the
covariates (MI, age and gender) were derived using a pooled sample using these predicted
values in combination with the observed EQ-5D values (from the RITA-3 and NHMS
datasets). In contrast, Model 6.3 accounted for the impact of the covariates upon the
latent factor first and then EQ-5D predictions were derived for each patient profile.
Table 6.4: Mean HRQoL Parameter Inputs
No Previous MI Post MI
50 - 80 years 80 years + 50 - 80 years 80 years +
Model 5.1 0.742 0.759 0.574 0.592
Model 5.2 0.671 0.593 0.502 0.424
Model 5.3 0.640 0.605 0.533 0.480
Model 5.4 0.647 0.513
In addition to looking at the expected EQ-5D values for model inputs, it is important
to also consider the impact of the alternative synthesis methods upon the uncertainty
associated with these values. In the case of the inputs derived via Models 6.1, 6.2 and
6.4, the uncertainty associated with the expected values is a function of the standard
errors surrounding the parameter estimates listed in Tables 6.2 and 6.3 (i.e. those for the
factor loadings, threshold values and structural components). The forest plot in Figure
6.3 provides a graphical representation of the estimated EQ-5D distributions for all of the
patient profiles defined in the RITA-3 model, which were obtained in the probabilistic
sensitivity analysis.
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Figure 6.3: HRQoL Parameter Estimates
Whilst the figures suggest that the uncertainty associated with the model inputs is lowest
when statistical Model 6.4 is employed, the results from this model are not directly compa-
rable to the other methods given that there were fewer covariates utilized (age and gender).
It may be that the lack of adjustment for these covariates partially explains the reduced
uncertainty compared with the other methods presented. The simulations obtained from
statistical Model 6.2 exhibited reduced uncertainty compared to those from the reference
case approach (Model 6.1). This was particularly pronounced for the inputs associated
with patients aged 80 years or older. However, comparison of the results for Models 5.1
and 5.3 would suggest that the impact of additional, non-reference case evidence has an
ambiguous effect upon the uncertainty surrounding the HRQoL inputs.
6.4.5 Predictive performance
The external validity of Model 6.2, estimated using the NHMS data, was verified by
comparing EQ-5D predictions against observed EQ-5D values in the MEPS dataset. Table
6.5 shows that the predictive performance of Model 6.2, measured using the mean squared
error, is superior overall to that of the common factor model approach, first proposed by
Lu and colleagues (2013), across most of the EQ-5D distribution.
6.4.6 Cost-Effectiveness Results
The differences between parameter estimates obtained via the different synthesis tech-
niques only really matter if they give rise to substantial differences in the cost-effectiveness
estimates used to inform the associated reimbursement decisions. In view of that, parame-
ter estimates from statistical Models 6.1 to 6.4 were utilized in the RITA-3 model in order
to explore the impact of the methodological differences upon the cost-effectiveness results.
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Table 6.5: Mean Predictive Performance (MEPS data)
CFM Bi-factor CFA
Whole Sample 0.059 0.046
EQ-5D ≤ 0 0.096 0.084
0 < EQ-5D ≤ 0.25 0.053 0.075
0.25 < EQ-5D ≤ 0.5 0.063 0.072
0.5 < EQ-5D ≤ 0.75 0.064 0.049
0.75 < EQ-5D ≤ 1 0.049 0.028
Tables 6.6 – 6.9 show the implications of using the different methods in terms of the im-
pact upon the expected cost-effectiveness results. In addition, four separate probabilistic
sensitivity analyses were run, one for each of the statistical models, the results of which
have been presented in the form of cost-effectiveness acceptability curves in Figure 6.4. .
This information is also presented in terms of error probabilities in Table 6.10, assuming
threshold values of £20,000 per QALY and £30,000 per QALY respectively. These results
present the probability of making an incorrect decision, for a given patient, on the basis of
the expected cost-effectiveness results. Finally, the expected value of perfect information
was estimated for each of the statistical models and curves presenting this information can
be found in Figure 6.5.
Table 6.6: Cost-Effectiveness Results Using Model 6.1 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £39,940 £32,188 £4,752
QALYs (discounted) 12.34 12.21 0.13
Cost-per-QALY - - £36,163
Table 6.7: Cost-Effectiveness Results Using Model 6.2 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £39,940 £32,188 £4,752
QALYs (discounted) 11.00 10.88 0.12
Cost-per-QALY - - £39,960
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Table 6.8: Cost-Effectiveness Results Using Model 6.3 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £39,940 £32,188 £4,752
QALYs (discounted) 11.12 11.00 0.12
Cost-per-QALY - - £39,198
Table 6.9: Cost-Effectiveness Results Using Model 6.4 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £39,940 £32,188 £4,752
QALYs (discounted) 10.76 10.65 0.11
Cost-per-QALY - - £42,054
One notable observation in each of these figures is the close proximity of the curves involv-
ing heterogeneous HRQoL evidence (Models 6.2, 6.3 and 6.4). Moreover, Figure 6.4 shows
that the uncertainty surrounding the decision in question is reduced in these cases when
compared to the results obtained using the homogeneous HRQoL evidence (statistical
Model 6.3). This is because the probability of the early intervention being cost-effective is
reduced, i.e. we can be more confident that it is not cost-effective. Figure 6.5 also shows
that, over a threshold range between £20,000 and £30,000 per QALY, the cost associated
with the decision uncertainty is greater for the scenario involving homogeneous HRQoL
evidence compared to the scenarios with heterogeneous evidence.
6.5 Discussion
The primary objective of this chapter was to explore the benefits of having access to IPD
– specifically, item-level data – when synthesising HRQoL evidence for the purposes of
cost-effectiveness analysis. Investigations were focused on the use of methods capable of
handling item responses given that this would apply to all PRO measures involving likert-
type questionnaire responses. Moreover, item-level analyses allow researchers to make
greater use of the available information and, unlike analyses involving summary scores,
avoid overlooking item-level effects.
Structural equation modelling with categorical item variables is possible thanks to the
development of polychoric methods. These methods are extremely flexible and typically
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Table 6.10: Error Probabilities
Threshold = £20K Threshold = £30K
Model 6.1 0.083 0.340
Model 6.2 0.046 0.253
Model 6.3 0.049 0.277
Model 6.4 0.033 0.224
Figure 6.4: Cost-Effectiveness Acceptability Curves
assume that item responses correspond to points on an underlying latent factor with a con-
tinuous scale. There is only one existing study known to have implemented these methods
in the context of HRQoL evidence synthesis for CEA. Gibbons and colleagues employed
a bi-factor IRT model and found that this approach showed good predictive performance
when compared to other mapping techniques (Gibbons et al., 2014). Unfortunately, the
study by Gibbons and colleagues only demonstrated the predictive performance of the
bi-factor IRT approach in terms of its internal validity. Moreover, their study did not con-
sider some of the challenges likely to be encountered by researchers implementing these
methods in conjunction with a cost-effectiveness model, principally of how to account for
the uncertainty surrounding the parameter estimates.
Whilst fitting SEM models is relatively straightforward, the prediction of PRO responses
via latent factor variables is made more challenging by the need to predict latent factors.
Furthermore, there is additional complexity involved in the process of accounting for
parameter uncertainty. In this chapter, two alternative approaches have been put forward
for the prediction of PRO responses. The first method involved fitting a CFA-type model
to data containing all of the items of interest and then using the output to estimate latent
factor scores in data that only collected a subset of the items. The second method involved
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Figure 6.5: Expected Value of Perfect Information
fitting an SEM-type model with an additional structural component in order to control for
the variables of interest in the cost-effectiveness model. Once this model was fitted, the
predictors assigned values to reflect the patient profiles of interest in the CE model. For
each of the aforementioned prediction methods, it is vital that researchers take account
of the uncertainty surrounding the factor loadings and threshold values. Otherwise, they
might risk underestimating the uncertainty that is introduced by using indirect estimates
of HRQoL.
Of the two item-level methods put forward in this chapter, the SEM approach offers a
more computationally efficient approach to the prediction of PRO responses. This method
simply involves fitting the specified model to a dataset combining all of the relevant data
and then using the output of this analysis to predict PRO responses. The CFM approach
involves two stages before PRO responses can be predicted: first, fitting a model to the data
that collected all of the items of interest and, second, using the output of this analysis in a
subsequent model that is then fitted to the dataset(s) containing a subset of the items in
the original model. Unfortunately, the SEM approach cannot currently be implemented in
the R software package. Instead, this approach requires software, such as Mplus, capable of
deriving latent factor scores following the implementation of a FIML-estimation procedure.
The case study in this chapter did not show any clear impact of incorporating a broader
range of HRQoL measures in terms of either parameter or decision uncertainty. However,
it is important to acknowledge that these findings are case study dependent. While the ‘all-
inclusive’ approach can potentially lead to increased statistical power for the estimation of
HRQoL parameters compared to the ‘reference case’ approach, this does not guarantee that
the decision uncertainty will be reduced. For instance, the gains from having an increased
sample size might be offset by the uncertainty introduced as a result of the additional
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parameters included to estimate factor scores and to predict HRQoL responses (i.e. factor
loadings and threshold values). Several of the issues pertaining to uncertainty around cost-
effectiveness results obtained using SEM methods from the previous chapter also apply
to this chapter. The ‘all-inclusive’ approach to evidence synthesis with SEM methods is
likely to be most beneficial when the reference case measure (e.g. EQ-5D in the UK) is
subject to large amounts of measurement error in the estimation of population parameters.
There is also methodological uncertainty stemming from the indirect estimation of HRQoL
effects (i.e. mapping).
As with the methods in the previous chapter, there is uncertainty regarding the structural
assumptions made in the specification of the SEM models in this chapter. One might
question whether it is appropriate to assume that all of the HRQoL effects of interest
should be captured on a single health domain (i.e. CF). Depending upon the condition
under evaluation and the outcome measures available, it may be necessary to employ
more complex model specifications in order to disentangle HRQoL effects. For instance,
it may be more appropriate to model physical and mental health effects separately from
one another (Gibbons et al., 2014). Although this potential complexity may seem overly
burdensome, it could also present additional opportunities in the modeling of HRQoL
effects. For certain disease areas, such as psoriatic arthritis (Kavanaugh et al., 2016),
patients may experience several distinctive morbidity effects that need to be captured in a
cost-effectiveness model. The flexibility of SEM methods means that it would be possible
to explicitly account for these morbidity effects in the modeling approach. Future research
is required to explore the issue of structural uncertainty in the specification of SEM models
for the purposes of evidence synthesis. Existing research from the field of psychometrics
would be well placed to inform these investigations given that there have been significant
methodological advances to contend with the complex relationships often hypothesized in
this field.
The empirical exercise conducted in this chapter demonstrated that parameter estima-
tion involving the synthesis of heterogeneous HRQoL evidence with SEM techniques is
preferable using IPD, rather than AD, for several reasons. First, IPD allows researchers
to control for covariate imbalances in the data that would otherwise bias the parameter
estimates of interest. Related to this is the fact that IPD facilitates the exploration of
heterogeneity according to patient characteristics, which can reduce the uncertainty sur-
rounding cost-effectiveness results. Although covariate adjustment can also be conducted
using aggregate data, there is always a danger of bias (Piantadosi et al., 1988). Further-
more, access to IPD ensures that any correlations between covariates can be accounted for
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in the probabilistic sensitivity analysis. IPD also allows researchers to conduct analyses at
the item level, rather than having to rely upon linear analyses of summary scores, which
have been shown to be superior in terms of predictive performance.
The models employed in this chapter assume that observations obtained from different
studies can be treated as being random samples from a single population. Given that the
datasets in this chapter differ in a number of respects – in terms of patient demographics,
inclusion criteria, study setting and study design – it may be more appropriate to treat
the data as being heterogeneous with observations being drawn from different groups, i.e.
a hierarchical structure. Unfortunately, the fact that the datasets also differed from one
another in terms of the item variables collected meant that a hierarchical model could not
be implemented in Mplus.3 Further research around this issue is necessary, particularly
in relation to the use of a Bayesian multi-level approach (Lee, 2007).
Finally, the results of this chapter cannot be extrapolated should not be extrapolated to
scenarios beyond the synthesis of heterogeneous generic PRO measures. While it is an-
ticipated that the same methods could be employed in other scenarios, the implications
of incorporating disease-specific measures in addition are unclear. Existing research has
shown that mapping via disease-specific measures generally tends to exhibit a worse pre-
dictive performance than that via generic measures (Brazier et al., 2010). Comparatively,
recent work has proposed that mapping via disease-specific measures has the potential to
improve the precision of parameter estimates (Ades et al., 2013). Further research should
prioritize the application of these methods in scenarios involving disease-specific measures.
3Lavaan does not currently include a hierarchical SEM estimation procedure.
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Chapter 7
Case Study III: Synthesis of
Aggregate and Individual Patient
Data
7.1 Introduction
Chapter 6 demonstrated that the availability of HRQoL evidence at the IPD level offers
substantial benefits for researchers seeking to synthesise that evidence with SEM tech-
niques. Access to IPD permits the analysis of PBMs in terms of their item responses
- rather than their index values - yielding parameter estimates that exhibit lower lev-
els of prediction error compared to the estimates that would have been obtained from
AD. Furthermore, IPD allows researchers to adjust for covariate imbalances and explore
heterogeneity according to patient characteristics. Unfortunately, it is unlikely that re-
searchers will be able to obtain raw data for all of the studies that are relevant to their
cost-effectiveness model and instead will have to rely upon a combination of IPD and AD.
This poses the question over how such evidence should be combined given that it will be
composed of summary scores and/or index scores (in the case of AD), as well as item-
level evidence (in the case of IPD). A simple solution would be to obtain summary scores
and/or index values from the IPD studies available and to synthesise these in the AD for-
mat, along with the remaining AD studies (using one of the methods outlined in Chapter
5). However, the downside of this approach is that it fails to exploit the aforementioned
advantages of having access to IPD. The objective of this chapter is to explore how re-
searchers might simultaneously address the challenges encountered in this scenario: on the
one hand, using methods that exploit the benefits of having access to IPD, whilst on the
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other, ensuring that parameter estimates make comprehensive use of the available data.
An empirical case study is conducted that investigates the use of a multistage Bayesian
approach to evidence synthesis for the estimation of HRQoL inputs.
7.2 Background
The aforementioned challenges associated with the synthesis of evidence comprised of both
IPD and AD can be circumvented through the application of Bayes’ theorem. There are
two steps involved in this approach, which is illustrated in Equation 7.1: (1) the evidence
in the IPD format is used to estimate the unknown HRQoL parameter estimates, θ, which
are subsequently used as informed priors; (2) the evidence in the AD format is used in
the likelihood function, L(θ; y), to obtain an updated posterior distribution, p(θ|y), for
the HRQoL parameter estimates. The main strength of this approach is that it allows
researchers to exploit the SEM techniques capable of handling item-level responses and to
combine the output with evidence in the AD format.
p(θ|y) = L(θ; y) · p(θ) (7.1)
Whilst the Bayesian approach might allow researchers to exploit item-level responses for
the synthesis of IPD, it does not get away from the fact that the subsequent synthesis of
evidence at the AD level involves HRQoL index values. However, any concerns regarding
the plausibility of the LISREL method can be avoided if researchers have access to a
dataset containing all of the PRO measures found in evidence available in the AD format.
The availability of IPD containing all such measures enables the prediction of the reference
case PRO measure at the item level using evidence from alternative measures in the
AD format, thus ensuring the prediction of feasible HRQoL index values. As such, an
SEM model is specified to include a mixture of both categorical and continuous indicator
variables.
An illustrative example is shown in Figure 7.1 depicting a SEM incorporating information
from three PRO measures. Two of the measures are represented in terms of their index
values (SF-6D and HUI-3), and thus captured as continuous variables. The reference
case measurement, the EQ-5D, is represented in terms of the item-level responses to its
descriptive system (i.e. categorical variables).
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Figure 7.1: Graphical Representation of a Mixed Outcome SEM Model
7.3 Methods
The case study in this chapter seeks to combine evidence from the motivating examples
used in Chapters 5 and 6 for the estimation of HRQoL input parameters in the RITA-
3 cost-effectiveness model. The primary aim of the case study is to demonstrate how
Bayesian methods can help to facilitate the synthesis of heterogeneous HRQoL evidence in
both IPD and AD formats, via SEM techniques. Two alternative techniques for combining
AD will be compared: one using the LISREL method (see Chapter 5) to map between
outcome measures and another using a novel mixed outcomes SEM approach. In addition,
parameter estimates obtained using the two methods for combining IPD and AD evidence
will be compared with those derived using the EQ5D IPD alone (i.e. the methods observed
in the previous chapter). Once again, the parameter estimates are fed into the RITA-3
model and cost-effectiveness estimates are obtained for each of the alternative methods.
7.3.1 HRQoL Evidence
PRO evidence in the IPD format was obtained from four studies: the National Health
Measurement Survey (NHMS), the Medical Expenditure Panel Survey (MEPS), the Welsh
Health Survey (WHS) and the Randomized Intervention Trial of unstable Angina (RITA-
3) trial (Fryback et al., 2007; Kim et al., 2005; NatCen Social Research, 2013; Sullivan
et al., 2011). Further details describing these datasets can be found in chapter 6. Evidence
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in the AD format was extracted from an existing meta-analysis that assessed the effects
of diabetes and related complications upon HRQoL (Lung et al., 2011). Further details
describing this data can be found in Chapter 5.
7.3.2 Health Economic Model
The health economic model employed is the same as that used in Chapter 5, where further
details describing this model can be found.
7.3.3 Estimation of Parameter Inputs
As with the previous two chapters, the aim of this empirical exercise is to estimate HRQoL
values associated with two defined health states: one for patients with diabetes who have
yet to experience a myocardial infarction and another for patients with diabetes who have
experienced a myocardial infarction. A “reference case” approach is conducted to estimate
HRQoL parameter inputs solely using the EQ-5D evidence in both IPD and AD formats
(Method 7.1). This involves aggregating the IPD evidence and then synthesising it in
combination with the AD evidence using Model 5.1.1
An alternative method is considered for the synthesis of evidence selected as part of the
“all-inclusive” approach (i.e. including evidence beyond the reference case measurement).
This method (Method 7.2) conducts the mapping and evidence synthsis procedures sepa-
rately. HRQoL evidence in the IPD format is mapped onto the EQ-5D scale using Model
6.2 from Chapter 6. A regression analysis is then implemented using all of the IPD
observations available to obtain two parameter estimates, an intercept and a coefficient
capturing the impact of an MI on HRQoL.2 The parameter estimates obtained from the
IPD analysis will then be combined with evidence in the AD format through the specifi-
cation of a Bayesian meta-regression model. However, before this task can be undertaken
all of the evidence in the AD format has to be mapped onto the scale of the reference case
measurement.
The availability of IPD linking all of the relevant outcomes means that we are no longer
restricted to using the LISREL method as in Chapter 5. A mixed outcomes SEM approach,
illustrated in Figure 7.1, is fitted to the NHMS dataset and the resulting output used to
1Note that sample statistics obtained from the IPD data are split according to the patient health state
(i.e. no MI versus post MI) and study.
2Although the case study in Chapter 5 also included covariates for age and gender, these are removed
for illustrative purposes to show a scenario with corresponding parameters across the evidence formats.
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convert SF-6D and HUI-3 scores in the AD format onto the latent factor (CF) scale. This
model is represented in Equations 7.2 - 7.6.
Pr(EQ5Dij = 1) = Φ(−τ1,j + λj · fi) (7.2)
Pr(EQ5Dij = 2) = Φ(−τ2,j + λj · fi)− Φ(−τ1,j + λj · fi) (7.3)
Pr(EQ5Dij = 3) = 1− Φ(−τ2,j + λj · fi) (7.4)
SF6Di = αSF6D − λSF6D · fi (7.5)
HUI3i = αHUI3 − λHUI3 · fi (7.6)
Where EQ − 5Dij represents individual i’s response to the jth item of the EQ-5D, fi
is individual i’s latent factor score and λj is the factor loading for EQ-5D item j. The
τk,j terms are thresholds indicating the point on the latent factor response scale where
individuals switch their item response. Φ is the standard cumulative distribution function.
The SF6Di and HUI3i terms represents individual i’s valuations for the SF-6D and HUI-3
instruments. These measures have intercepts represented by the terms αSF6D and αHUI3,
and factor loadings represented by the terms λSF6D and λHUI3.
EQ-5D responses first need to be predicted before values can be obtained. A simulation
exercise is implemented to this extent that predicts EQ-5D responses using the latent
factor statistics in combination with the relevant factor loadings and threshold values
from Equations 7.2 - 7.4. Once a sufficiently large number of simulations have been run,
the UK EQ-5D population value set is applied to the predicted responses and sample
statistics derived for the resulting values. The Bayesian meta-regression approach used to
synthesise evidence in the AD format is the same as Model 5.2 (see Equations 5.1 - 5.5)
with exception of the priors specified. Whilst Model 5.2 used plausible but uninformed
priors (Equations 5.3 and 5.4) for the parameter estimates of interest, the priors used in
this chapter are informed by the IPD analysis. A different assumption is needed regarding
the distribution of the constant term, µ, given that the uniform distribution is no longer
applicable. Instead, a beta distribution is assumed and, as such, the parameter estimates
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obtained from the synthesis of IPD evidence need to be modified via methods of moments
calculations (see Briggs et al. (2006)).3
7.3.4 Statistical Software
The meta-analytic models are estimated using the JAGS software, which is run through
the R program using the R2jags package (Su and Yajima, 2012). Each model is run with
three Markov chains over total of 10,000 iterations, the first 1,000 of which are discarded
as the burn-in period. For each method, the posterior distribution is fed directly into the
health economic model for the probabilistic sensitivity analysis. The factor loadings are
estimated using the Lavaan package in R (Rosseel, 2012).
7.4 Results
7.4.1 Parameter Estimates
Table 7.1 shows the estimated HRQoL parameter inputs for the cost-effectiveness model.
This shows that there are substantial differences between the estimates derived using
heterogeneous outcome measures (Model 7.2) compared to those that solely relied upon the
reference case instrument (Model 7.1). The forest plot in Figure 7.2 provides a graphical
representation of the estimated EQ-5D distributions for all of the patient profiles defined
in the RITA-3 model, which were obtained in the probabilistic sensitivity analysis. The
parameters derived by taking an “all-inclusive” approach to evidence synthesis exhibit
significantly reduced uncertainty.
Table 7.1: Mean HRQoL Parameter Inputs
No Previous MI Post MI
Model 6.1 0.736 0.667
Model 6.2 0.623 0.466
Model 6.2 0.778 0.713
(No IPD Prior)
Model 6.2 0.620 0.457
(IPD Only)
3Note that there is still a discrepancy between the EQ-5D and the beta distribution in terms of their
ranges; transformations are required to account for these differences in scale.
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The evidence used in Model 7.2 has been split up according to the format (i.e. IPD and
AD) in an effort to understand the parameter estimates. The estimates labelled ‘Model
7.2 (No IPD Prior)’ show the results form an additional scenario analysis performed using
Model 7.2 but with the priors set to be the same as those in Model 5.1. The estimates
labelled ‘Model 7.2 (IPD only)’ show the parameter estimates obtained using the IPD
only. These results clearly demonstrate that the IPD evidence is the main driver behind
the results. This can be explained by the fact that the parameter estimates derived from
the IPD exhibit far greater precision when compared to those derived from the AD.
Figure 7.2: HRQoL Parameter Estimates
7.4.2 Cost-Effectiveness Results
HRQoL parameter inputs obtained via Models 7.1 and 7.2 were utilized in the RITA-3
model in order to explore the impact of the methodological differences upon the cost-
effectiveness results. Tables 7.2 – 7.3 show the implications of using the different methods
in terms of the impact upon the expected cost-effectiveness results. In addition, prob-
abilistic sensitivity analyses were run, the results of which are presented as CEACs in
Figure 7.3. This information is also presented in terms of error probabilities in Table
7.4, assuming threshold values of £20,000 per QALY and £30,000 per QALY respectively.
These results present the probability of making an incorrect decision, for a given patient,
on the basis of the expected cost-effectiveness results. Finally, the EVPI was estimated
for each method and curves presenting this information can be found in Figure 7.4.
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Table 7.2: Cost-Effectiveness Results Using Model 7.1 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £36,940 £32,188 £4,752
QALYs (discounted) 12.36 12.24 0.12
Cost-per-QALY - - £39,495
Table 7.3: Cost-Effectiveness Results Using Model 7.2 Parameter Estimates
Treatment Comparator
Incremental
Difference
Costs (discounted) £36,940 £32,188 £4,752
QALYs (discounted) 10.32 10.21 0.11
Cost-per-QALY - - £42,549
Table 7.4: Error Probabilities
Threshold = £20K Threshold = £30K
Model 7.1 0.006 0.139
Model 7.2 0.005 0.098
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Figure 7.3 shows that the uncertainty surrounding the decision in question is reduced
when the “all-inclusive” approach to evidence selection is employed as opposed to the
“reference case” approach. This is because the probability of the early intervention being
cost-effective is reduced, i.e. we can be more confident that it is not cost-effective. Figure
7.4 shows that, over a threshold range between £20,000 and £30,000 per QALY, the
cost associated with the decision uncertainty is greater for the “reference case” approach
compared to the “all-inclusive” approach.
Figure 7.3: Cost Effectiveness Acceptability Curves
Figure 7.4: Expected Value of Perfect Information
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7.5 Discussion
The primary objective of this chapter was to explore methods for the synthesis of hetero-
geneous HRQoL evidence in both IPD and AD formats, via SEM techniques. The main
challenge in this task is finding a means to exploit the benefits of having access to item-
level responses in the IPD, whilst also ensuring that the AD evidence is used to inform
parameter estimates. This chapter proposes the combination of evidence in multiple steps
through a process of Bayesian updating and an empirical case study was also conducted to
explore the use of this method for the estimation of HRQoL inputs. The case study showed
this multi-stage method to be successful in making optimal use of the available evidence
and found that parameter uncertainty was dramatically reduced when a combination of
IPD and AD evidence was used compared to IPD alone.
In addition to the multi-stage approach to parameter estimation, the case study in this
chapter also illustrated how IPD can be used for the prediction of item-level responses
on the reference case measurement using evidence from alternative measures in the AD
format. This method is preferable for mapping from AD given that it ensures the predic-
tion of plausible item responses. Given the concerns regarding use of LISREL methods
in Chapter 4, this exercise illustrates the benefits of having access to IPD in terms of the
opportunities it affords researchers seeking to synthesise heterogeneous AD evidence. The
methods considered in this chapter are particularly relevant given that a scenario involv-
ing some combination of IPD and AD probably reflects that most plausible situation in
practice. This is partly due to the fact that implementing SEM methods for the synthesis
of HRQoL evidence is likely to rely upon the availability of IPD in order to estimate factor
loadings (see chapter 5 for further details). However, researchers are unlikely to be able
to obtain all relevant evidence in IPD format and, thus, will have to make do with results
in AD format for many studies.
The case study in this chapter found clear evidence that parameter uncertainty was re-
duced using the ‘all-inclusive’ approach to evidence synthesis (Model 7.2) compared to
the ‘reference case’ approach (Model 7.1). Furthermore, HRQoL estimates obtained with
the ‘all-inclusive’ approach were considerably reduced compared to the ‘reference case’
approach’. However, these differences would appear to be largely explained by the addi-
tional IPD employed in the ‘all-inclusive’ approach, given the similar parameter estimates
obtained from Model 7.2 with and without the AD evidence. This raises doubts over the
consistency of the results from the non-reference case IPD data compared to the remaining
evidence, which begs the question of whether or not they should be included in the synthe-
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sis. It may be reasonable to distinguish the non-reference case IPD data, taken from the
WHS and MEPS studies, from the remaining studies given that the patient populations
were selected on the basis of their self-reported comorbidities. As such, these patients may
not be directly comparable to patients identified by clinicians.
It is important to acknowledge that the case study in this chapter is subject to a number
of limitations. Unlike the previous chapter, the model specified for the meta-regression
in this chapter did not include covariates for age and gender. Although the age and
gender covariates were removed in this chapter for illustrative purposes, the findings from
Chapter 6 indicated that these are important predictors. Given that the decision problem
of interest relates to a male patient population aged 52 years old, a failure to control for
these variables may distort the estimated cost-effectiveness results. There are likely to be
many cases, such as this one, where it would be more appropriate to disregard the AD
evidence for the sake of exploiting additional covariates from the IPD.
Even where covariates are found to be important predictors of cost-effectiveness, this does
not necessarily imply that the results should be used to make stratified health care deci-
sions. This is because there may be transaction costs associated with the stratification of
patients that outweigh the benefits accrued from having controlled for additional covari-
ates (Basu and Meltzer, 2007; Espinoza et al., 2014). Espinoza and colleagues developed
a framework to estimate the value of heterogeneity in order to determine the optimal
level of stratification (Espinoza et al., 2014). This framework could potentially be used
to determine whether it would be better to use IPD evidence alone or in combination
with AD evidence depending upon the value of heterogeneity. Note that this concept is
not unique to HRQoL parameters – the same idea applies to other parameters including
clinical evidence, resource use and costs.
Another issue regarding the inclusion of covariates is that of omitted variable bias. The
validity of the approach in this chapter, as with any model, relies upon an assumption
that there are no confounding variables that could give rise to biased parameter estimates.
Researchers will often find that the existing studies from which their AD evidence was ob-
tained did not analyse the raw data using a method in-keeping with the needs of their
decision model, e.g. controlling for variables such as age or gender. There are several
options to consider pursuing in this type of situation. First, one could consider extending
the meta-regression to control for additional covariates although there is an additional risk
of obtaining biased estimates when exploring statistical relationships between variables at
the aggregate level (Piantadosi et al., 1988). Instead, one could employ a strict study se-
lection strategy and disregard such evidence; however, this could prove to be inappropriate
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if the IPD is subject to some alternative form of bias.
A third possibility would be to employ an evidence discounting method (Lunn et al., 2012).
This method allows researchers to discount biased evidence – specifically, where there are
concerns about bias either in terms of relevance or methodological rigor – such that it
does not carry a full weighting compared to evidence assumed to be free of bias. However,
this approach has yet to be explored in the context of HRQoL parameter estimation and
it is unclear as to how one would go about quantifying these biases. Further research is
required for this method to be considered for use in practice.
Although the specification of Model 7.2 might be preferable to the LISREL method in
terms of its ability to predict plausible responses for the reference case measurement, this
approach is still subject to flaws regarding the specification of the remaining outcome
measures. Model 7.2 assumes that the SF-6D and HUI-3 are both continuous variables,
and are linearly related to the latent factor. Given that both instruments exhibit a bounded
range of plausible values and non-normal error terms, the assumptions necessary for this
approach to be valid are likely to be violated. Further research is necessary to develop
novel methods for handling this issue. However, it should be noted that – as with the
empirical applications in Chapters 5 and 6 – there is additional structural uncertainty
introduced with the ‘all-inclusive’ approach to evidence synthesis given that it requires a
modelling approach to incorporate multiple HRQoL outcomes.
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Chapter 8
Discussion and Conclusions
“...and all the pieces matter”
Lester Freamon, The Wire
8.1 Summary of the thesis
One of the main tenets of the decision analytical modeling approach to CEA is that
researchers should aim to make comprehensive use of all relevant evidence to minimize the
potential risk of obtaining misleading results. In this regard, there has been a large body
of methodological research devoted to the statistical methods used to synthesizing clinical
evidence in CEA (Sutton et al., 2012). However, this issue has been largely overlooked in
the context of HRQoL evidence. As such, the main purpose of this thesis was to contribute
to the understanding of statistical methods for incorporating HRQoL evidence within the
decision-analytic modelling framework. The thesis addressed this overall aim by exploring
four research questions, set out in Chapter 1.
The first research question sought to evaluate the current state of practice with regards
to the use of statistical methods to incorporate HRQoL data in applied cost-effectiveness
studies. A review of NICE technology appraisals was conducted to evaluate the use of
statistical methods to incorporate HRQoL evidence in applied cost-effectiveness studies
(Chapter 2). The results of the review found that the following statistical procedures were
used on an irregular basis: pooling techniques for the synthesis of evidence from multi-
ple studies; mapping techniques for the prediction of reference case HRQoL values using
alternative outcome measures; adjustment techniques used to combine HRQoL values for
comorbidities. These findings suggest that there are fundamental inconsistencies regard-
ing the utilization of HRQoL evidence for the purposes of informing technology adoption
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decisions. In light of these findings, a decision was made to focus research efforts upon
the identification of statistical methods capable of utilizing HRQoL evidence in both a
comprehensive and consistent manner.
The second research question of the thesis sought to evaluate the guidance currently avail-
able with respect to the use of statistical methods for the synthesis of HRQoL evidence in
CEA. A review of the policy guidance and published literature was conducted to evalu-
ate the methodological guidance currently available (Chapter 3). Recommendations from
policy-makers regarding the synthesis of HRQoL evidence were found to be lacking. Chap-
ter 3 concluded that taking a vague stance on this issue might actually risk promoting
future inconsistencies in the utilisation of HRQoL evidence. This conclusion has impor-
tant implications for policy makers as it suggests that more prescriptive methodological
guidance may be required.
A frequently observed issue in the published literature was the predicament of how to
deal with between-study heterogeneity (i.e. a lack of comparability amongst the alter-
native instruments for measuring and valuing HRQoL). Some studies attempted to get
around this problem by restricting syntheses to only include evidence for a reference case
instrument to ensure that the evidence being incorporated is comparable. However, this
approach may provide an incomplete representation of HRQoL effects or, in some cases,
no evidence at all. One of the studies identified in the review in Chapter 3 proposed the
use of mapping techniques as a means to resolve the issue of between-instrument hetero-
geneity (Peasgood and Brazier, 2015). Chapter 3 concluded that incorporating mapping
procedures within a broader evidence synthesis framework could potentially pave the way
towards a more appropriate utilisation of HRQoL evidence for CEA. In particular, it was
felt that this suggested approach would avoid researchers having to make a compromise
between thoroughness and comparability in the selection of HRQoL evidence.
Chapter 4 explored the potential role of mapping techniques in combination with evidence
synthesis techniques. It began by reviewing some of the statistical issues associated with
the development of mapping algorithms. SEM techniques were identified as exhibiting a
number of important characteristics with regards to the analysis of HRQoL data, most
notably their ability to account for measurement error in applications involving multiple
outcomes (Lu et al., 2013). Next, a detailed outline of the SEM framework was provided
with particular emphasis upon the opportunities and challenges involved in the analysis
of preference-based measures of HRQoL. This description constitutes a valuable contribu-
tion on the grounds that it provides the health economic evaluation community with an
introduction to the use of the SEM framework, a methodology not traditionally associated
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with this discipline.
Despite the early promise exhibited by the SEM methodology however, it was felt that
further empirical research should be undertaken before any recommendation with regards
to their use in applied research could be made. It was decided that this should include
the following: (i) validation of this approach across the variety of plausible scenarios that
researchers might encounter, (ii) comparison of the methods against those employed in
the present circumstances, and (iii) demonstration in the context of a cost-effectiveness
model involving HRQoL parameters associated with defined health states and events.
The third research question of the thesis sought to determine the plausibility of the SEM
approach serving as a generalised framework for the synthesis of heterogeneous HRQoL
evidence in CEA. A series of empirical case studies were conducted to explore the method-
ological challenges associated with the use of these methods, and to compare parameter
estimates obtained via the synthesis of heterogeneous HRQoL evidence with SEM tech-
niques against those obtained via synthesis of homogeneous HRQoL evidence with stan-
dard synthesis techniques. The latter method was selected as being representative of cur-
rent practice based upon an assumption that cost-effectiveness evidence developed for the
purposes of policy decision making should strive to incorporate HRQoL effects captured
using some reference case measurement.
The SEM approach to evidence synthesis was employed in three separate scenarios that
differed in terms of the format of the available evidence. Each of these scenarios revolved
around an existing cost-effectiveness model comparing an early surgical intervention to
medical management for the treatment of acute coronary syndrome in a patient subgroup
with diabetes. This case study was selected for two reasons: (i) there were a range of
freely-available HRQoL studies pertaining to this case study and these studies facilitated
methodological investigations for each of the scenarios considered; (ii) the availability of
an existing model meant that the competing methods could be compared in terms of
their impact upon the cost-effectiveness results. The case study stands out as the first
application to date involving the use SEM methods to derive HRQoL parameter estimates
for a cost-effectiveness model.
Chapter 5 focused upon a scenario where researchers, seeking to estimate HRQoL param-
eters for a CEA, are faced with an evidence base involving multiple sources of evidence
in the AD format and composed of a variety of instruments. HRQoL evidence in the
AD format was obtained from an existing meta-analytic study and two approaches were
considered with regards to the selection of evidence: (i) a “reference case” approach, that
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only used evidence from studies that collected the reference case measurement, and (ii) an
“all-inclusive” approach, that incorporated a range of other outcome measures in addition
to the reference case measurement. For the “reference case” scenario, a hierarchical meta-
regression method was used to synthesise the available EQ-5D evidence. Two methods
were proposed for the synthesis of evidence in the “all-inclusive” scenario, both of which
utilized SEM techniques to map between the different outcome measures. One of the
methods involved a two-step procedure, starting with the mapping of outcomes onto the
same scale followed by the evidence synthesis. The other, so-called integrated approach
conducted these tasks simultaneously.
The parameter estimates derived using the two-step synthesis approach exhibited confi-
dence intervals that were noticeably reduced when compared to those obtained by synthesis
of the reference case evidence. This finding was encouraging given that it would seem to
validate the rationale for embracing the “all inclusive” approach to evidence synthesis; that
is, by incorporating more relevant evidence, we increase the chances of gaining statistical
power for the estimation of parameters (Higgins et al., 2009). However, it is important
to acknowledge that other forms of uncertainty are introduced into the CEA when these
methods are adopted. There is additional methodological uncertainty due to the lack of
consensus regarding validity of using indirect estimates of HRQoL (i.e. mapped values).
Furthermore, structural uncertainty is also introduced given that the validity of the statis-
tical methods has been questioned in the context of HRQoL research (Alava et al., 2012;
Basu and Manca, 2012).
Overall, decision uncertainty in the RITA-3 model did not vary greatly when different
HRQoL parameter estimates, derived using the alternative methods considered in this
chapter, were employed. A supplementary analysis was conducted to estimate EVPPI
and this showed that the impact of HRQoL is modest in the RITA-3 model compared to
other parameters. For this reason, Chapter 5 concluded that the choice of method for
the estimation of HRQoL parameters would have been unlikely to impact upon a policy
reimbursement decision for this specific application. However, it was also recognised that
the role of HRQoL parameters within a given decision model is case study dependent. As
such, this finding would not constitute grounds for making a recommendation about the
implications of the SEM methodology for policy-making more broadly.
In Chapter 6, a scenario involving multiple sources of heterogeneous HRQoL evidence
in the IPD format was considered. As well as comparing an “all-inclusive” approach to
evidence synthesis to a “reference case” approach, the investigations in this chapter focused
on the potential benefits of adopting synthesis techniques capable of exploiting item-level
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responses. The latter point was considered to be particularly important given that this
pertains to all PRO measures involving likert-type questionnaires.
An empirical case study was conducted using evidence in the IPD format from several
freely available studies, in addition to data from a clinical trial associated with the cost-
effectiveness model. Two methods for synthesising evidence were proposed using SEM
methods, both of which specified the HRQoL measures in terms of item-responses using
polychoric methods. Once again, a distinction was made between the “reference case”
approach to evidence synthesis and an “all-inclusive” approach. As with Chapter 5, two
methods were proposed for the synthesis of evidence in the “all-inclusive” scenario, both
of which utilised SEM techniques to map between the different outcome measures.
The first of the proposed SEM methods implemented mapping and synthesis procedures
in separate stages, while the second method combined these procedures into a single
modelling approach using an FIML estimation method. Despite offering a more computa-
tionally efficient approach, the latter method could only be implemented in one software
package, Mplus (Muthe´n and Muthe´n, 2010). It was felt that the lack of alternative soft-
ware options represents a significant obstacle for the uptake of this method. As such, it is
hoped that this capability will be extended to other software packages in the future.
The HRQoL parameter estimates derived using the SEM methods were noticeably lower
than those obtained using the reference case data. The discrepancies appear to have
been caused by differences in the estimated impact of age upon HRQoL. One possible
explanation for this finding might be that the additional evidence incorporated in the
“all-inclusive” scenario was able to offset the spurious covariate associations between age
and HRQoL in the “reference case” scenario. The case study in Chapter 6 did not show
any clear impact of incorporating a broader range of HRQoL measures in terms of ei-
ther parameter or decision uncertainty. As with the scenario considered in Chapter 5,
parameter estimation with SEM methods introduces both methodological and structural
uncertainty.
Chapter 6 concluded that there are substantial benefits to be gained from synthesising
heterogeneous HRQoL measures using item-level responses rather than summary scores
and/or index values. Unlike the LISREL methods considered in the Chapter 5, item-level
SEM methods ensure the prediction of plausible HRQoL responses. The empirical case
study conducted in Chapter 6 found that the item-level approach had a superior predictive
performance when compared to the LISREL approach. IPD evidence brings additional
benefits including the ability to produce HRQoL parameter estimates stratified according
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to patient characteristics, which is needed to explore heterogeneity in cost-effectiveness
estimates. Furthermore, IPD allows researchers to control for covariate imbalances in the
data that would otherwise bias the parameter estimates of interest.
Chapter 7 examined the application of SEM methods in a scenario involving a combination
of evidence in the IPD and AD formats. This chapter sought to develop an SEM-based
approach to evidence synthesis capable of both exploiting the benefits of having access
item-level responses in the IPD, whilst also ensuring that the AD evidence is used to
inform parameter estimates. Of all of the scenarios considered in the thesis, this one was
considered to be particularly important given that it probably reflects the most plausible
situation encountered in practice. This is partly due to the fact that implementing SEM
methods for the synthesis of HRQoL evidence is likely to rely upon the availability of
IPD in order to estimate factor loadings (see Chapter 5 for further details). However,
researchers are unlikely to be able to obtain all relevant evidence in IPD format and, thus,
will have to make do with results in AD format for many studies.
A method was proposed that involved combining evidence in multiple stages via a Bayesian
updating process. Heterogeneous IPD evidence would be synthesised first using either
of one the item-level SEM techniques proposed in Chapter 6. The resulting parameter
estimates from this first step would then be used as informed priors in a subsequent
synthesis of the heterogeneous AD evidence. Assuming that there is IPD linking all of the
relevant outcome measures in the AD format, then the synthesis of evidence in the AD
format is no longer restricted to the use of the LISREL methods employed in Chapter 5.
Instead, Chapter 7 proposed that the IPD evidence could be used to predict item-level
responses on the reference case measurement using evidence from alternative measures
in the AD format. This method is preferable to the LISREL approach given that it
guarantees the prediction of plausible HRQoL responses (unlike the LISREL approach).
The proposed method was employed to estimate HRQoL parameters in an empirical case
study using the AD evidence from Chapter 5 and the IPD evidence from Chapter 6.
These estimates were then compared to parameter estimates obtained via a “reference
case” approach to evidence synthesis. The case study showed this multi-stage method to
be successful in making optimal use of the available evidence and found that parameter
uncertainty was dramatically reduced when a combination of IPD and AD evidence was
used compared to IPD alone. However, there were doubts raised over the comparability of
the IPD and AD evidence given that there were large differences observed in the HRQoL
estimates. Chapter 7 suggested that these differences might have been explained by dif-
ferences in the way that the patient populations were defined. This finding illustrates the
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importance of considering the consistency of the evidence when combining the results from
multiple studies.
8.1.1 Original Contributions
Chapter 2 of the thesis provides three important contributions. Firstly, there is no pub-
lished article, to the author’s knowledge, to have explored the consistency with which sta-
tistical methods are employed in applied CEA research to incorporate HRQoL evidence.
To this end, Chapter 2 can be considered as being a contribution to the field. Secondly,
the findings in Chapter 2 indicate that there are fundamental inconsistencies regarding
the utilisation of HRQoL evidence for the purposes of informing technology adoption deci-
sions. This has important implications for policy-making given that these inconsistencies
undermine the comparability of evidence used to inform different reimbursement decisions.
Finally, the methodological inconsistencies indicate that there may be deficiencies in the
published literature and policy guidance pertaining to the statistical methods employed
in applied CEA research to synthesise HRQoL evidence.
An important contribution of the research in this thesis is the fact that the investigations
reflect a range of scenarios that might be encountered in practice. Overall, the empirical
research conducted in this thesis has shown that the “all-inclusive” approach to evidence
selection, via SEM methods, can potentially improve precision in the estimation of HRQoL
parameters for CEA compared to an approach relying on evidence collected using some pre-
specified reference case measurement. Relevant code has been provided with instructions
on how to implement the methods in each scenario in open source software (Team, 2014).
It is hoped that this will facilitate the use of these methods and encourage future research
efforts in this area.
Chapter 7 represents the first known study to have considered the synthesis of hetero-
geneous HRQoL evidence in both IPD and AD formats. This chapter presents a novel
multi-stage method for incorporating HRQoL evidence in a way that exploits the benefits
of having access to item-level data, whilst also incorporating AD evidence. Furthermore,
it illustrates how researchers can exploit available IPD evidence to predict item-level re-
sponses for a reference case measurement using evidence from alternative measures in
the AD format. Previous research exploring the use of SEM methods for the analysis of
HRQoL evidence has relied on LISREL methods (Lu et al., 2013, 2014), despite the fact
that linear modeling techniques such as these have been shown to be inappropriate for
the analysis of HRQoL preference values (Alava et al., 2012; Basu and Manca, 2012). The
item-level approach is preferable for mapping from AD given that it ensures the prediction
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of plausible item responses.
Although a previous study was found to have employed SEM techniques for the synthesis
of HRQoL evidence in the AD format, this did not involve HRQoL preference values (Lu
et al., 2013). Chapter 5 is the first study, to the author’s knowledge, to have employed SEM
techniques for the synthesis for the synthesis of HRQoL preference values. There is only
one existing study known to have implemented item-level SEM methods for the analysis
of HRQoL evidence (Gibbons et al., 2014). However, this study did not consider some
of the challenges likely to be encountered by researchers implementing these methods in
conjunction with a cost-effectiveness model. Another original aspect of the research in this
thesis is that it considers the implementation these methods in the context of an associated
cost-effectiveness model, principally of how to account for the uncertainty surrounding the
parameter estimates.
8.1.2 Limitations
Although the investigations in this thesis provide a number of valuable contributions to the
field of health economic evaluation, it is important to acknowledge the limitations of the
research. The limitations chiefly pertain to the difficulties in forming methodological rec-
ommendations on the basis of empirical findings that are case study specific. The benefits
of adopting a more comprehensive approach to evidence synthesis, via SEM methods, are
likely to differ depending upon the condition under evaluation. To this end, a key priority
for future research will be to undertake simulation exercises to test the implications of
using competing methods across a variety of scenarios. The benefit of simulation exercises
is that the researcher has full control over all of the underlying parameters feeding into
the model to understand the mechanisms at work.
Another limitation of the case studies in this thesis is that they are solely concerned with
a limited number of preference-based measures of HRQoL. In theory, the SEM methods
for evidence synthesis would allow researchers to draw upon the wealth of non-preference-
based HRQoL measures available. As well as synthesising a broader range of outcome
measures, the SEM methodology is capable of estimating parameters with greater preci-
sion by incorporating disease-specific outcome measures. The latter point has important
implications for the identification of evidence given that the range of relevant outcomes
would vary according to the condition under evaluation. Further research is needed to
establish how researchers would go about identifying the range of outcomes that might
potentially be considered within a search strategy.
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By only focusing upon applications involving generic measures of HRQoL, this thesis
also overlooks the potential complexities involved in the specification of models that also
incorporate disease-specific measures. The case studies in this thesis dealt purely with
models assuming that HRQoL effects could be captured by a unitary construct. For certain
disease areas, such as psoriatic arthritis (Kavanaugh et al., 2016), patients may experience
several distinctive morbidity effects that need to be captured in a cost-effectiveness model.
To this end, additional exemplars are required to explicitly demonstrate the modeling
techniques that might be performed.
The cost-effectiveness study selected in this thesis was flawed for the purposes of explor-
ing the implications of employing alternative methods for synthesising HRQoL evidence.
Taken at face value, the findings would suggest that the methodological issues are unim-
portant from a policy-maker’s perspective, given that there was no observable impact
upon decision uncertainty. However, a supplementary analysis to estimate EVPPI results
in the RITA-3 model showed that the impact of HRQoL is modest compared to other
parameters. As such, it is unlikely that the choice of method for the estimation of HRQoL
parameters would have had a substantial impact upon the decision uncertainty.
8.2 Recommendations
8.2.1 Recommendations for researchers and decision makers
Researchers are advised to consider using SEM techniques for the synthesis of evidence
involving multiple heterogeneous outcome measures. Empirical research conducted in this
thesis has shown that this “all-inclusive” approach to evidence selection can potentially
improve precision in the estimation of HRQoL parameters for CEA compared to an ap-
proach relying on evidence collected using some pre-specified reference case measurement.
Relevant code has been provided with instructions on how to implement the SEM-based
synthesis techniques in open source software (Team, 2014). It is hoped that this will fa-
cilitate the use of these methods and encourage future research efforts in this area. It
is vital that researchers take account of the uncertainty surrounding the factor loadings
and threshold values. Otherwise, they might risk underestimating the uncertainty that is
introduced by using indirect estimates of HRQoL.
Researchers should be aware that access to IPD containing all of the measurements of in-
terest is likely to be a pre-requisite for the implementation of SEM-based methods. While
these methods can also be employed using sample covariance data (as in Chapter 5), it is
doubtful that this information can be obtained from published studies. Researchers are
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advised to take advantage of having access to IPD wherever possible. The availability
of IPD enables investigations into patient heterogeneity as well as allowing analyses to
control for missing data or covariate imbalances. Significantly, HRQoL evidence in the
IPD format also permits the implementation of SEM techniques that exploit item-level
responses. The analysis of item responses, rather than index or summary scores, is prefer-
able on the grounds that it ensures the prediction of plausible HRQoL values. Moreover,
analyses involving item responses have been shown to exhibit lower levels of bias than
those involving summary scores.
Decision makers are recommended to consider providing more prescriptive methodological
guidance in relation to the methods employed to synthesise HRQoL evidence. Chapter
3 found the recommendations currently on offer to be lacking in this regard. In partic-
ular, decision makers are advised to consider recommending a more inclusive approach
with regards to the synthesis of HRQoL evidence, i.e. consider the use of non-reference
case HRQoL evidence, even where directly relevant, reference case evidence is available.
Although concerns may exist in relation to the use of indirect estimates of HRQoL (i.e.
mapped estimates), there are other examples in the field of health economic evaluation
where indirect evidence is employed in evidence synthesis for parameter estimation, i.e.
treatment comparisons (Sutton et al., 2012).
8.2.2 Recommendations for future research
Further research is needed to establish the precise set of circumstances in which the meth-
ods for synthesising heterogeneous HRQoL evidence via SEM techniques are likely to be
most important. The most appropriate approach for handling investigations on this mat-
ter would be to undertake simulation exercises to test the implications of using competing
methods across a variety of scenarios. This approach would permit the analyst to both
specify and vary some of the key assumptions underlying the data including the pop-
ulation distribution of HRQoL responses/values for the parameters of interest and the
measurement error associated with alternative HRQoL measures.
Although the case studies in this thesis dealt exclusively with generic, preference-based
measures of HRQoL, it is anticipated that the SEM framework is sufficiently flexible for
use in other scenarios. However, additional empirical research is needed to demonstrate
the use of these methods in a wider range of scenarios, particularly those involving disease-
specific measures of HRQoL. As previously mentioned, disease-specific measures sometimes
capture distinctive morbidity effects with separate domains and this would bring additional
complexities into the model specification process. Existing research from the field of
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psychometrics would be well placed to inform these investigations given that there have
been significant methodological advances to contend with the complex relationships often
hypothesized in this field.
If policy makers were to endorse an “all-inclusive” approach to evidence synthesis, then
this would have important implications for the methods used to identify HRQoL evidence.
Further research is needed to establish how these considerations would be integrated within
a search strategy. For instance, this could encompass a scoping process prior to the
commencement of the literature search to identify all relevant outcome measures. For
certain conditions, research may have even been conducted already to determine which
patient-reported outcomes are appropriate for the measurement of HRQoL (Gibbons et al.,
2014; Hadi et al., 2010; Mackintosh et al., 2009).
Chapter 6 identified a number of deficiencies in the statistical software considered regarding
the implementation of SEM models for evidence synthesis involving IPD. Unfortunately,
the methods employed could not incorporate hierarchical structures to reflect heterogeneity
existing between different studies. This was considered to be a simplifying assumption and
further research was recommended, particularly in relation to the use of a Bayesian multi-
level approach (Lee, 2007). Another issue was the fact that the FIML estimation method
proposed in Chapter 6 could only be implemented in a single software package (Mplus).
As such, this constitutes a significant obstacle in the implementation of this methodology.
Further developments are recommended to facilitate the implementation of this method
in other software packages.
8.3 Conclusions
This thesis set out to explore the plausibility of the SEM approach serving as a generalised
framework for the synthesis of heterogeneous HRQoL evidence in CEA. The research
has demonstrated that this methodology can, theoretically, be implemented to synthesise
evidence in a range of formats and has the potential to deliver more precise estimates of
HRQoL. However, the research has also recognised that the fact that a scenario solely
involving evidence in the AD format is unlikely to occur in practice given that covariance
data are rarely available in the published literature. As such, a pre-requisite for the
implementation of the SEM approach is that researchers have access to at least one source
of IPD evidence capturing all of the HRQoL measures of interest. It is hoped that the
findings of the thesis will encourage health economists to consider implementing the SEM
approach in order to synthesise HRQoL evidence in a more comprehensive and transparent
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manner. It is also hoped that this research will prompt further discussions amongst policy
makers in regards to the methods for synthesising HRQoL evidence.
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Appendix B
Chapter 5 Code
#####################
# R Code ############
# Model 4 . 1 #########
#####################
l i b r a r y ( R2jags )
l i b r a r y ( coda )
l i b r a r y ( l a t t i c e )
l i b r a r y (R2WinBUGS)
l i b r a r y ( r j a g s )
# Data Inputs #######
EQ5D #mean va lue s
EQ5D. SE #standard e r r o r s
p r e c i s i o n <− 1/(EQ5D. SEˆ2)
MI #dummy v a r i a b l e f o r prev ious MI
N #the number o f va lue s being synthe s i z ed
Nstudy #the number o f s t u d i e s invo lved
study #study r e f e r e n c e number
data . inputs <− l i s t (”EQ5D” ,” p r e c i s i o n ” ,
”MI” ,”N” ,” Nstudy ” ,” study ”)
# Model s p e c i f i c a t i o n
model <− f unc t i on ( ){
f o r ( i in 1 :N){
EQ5D[ i ] ˜ dnorm(THETA[ i ] , p r e c i s i o n [ i ] )
THETA[ i ] <− theta [ study [ i ] ] + beta ∗MI[ i ]
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}
f o r ( z in 1 : Nstudy ){
theta [ z ] ˜ dnorm(mu, tau . z )
}
mu ˜ duni f (−0.594 ,1)
tau . z <− 1/( s i g . z ˆ2)
s i g . z ˜ dun i f ( 0 . 0 0 1 , 0 . 2 )
beta ˜ dnorm (0 , 10)
}
# Parameters o f i n t e r e s t
combined . params <− c (”mu” , ” beta ” , ” s i g . z ”)
# I n i t i a l va lue s
i n i t s<− l i s t (
l i s t (mu=c ( 0 . 8 ) , beta=c (−0.05) , s i g . z=c ( 0 . 0 0 1 ) ) ,
l i s t (mu=c ( 0 . 6 5 ) , beta=c (−0.1) , s i g . z=c ( 0 . 0 1 ) ) ,
l i s t (mu=c ( 0 . 5 ) , beta=c (−0.2) , s i g . z=c ( 0 . 1 ) ) )
# Run Model
model . f i t <− j a g s ( data = data . inputs , i n i t s = i n i t s ,
n . cha ins = 3 , n . i t e r = 9000 ,
parameters . to . save = combined . params ,
n . burnin = 1000 , model . f i l e = model )
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#####################
# R Code ############
# Model 4 . 2 #########
# Step 1 ############
#####################
l i b r a r y ( lavaan ) #f o r more i n f o : http :// lavaan . ugent . be/
# Data Inputs #######
N #Number o f p a t i e n t s in the mapping study
EQ5D. mean #EQ−5D mean from the mapping study
SF6D . mean #SF−6D mean from the mapping study
HUI3 . mean #HUI−3 mean from the mapping study
means <− c (EQ5D. mean , SF6D . mean , HUI3 . mean)
COV.EQ5D. SF6D #Covariance term #1 from the mapping study
COV.EQ5D. HUI3 #Covariance term #2 from the mapping study
COV. SF6D . HUI3 #Covariance term #3 from the mapping study
EQ5D. var #EQ−5D var iance from the mapping study
SF6D . var #SF−6D var iance from the mapping study
HUI3 . var #HUI−3 var iance from the mapping study
# Formulate covar iance matrix
lower <− ’
EQ5D. var
COV.EQ5D. SF6D SF6D . var
COV.EQ5D. HUI3 COV.EQ5D. SF6D HUI3 . var ’
covar iance . matrix <−
getCov ( lower , names = c (”EQ5D” ,”SF6D” ,”HUI3”) )
# Model S p e c i f i c a t i o n
model <− ’CF =˜ EQ5D + SF6D + HUI3 ’
# Run Model
f i t <− sem( model ,
sample . cov = covar iance . matrix ,
sample . mean = means ,
sample . nobs = N,
meanstructure=TRUE)
param . e s t imate s <− parameterEst imates ( f i t )
# Note s tep 2 uses the same model s p e c i f i c a t i o n as Model 4 . 1
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#####################
# R Code ############
# Model 4 . 3 #########
#####################
l i b r a r y ( R2jags )
l i b r a r y ( coda )
l i b r a r y ( l a t t i c e )
l i b r a r y (R2WinBUGS)
l i b r a r y ( r j a g s )
# Data Inputs #######
EQ5D. i n t #EQ5D i n t e r c e p t − der ived us ing Model 4 . 2 − Step 1
SF6D . i n t #SF6D i n t e r c e p t − der ived us ing Model 4 . 2 − Step 1
HUI3 . i n t #HUI3 i n t e r c e p t − der ived us ing Model 4 . 2 − Step 1
lambda2 #This i s der ived us ing Model 4 . 2 − Step 1
lambda2 . SE #This i s der ived us ing Model 4 . 2 − Step 1
lambda2 . p r e c i s i o n <− 1/( lambda2 . SEˆ2)
lambda3 #This i s der ived us ing Model 4 . 2 − Step 1
lambda3 . SE #This i s der ived us ing Model 4 . 2 − Step 1
lambda3 . p r e c i s i o n <− 1/( lambda3 . SEˆ2)
EQ5D. mean [ i ] #mean va lue s ; NA where miss ing
EQ5D. SE [ i ] #standard e r r o r s ; NA where miss ing
SF6D . mean [ i ] #mean va lue s ; NA where miss ing
SF6D . SE [ i ] #standard e r r o r s ; NA where miss ing
HUI3 . mean [ i ] #mean va lue s ; NA where miss ing
HUI3 . SE [ i ] #standard e r r o r s ; NA where miss ing
MI #dummy v a r i a b l e f o r prev ious MI
N #the number o f va lue s being synthe s i z ed
Nstudy #the number o f s t u d i e s invo lved
study #study r e f e r e n c e number
data . inputs <− l i s t (” lambda2 ” ,” lambda2 . SE” ,
” lambda3 ” ,” lambda2 . SE” ,
”EQ5D. i n t ” ,”SF6D . i n t ” ,”HUI3 . i n t ” ,
”EQ5D. mean [ i ] ” , ”EQ5D. SE [ i ] ” ,
”SF6D . mean [ i ] ” , ”SF6D . SE [ i ] ” ,
”HUI3 . mean [ i ] ” , ” HUI3 . SE [ i ] ” ,
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”MI” ,”N” ,” Nstudy ” ,” study ”)
# Model s p e c i f i c a t i o n
model <− f unc t i on ( ){
FL2 ˜ dnorm( lambda2 , lambda2 . p r e c i s i o n )
FL3 ˜ dnorm( lambda3 , lambda3 . p r e c i s i o n )
f o r ( i in 1 :N){
EQ5D. se [ i ] ˜ dnorm( theta1 . se [ i ] , phi1 . prec )
SF6D . se [ i ] ˜ dnorm( theta2 . se [ i ] , phi2 . prec )
HUI3 . se [ i ] ˜ dnorm( theta3 . se [ i ] , phi3 . prec )
var1 [ i ] <− EQ5D. se [ i ] ˆ2
var2 [ i ] <− SF6D . se [ i ] ˆ2
var3 [ i ] <− HUI3 . se [ i ] ˆ2
prec1 [ i ] <− 1/( var1 [ i ] )
prec2 [ i ] <− 1/( var2 [ i ] )
prec3 [ i ] <− 1/( var3 [ i ] )
EQ5D. mean [ i ] ˜ dnorm(THETA1[ i ] , prec1 [ i ] )
SF6D . mean [ i ] ˜ dnorm(THETA2[ i ] , prec2 [ i ] )
HUI3 . mean [ i ] ˜ dnorm(THETA3[ i ] , prec3 [ i ] )
THETA1[ i ] <− Int1 + LF[ i ]
THETA2[ i ] <− Int2 + lambda2∗LF[ i ]
THETA3[ i ] <− Int3 + lambda3∗LF[ i ]
theta1 . se [ i ] <− LF. se [ i ]
theta2 . se [ i ] <− FL2∗LF. se [ i ]
theta3 . se [ i ] <− FL3∗LF. se [ i ]
LF [ i ] ˜ dnorm( de l t a [ i ] , phi . prec )
d e l t a [ i ] <− SLE [ study [ i ] ] + beta ∗HA[ i ]
LF . se [ i ] ˜ dun i f ( 0 . 0 0 1 , 0 . 2 )
}
f o r ( z in 1 : Nstudy ){
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SLE [ z ] ˜ dnorm(mu, tau . z )
}
phi1 . se ˜ dun i f ( 0 . 0 0 1 , 0 . 2 )
phi2 . se ˜ dun i f ( 0 . 0 0 1 , 0 . 2 )
phi3 . se ˜ dun i f ( 0 . 0 0 1 , 0 . 2 )
phi1 . prec <− 1/( phi1 . se ˆ2)
phi2 . prec <− 1/( phi2 . se ˆ2)
phi3 . prec <− 1/( phi3 . se ˆ2)
phi . se ˜ dun i f ( 0 . 0 0 1 , 0 . 2 )
phi . prec <− 1/( phi . se ˆ2)
mu ˜ dnorm (0 ,10 )
beta ˜ dnorm (0 ,10 )
tau . z <− 1/( s i g . z )
s i g . z ˜ dun i f ( 0 . 0 0 1 , 0 . 2 )
}
# Parameters o f i n t e r e s t
combined . params <− c (”mu” , ” beta ” , ” s i g . z ”)
# I n i t i a l va lue s
i n i t s<− l i s t (
l i s t ( phi1 . se=c ( 0 . 1 ) , phi2 . se=c ( 0 . 1 ) , phi3 . se=c ( 0 . 1 ) ,
mu=c (−0.05) , beta=c (−0.05) , phi . se=c ( 0 . 1 ) ,
s i g . z=c ( 0 . 0 0 1 ) ) ,
l i s t ( phi1 . se=c ( 0 . 0 1 ) , phi2 . se=c ( 0 . 0 1 ) , phi3 . se=c ( 0 . 0 1 ) ,
mu=c (−0.1) , beta=c (−0.1) , phi . se=c ( 0 . 0 1 ) ,
s i g . z=c ( 0 . 0 1 ) ) ,
l i s t ( phi1 . se=c ( 0 . 0 0 1 ) , phi2 . se=c ( 0 . 0 0 1 ) , phi3 . se=c ( 0 . 0 0 1 ) ,
mu=c (−0.2) , beta=c (−0.2) , phi . se=c ( 0 . 0 0 1 ) ,
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s i g . z=c ( 0 . 1 ) ) )
# Run Model
model . f i t <− j a g s ( data = data . inputs , i n i t s = i n i t s ,
n . cha ins = 3 , n . i t e r = 9000 ,
parameters . to . save = combined . params ,
n . burnin = 1000 , model . f i l e = model )
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Appendix C
Expected Value of Perfect
Information for Parameters
The expected value of perfect information for parameters (EVPPI) is conceptually similar
to the EVPI and represents the value of reducing uncertainty around specific parameters
(Briggs et al., 2006). Traditionally, the rationale for estimating the EVPPI has been to
identify the priority areas for further research. However, the EVPPI is also a useful method
for exploring the extent to which different parameters contribute to the final outputs and
impact upon the decision uncertainty (i.e. expected costs and QALYs). As an additional
exercise, the EVPPI was estimated for each of the parameters in the RITA-3 model in order
to evaluate the relative contribution of the HRQoL parameters. Figure C.1 illustrates the
relationship between EVPPI for the model parameters and the cost-effectiveness threshold.
Figure C.1: Expected Value of Perfect Information for Parameters
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These results show that additional HRQoL evidence would not be valuable given that
it would be unlikely to change the decision. This provides important context for the
findings in Chapter 5 (as well as the subsequent chapters) because it illustrates the fact
that there is little scope for the methodological differences to have an impact upon the
decision uncertainty for this particular case study. In conclusion, the impact of differing
HRQoL synthesis techniques upon the expected cost-effectiveness is likely to be case study
dependent (i.e. it will also depend upon other factors such as the model structure and
evidence on the other parameters).
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Appendix D
Chapter 6 Code
#####################
# R Code ############
# Model 5 . 2 #########
# Step 1 ############
#####################
l i b r a r y ( lavaan ) #package r equ i r ed f o r SEM a n a l y s i s
Model <− #This i s the bi−f a c t o r model s p e c i f i c a t i o n
#e x p l a i n i n g SF−12 and EQ−5D re sponse s
”CF =˜ SF36 .Q1 + SF36 .Q2 + SF36 .Q3 +
SF36 .Q4 + SF36 .Q5 + SF36 .Q6 +
SF36 .Q7 + SF36 .Q8 + SF36 .Q9 +
SF36 . Q10 + SF36 . Q11 + SF36 . Q12 +
EQ5D.Q1 + EQ5D.Q2 + EQ5D.Q3 +
EQ5D.Q4 + EQ5D.Q5
EQ =˜ EQ5D.Q1 + EQ5D.Q2 + EQ5D.Q3 +
EQ5D.Q4 + EQ5D.Q5
SF =˜ SF36 .Q1 + SF36 .Q2 + SF36 .Q3 +
SF36 .Q4 + SF36 .Q5 + SF36 .Q6 +
SF36 .Q7 + SF36 .Q8 + SF36 .Q9 +
SF36 . Q10 + SF36 . Q11 + SF36 . Q12
CF ˜ 0∗EQ
CF ˜ 0∗SF
EQ ˜ 0∗SF
SF36 .Q1 | t1 + t2 + t3 + t4
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SF36 .Q2 | t1 + t2
SF36 .Q3 | t1 + t2
SF36 .Q4 | t1 + t2 + t3 + t4
SF36 .Q5 | t1 + t2 + t3 + t4
SF36 .Q6 | t1 + t2 + t3 + t4
SF36 .Q7 | t1 + t2 + t3 + t4
SF36 .Q8 | t1 + t2 + t3 + t4
SF36 .Q9 | t1 + t2 + t3 + t4
SF36 . Q10 | t1 + t2 + t3 + t4
SF36 . Q11 | t1 + t2 + t3 + t4
SF36 . Q12 | t1 + t2 + t3 + t4
EQ5D.Q1 | t1 + t2
EQ5D.Q2 | t1 + t2
EQ5D.Q3 | t1 + t2
EQ5D.Q4 | t1 + t2
EQ5D.Q5 | t1 + t2 ”
Dataset [ , # d e f i n e the datase t as being o r d i n a l
c (” SF36 .Q1” ,” SF36 .Q2” ,” SF36 .Q3” ,
”SF36 .Q4” ,” SF36 .Q5” ,” SF36 .Q6” ,
”SF36 .Q7” ,” SF36 .Q8” ,” SF36 .Q9” ,
”SF36 . Q10” ,” SF36 . Q11” ,” SF36 . Q12” ,
”EQ5D.Q1” ,”EQ5D.Q2” ,”EQ5D.Q3” ,
”EQ5D.Q4” ,”EQ5D.Q5” ) ]
<− l app ly ( Dataset [ ,
c (” SF36 .Q1” ,” SF36 .Q2” ,” SF36 .Q3” ,
”SF36 .Q4” ,” SF36 .Q5” ,” SF36 .Q6” ,
”SF36 .Q7” ,” SF36 .Q8” ,” SF36 .Q9” ,
”SF36 . Q10” ,” SF36 . Q11” ,” SF36 . Q12” ,
”EQ5D.Q1” ,”EQ5D.Q2” ,”EQ5D.Q3” ,
”EQ5D.Q4” ,”EQ5D.Q5” ) ] , ordered )
f i t <− #now f i t the model
sem( Model , data = NHMS, std . l v=TRUE,
ordered=c (” SF36 .Q1” ,” SF36 .Q2” ,
”SF36 .Q3” ,” SF36 .Q4” ,
”SF36 .Q5” ,” SF36 .Q6” ,
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”SF36 .Q7” ,” SF36 .Q8” ,
”SF36 .Q9” ,” SF36 . Q10” ,
”SF36 . Q11” ,” SF36 . Q12” ,
”EQ5D.Q1” ,”EQ5D.Q2” ,
”EQ5D.Q3” ,”EQ5D.Q4” ,
”EQ5D.Q5”) )
# Same r e s u l t s as that in Mplus
model . 5 . 2 . output <−
parameterEst imates ( f i t ) #capture the model output
parameter . covar iance <−
lavaan : : vcov ( f i t ) #covar iance matrix f o r parameters
vars <− c ( 1 : 1 7 , 3 5 : 8 8 ) # s e l e c t v a r i a b l e s r equ i r ed
model . 5 . 2 . vcov <− parameter . covar iance [ vars , vars ]
model . 5 . 2 . cho l e sky . decompos it ion <−
cho l ( model . 5 . 2 . vcov ) #cho le sky decomposit ion
model . 5 . 2 . cho l e sky . decompos it ion <− #transpose cho le sky decomp
t ( model . 5 . 2 . cho l e sky . decomposit ion )
model . 5 . 2 . s p e c i f i c a t i o n <− parTable ( f i t )
134
#####################
# R Code ############
# Model 5 . 2 #########
# Step 2 ############
#####################
l i b r a r y ( lavaan )
# Analyse MEPS & WLS
# Need model with f i x e d parameters
# We s e t up a model template us ing
# parameters obta ined in prev ious s tep
model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [ 1 : 1 7 ] <−
model . 5 . 2 . output$est [ 1 : 1 7 ]
model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [ 3 8 : 9 1 ] <−
model . 5 . 2 . output$est [ 3 8 : 9 1 ]
# Only i n t e r e s t e d in SF−12 rows
vars <− c ( 1 : 1 2 , 3 8 : 81 , 1 0 9 , 12 9 )
model . 5 . 2 . s p e c i f i c a t i o n . SF12 <−
model . 5 . 2 . s p e c i f i c a t i o n [ vars , ]
model . 5 . 2 . s p e c i f i c a t i o n . SF12 [ 5 7 , 8 ] <− NA
model . 5 . 2 . s p e c i f i c a t i o n . SF12 [ 5 8 , 8 ] <− NA
model . 5 . 2 . s p e c i f i c a t i o n . SF12[58 ,3]<− ”˜”
model . 5 . 2 . s p e c i f i c a t i o n . SF12[58 ,4]<− 1
# The next s tep trans forms t h i s i n to an
# s p e c i f i c a t i o n that Lavaan can i n t e r p r e t
model . 5 . 2 . s p e c i f i c a t i o n . SF12 <−
paste0 ( model . 5 . 2 . s p e c i f i c a t i o n . SF12$lhs ,
model . 5 . 2 . s p e c i f i c a t i o n . SF12$op ,
model . 5 . 2 . s p e c i f i c a t i o n . SF12$ustart ,
”∗” , model . 5 . 1 . s p e c i f i c a t i o n . SF12$rhs ,
c o l l a p s e = ”\n”)
# Now take the MEPS/WLS [ Dataset2 ]
Dataset2 [ , # d e f i n e the datase t as being o r d i n a l
c (” SF36 .Q1” ,” SF36 .Q2” ,” SF36 .Q3” ,
”SF36 .Q4” ,” SF36 .Q5” ,” SF36 .Q6” ,
”SF36 .Q7” ,” SF36 .Q8” ,” SF36 .Q9” ,
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”SF36 . Q10” ,” SF36 . Q11” ,” SF36 . Q12 ” ) ] <−
l app ly ( Dataset2 [ ,
c (” SF36 .Q1” ,” SF36 .Q2” ,” SF36 .Q3” ,
”SF36 .Q4” ,” SF36 .Q5” ,” SF36 .Q6” ,
”SF36 .Q7” ,” SF36 .Q8” ,” SF36 .Q9” ,
”SF36 . Q10” ,” SF36 . Q11” ,” SF36 . Q12 ” ) ] , ordered )
f i t <− #now f i t the model
sem( model . 5 . 2 . s p e c i f i c a t i o n . SF12 ,
data = Dataset2 , std . l v=TRUE,
ordered=c (” SF36 .Q1” ,” SF36 .Q2” ,” SF36 .Q3” ,
”SF36 .Q4” ,” SF36 .Q5” ,” SF36 .Q6” ,
”SF36 .Q7” ,” SF36 .Q8” ,” SF36 .Q9” ,
”SF36 . Q10” ,” SF36 . Q11” ,” SF36 . Q12”) )
# This w i l l g ive us a model with parameter
# es t imate s the same as those from the NHMS
# a n a l y s i s . The next s tep i n v o l v e s p r e d i c t i n g
# l a t e n t f a c t o r s c o r e s
Datase t2$ la t ent <− p r e d i c t ( f i t )
# With these l a t e n t f a c t o r s c o r e s we
# now must trans form these in to re sponse
# p r o b a b i l i t i e s f o r the EQ−5D items .
Dataset2$Pred .EQ5D.Q1 . L1 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [82]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q1 . L2 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [83]−Datase t2$ la t ent ) −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [82]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q1 . L3 <− 1 −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [83]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q2 . L1 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [84]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q2 . L2 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [85]−Datase t2$ la t ent ) −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [84]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q2 . L3 <− 1 −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [85]−Datase t2$ la t ent )
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Dataset2$Pred .EQ5D.Q3 . L1 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [86]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q3 . L2 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [87]−Datase t2$ la t ent ) −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [86]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q3 . L3 <− 1 −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [87]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q4 . L1 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [88]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q4 . L2 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [89]−Datase t2$ la t ent ) −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [88]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q4 . L3 <− 1 −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [89]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q5 . L1 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [90]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q5 . L2 <−
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [91]−Datase t2$ la t ent ) −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [90]−Datase t2$ la t ent )
Dataset2$Pred .EQ5D.Q5 . L3 <− 1 −
pnorm( model . 5 . 2 . s p e c i f i c a t i o n $ u s t a r t [91]−Datase t2$ la t ent )
# Note that we w i l l e s t imate expected HRQoL va lue s so need
# p r o b a b i l i t y o f be ing in f u l l hea l th and N3 term
Dataset2$Prob . Fu l l . Health <− Dataset2$Pred .EQ5D.Q1 . L1∗
Dataset2$Pred .EQ5D.Q2 . L1∗Dataset2$Pred .EQ5D.Q3 . L1∗
Dataset2$Pred .EQ5D.Q4 . L1∗Dataset2$Pred .EQ5D.Q5 . L1
Dataset2$Prob . No . N3 <− Dataset2$Prob . Fu l l . Health +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L1∗
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Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L2 +
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Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L1∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L2∗
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Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L1∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L1∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L1∗
Dataset2$Pred .EQ5D.Q5 . L2 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L1 +
Dataset2$Pred .EQ5D.Q1 . L2∗Dataset2$Pred .EQ5D.Q2 . L2∗
Dataset2$Pred .EQ5D.Q3 . L2∗Dataset2$Pred .EQ5D.Q4 . L2∗
Dataset2$Pred .EQ5D.Q5 . L2
# And f i n a l l y apply EQ−5D weights
Dataset2$constant <− (1−Dataset2$Prob . Fu l l . Health )∗0 .081
Dataset2$N3 <− (1−Dataset2$Prob . No . N3)∗0 .269
Dataset2$decrement mob <− ( Dataset2$Pred .EQ5D.Q1 . L2 ∗0 .069) +
( Dataset2$Pred .EQ5D.Q1 . L3 ∗0 .314)
Dataset2$decrement sc <− ( Dataset2$Pred .EQ5D.Q2 . L2 ∗0 .104) +
( Dataset2$Pred .EQ5D.Q2 . L3 ∗0 .214)
Dataset2$decrement usual <− ( Dataset2$Pred .EQ5D.Q3 . L2 ∗0 .036) +
( Dataset2$Pred .EQ5D.Q3 . L3 ∗0 .094)
Dataset2$decrement pain <− ( Dataset2$Pred .EQ5D.Q4 . L2 ∗0 .123) +
( Dataset2$Pred .EQ5D.Q4 . L3 ∗0 .386)
Dataset2$decrement anx <− ( Dataset2$Pred .EQ5D.Q5 . L2 ∗0 .071) +
( Dataset2$Pred .EQ5D.Q5 . L3 ∗0 .236)
Dataset2$eq5d <− 1
Dataset2$eq5d <− 1 − Dataset2$constant − Dataset2$decrement mob −
Dataset2$decrement sc −
Dataset2$decrement usual − Dataset2$decrement pain −
Dataset2$decrement anx − Dataset2$N3
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#####################
# Mplus Code ########
# Model 5 . 3 #########
# Step 1 ############
#####################
TITLE : t h i s i s an example o f a th r e sho ld
s t r u c t u r e CFA f o r c a t e g o r i c a l f a c t o r i n d i c a t o r s
DATA: FILE IS Data . dat ;
VARIABLE: NAMES ARE HA sex SF36 Q1 SF36 Q4 SF36 Q6
SF36 Q14 SF36 Q15 SF36 Q18 SF36 Q19 SF36 Q22
SF36 Q26 SF36 Q27 SF36 Q28 SF36 Q32 EQ5D Q1
EQ5D Q2 EQ5D Q3 EQ5D Q4 EQ5D Q5 age1 age2 ;
CATEGORICAL ARE SF36 Q1 SF36 Q4 SF36 Q6
SF36 Q14 SF36 Q15 SF36 Q18 SF36 Q19 SF36 Q22
SF36 Q26 SF36 Q27 SF36 Q28 SF36 Q32 EQ5D Q1
EQ5D Q2 EQ5D Q3 EQ5D Q4 EQ5D Q5 ;
MISSING = . ;
ANALYSIS :
TYPE = gene ra l miss ing h1 ;
MODEL: f1 BY SF36 Q1∗ SF36 Q4 SF36 Q6
SF36 Q14 SF36 Q15 SF36 Q18 SF36 Q19 SF36 Q22
SF36 Q26 SF36 Q27 SF36 Q28 SF36 Q32 EQ5D Q1
EQ5D Q2 EQ5D Q3 EQ5D Q4 EQ5D Q5 ;
f2 BY SF36 Q1∗ SF36 Q4 SF36 Q6
SF36 Q14 SF36 Q15 SF36 Q18 SF36 Q19 SF36 Q22
SF36 Q26 SF36 Q27 SF36 Q28 SF36 Q32 ;
f 3 BY EQ5D Q1∗ EQ5D Q2 EQ5D Q3 EQ5D Q4 EQ5D Q5 ;
f1@1 ;
f2@1 ;
f3@1 ;
f 1 WITH f2@0 ;
f 1 WITH f3@0 ;
f 2 WITH f3@0 ;
f 1 ON HA sex age1 age2 ;
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[ SF36 Q1$1 SF36 Q4$1 SF36 Q6$1
SF36 Q14$1 SF36 Q15$1
SF36 Q18$1 SF36 Q19$1 SF36 Q22$1
SF36 Q26$1 SF36 Q27$1 SF36 Q28$1
SF36 Q32$1
EQ5D Q1$1 EQ5D Q2$1 EQ5D Q3$1 EQ5D Q4$1 EQ5D Q5$1
SF36 Q1$2 SF36 Q4$2 SF36 Q6$2 SF36 Q14$2 SF36 Q15$2
SF36 Q18$2 SF36 Q19$2 SF36 Q22$2 SF36 Q26$2 SF36 Q27$2
SF36 Q28$2 SF36 Q32$2
EQ5D Q1$2 EQ5D Q2$2 EQ5D Q3$2 EQ5D Q4$2 EQ5D Q5$2
SF36 Q1$3 SF36 Q14$3 SF36 Q15$3
SF36 Q18$3 SF36 Q19$3 SF36 Q22$3
SF36 Q26$3 SF36 Q27$3 SF36 Q28$3 SF36 Q32$3
SF36 Q1$4 SF36 Q14$4 SF36 Q15$4
SF36 Q18$4 SF36 Q19$4 SF36 Q22$4
SF36 Q26$4 SF36 Q27$4 SF36 Q28$4
SF36 Q32$4 ] ;
OUTPUT:
Standardized TECH3;
SAVEDATA:
D i f f t e s t i s d i f f t e s t f i l e . dat ;
142
#####################
# R Code ############
# Model 5 . 3 #########
# Step 2 ############
#####################
l i b r a r y ( MplusAutomation ) #use t h i s command to run models
# from R and then e x t r a c t the model output
l i b r a r y ( simsem ) # requ i r ed f o r s imu la t i on s
# In order to make conduct s imu la t i on s we need a
# ” template ” model to which we can add parameter
# es t imate s from the mplus output
# We run ana ly s e s on RITA data to obta in t h i s template
RITA[ , c (”EQ5D.Q1” ,
”EQ5D.Q2” ,
”EQ5D.Q3” ,
”EQ5D.Q4” ,
”EQ5D.Q5” ) ] <−
l app ly (RITA[ , c (”EQ5D.Q1” ,
”EQ5D.Q2” ,
”EQ5D.Q3” ,
”EQ5D.Q4” ,
”EQ5D.Q5” ) ] , ordered )
model <− ’ l a t e n t =˜ EQ5D.Q1 + EQ5D.Q2 + EQ5D.Q3 +
EQ5D.Q4 + EQ5D.Q5
EQ5D.Q1 | t1 + t2
EQ5D.Q2 | t1 + t2
EQ5D.Q3 | t1 + t2
EQ5D.Q4 | t1 + t2
EQ5D.Q5 | t1 + t2 ’
l i b r a r y ( lavaan )
f i t <− sem( model ,RITA,
ordered=c (”EQ5D.Q1” ,
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”EQ5D.Q2” ,
”EQ5D.Q3” ,
”EQ5D.Q4” ,
”EQ5D.Q5”) )
model . 5 . 3 . s p e c i f i c a t i o n <− parTable ( f i t )
# Next the appropr ia te parameter e s t imate s
# from the mplus model are a s s i gned to t h i s
# template . These w i l l vary depending upon
# the pa t i en t p r o f i l e . Now s imulate datase t
s imu la t i on <− data . frame ( sim (1 ,100000 ,
model . 5 . 3 . s p e c i f i c a t i o n ,
model = model , dataOnly = TRUE) )
# EQ5D va lue s then as s i gned to the s imu la t i on s
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Appendix E
Chapter 6 Results
Table E.1: CFA Approach - Threshold Values
Indicator Threshold 1 Threshold 2 Threshold 3 Threshold 4
SF36 Q1 -1.59 -0.70 0.23 1.21
SF36 Q2 -0.89 -0.40
SF36 Q3 -0.60 0.11
SF36 Q4 -1.37 -0.72 -0.04 0.51
SF36 Q5 -1.35 -0.83 -0.18 0.28
SF36 Q6 -1.59 -1.15 -0.60 -0.26
SF36 Q7 -1.84 -1.28 -0.72 -0.40
SF36 Q8 -0.05 0.48 0.91 1.54
SF36 Q9 -0.65 0.56 1.10 1.51
SF36 Q10 -1.21 -0.12 0.64 1.15
SF36 Q11 -1.90 -1.29 -0.72 -0.25
SF36 Q12 -1.57 -1.09 -0.50 0.00
EQ5D Q1 0.20 2.27
EQ5D Q2 1.23 2.34
EQ5D Q3 0.32 1.57
EQ5D Q4 -0.35 1.30
EQ5D Q5 0.42 1.56
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Table E.2: SEM Approach - Threshold Values
Indicator Threshold 1 Threshold 2 Threshold 3 Threshold 4
SF36 Q1 -1.84 -0.82 0.21 1.23
SF36 Q2 -0.96 -0.22
SF36 Q3 -0.74 0.06
SF36 Q4 -1.34 -0.78 -0.13 0.33
SF36 Q5 -1.37 -0.87 -0.27 0.15
SF36 Q6 -1.30 -0.84 -0.31 0.05
SF36 Q7 -1.39 -0.93 -0.39 -0.02
SF36 Q8 -0.36 0.24 0.69 1.41
SF36 Q9 -1.36 -0.12 0.61 1.25
SF36 Q10 -1.52 -0.41 0.40 1.01
SF36 Q11 -1.39 -0.83 -0.05 0.62
SF36 Q12 -1.35 -0.81 -0.20 0.24
EQ5D Q1 0.29 2.04
EQ5D Q2 0.90 2.13
EQ5D Q3 0.14 1.36
EQ5D Q4 -0.33 1.33
EQ5D Q5 -0.10 1.12
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Appendix F
Chapter 7 Code
#####################
# R Code ############
# Model 6 . 2 #########
# Mixed outcomes ####
# model #############
#####################
Model . 6 . 2 <−
”CF =˜ s f6d + hu i3 s co r e +
EQ5D.Q1 + EQ5D.Q2 + EQ5D.Q3 + EQ5D.Q4 + EQ5D.Q5
EQ5D.Q1 | t1 + t2
EQ5D.Q2 | t1 + t2
EQ5D.Q3 | t1 + t2
EQ5D.Q4 | t1 + t2
EQ5D.Q5 | t1 + t2 ”
NHMS[ , # we need to d e f i n e the datase t as be ing o r d i n a l
c (”EQ5D.Q1” ,”EQ5D.Q2” ,
”EQ5D.Q3” ,”EQ5D.Q4” ,
”EQ5D.Q5” ) ] <−
l app ly (NHMS[ , c (”EQ5D.Q1” ,
”EQ5D.Q2” ,”EQ5D.Q3” ,
”EQ5D.Q4” ,”EQ5D.Q5” ) ] ,
ordered )
f i t <− #now f i t the model
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sem( Model , data = NHMS, std . l v=TRUE,
ordered=c (”EQ5D.Q1” ,
”EQ5D.Q2” ,”EQ5D.Q3” ,”EQ5D.Q4” ,
”EQ5D.Q5”) )
param . e s t imate s <− parameterEst imates ( f i t )
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